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ABSTRACT 
  
Angiotensin-converting enzyme (ACE) and P. falciparum A M1 
(PfA-M1) are both zinc metalloproteases implicated in 
hypertension and malaria, respectively. Hypertension 
affects approximately 26 % of the world’s population while 
each year over 300 million cases of malaria occur worldwide 
resulting in between 1.5 and 2.7 million deaths annually. 
Hypertension treatment with current ACE inhibitors is 
marred by unpleasant side effects, such as cough and 
angioedema. In malaria, the parasites continuously develop 
resistance to anti-malarial drugs where the disease is 
endemic. There is therefore a need for continuous research 
into the application of new techniques as well as the 
design of new small molecule chemical entities as probes or 
chemotherapeutic agents. 
 
The work presented in this thesis is two-fold: 
 
(i)The design and synthesis of a new series of hydroxamate, 
sulfhydryl and carboxylic acid-based inhibitor activity-
based protein profiling probes for use in hypertension and 
malaria disease models. The hydroxamate probes were prepared 
by sequential Knoevanagel condensation of various aldehydes 
with Meldrums acid as starting material followed by conjugate 
reduction, alkylation with allyl bromide, decarboxylation and 
Ruthenium catalytic cleavage of a terminal alkene. Peptide 
coupling was then used to assemble the various sub-units, 
namely, the reactive groups, the probe linker, photocross-
linker and the biotin reporter tag. 
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(ii)Design and synthesis of a new series of α-amino-
phosphinic acid-based ACE inhibitors with an attenuated 
Zinc Binding Group (ZBG) using a one pot, 3-component 
synthesis involving equimolar quantities of amino acid, 
aldehyde and phosphonic acid. These were tested for ACE 
inhibition and the effect of the ZBG on domain-selectivity 
was investigated.   
 
The sulfhydryl and carboxylate ABP’s, hydroxamates as well 
as the phosphinic acids were evaluated with enzymatically 
active purified C- and N-domain constructs. Although the 
carboxylic acid probe 3.32a showed no inhibition, the 
sulfhydryl probe 3.32b exhibited an apparent IC50 of 25 µM.  
 
For the hydroxamate inhibitors, compound 4.7d was found to 
inhibit ACE by 86% at 5 µM. Amongst the phosphinic acid 
compounds with the attenuated zinc-binding group, 4.2i-7 
inhibited the C-domain construct by 53% whereas 4.2i-2, 
4.2i-14, and 4.2i-16 inhibited by 40, 39 and 36% 
respectively at 250nM. The different groups adjacent to the 
ZBG’s had varying degrees of effect on the activity of the 
compounds with the most active 4.2i-7 having a pseudo-
phenylalanine moiety in the α- and a propyl group in the 
α’-position relative to the phosphinic acid. On the other 
hand, compared to the 99% inhibition by Captopril in both 
domains, Enalaprilat analogue 4.4e inhibits by 30 and 20% 
in the C- and N domains where Captopril analogue 4.5d 
inhibit both domains by 20% respectively at 250 nM. None of 
the compounds showed significant selectivity for the C- or 
N-domains. 
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ABBREVIATIONS 
ACE   Angiotensin-converting enzyme 
Ang I  Angiotensin I 
Ang II  Angiotensin II 
AcSDKP  N-acetyl-seryl-aspartyl-lysyl-proline 
BP   Blood Pressure 
BK   Bradykinin 
BBr3   Boron Tribromide 
CPA   Carboxypeptidase A 
13C NMR  Carbon 13 Nuclear Magnetic Resonance 
CbzCl  Benzyl chloroformate 
DMF   Dimethylformamide 
DCC   Dicyclocarbodiimide 
DMSO   Dimethyl sulphoxide 
DCM   Dichloromethane 
3-D   Three Dimensional 
EDC-HCl   N-(3-Dimethylaminopropyl)-N’-
ethylcarbodiimide Hydrochloride 
EOPB   ethyl-2-oxo-4-phenyl butyrate 
FGI   Functional Group Interconversion 
GnRH   Gonadotropin-releasing hormone 
h   hours 
HHL   hippuryl-histidyl-leucine 
HOBt   1-Hydroxybenzotriazole 
1H NMR  Proton Nuclear Magnetic Resonance 
HPLC   High Pressure Liquid Chromatography 
IC50   Inhibitor concentration for 50% activity  
   reduction 
KKS   Kallikrein-Kinin System 
LHRH   Luteinising hormone-releasing hormone 
LRMS   low resolution mass spectroscopy 
MeOH   methanol 
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Mol   Mole 
NaHCO3  sodium bicarbonate 
o-p    o-phthaldialdehyde 
Pd/C   Palladium on Carbon 
iPr2Net  diisopropylethylamine 
RAS   Renin-angiotensin system 
SOCl2   Thionyl chloride 
sACE   Somatic ACE 
tACE   Testis ACE 
Z-FHL  Z-L-Phenalalyl-L-Histidyl-L-Leucine  
 
The following abbreviations are used in the Experimental 
chapter:  
s   singlet 
d   doublet 
dd   doublet of doublets  
ddd    doublet of doublets of doublets 
t   triplets 
td   triplet of doublets 
q   quartet 
m   multiplet 
mp   melting point 
J   coupling constant 
Hz   hertz 
m/z   mass to charge ratio 
δ   chemical shift 
ppm   parts per million 
Rf   retention factor 
nM   nanomolar 
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Chapter One  
 Introduction and Literature Review 
1.0 Introduction 
 
The first part of this thesis describes the design and 
synthesis of novel activity-based protein profiling probes 
based on the selective interaction of active metallo-
proteases with synthesized inhibitor molecules. The general 
introduction in Chapter 1 gives an overview of the current 
literature on the biological and patho-physiological role 
of the gluzincins with Angiotensin-Converting Enzyme (ACE) 
and P. falciparum A – M1 (PfA-M1) as examples. Excessive 
metalloprotease activity is a possible underlying cause for 
the development of many diseases ranging from inflammatory 
conditions to pathological tissue remodelling and cancer. 
The profiling of metalloprotease activity could thus 
provide a valuable diagnostic tool and shed light on the 
complicated role of these metalloproteases in health and 
disease. As metalloprotease activity is highly regulated in 
vivo, determination or profiling of the actual active 
isoforms that are present could provide a better picture of 
the (patho)-physiological situation. Several analytical 
techniques for distinguishing active from non-active, 
either in pro-protease, or zymogen form or inactivated by 
endogenous inhibitors from the literature have been 
outlined. Chapter 1 will also gives a broad overview of the 
traditional methods for activity determination based on 
monitoring of substrate conversion and expands to the 
recently developed field of activity-based proteomics. This 
methodology uses small molecular weight inhibitors as 
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ligands labelled with biotin for tagging and visualisation 
of active proteases. 
 
Chapter 2 will discuss the rationale behind the design and 
synthesis of activity based probes targeting 
metalloproteases in the malaria and hypertension disease 
models.  The hydroxamate-based inhibitor probe for the 
former as well as the sulfhydryl and carboxylic acid 
inhibitor probes for the latter include a photoreactive 
benzophenone moiety for cross-linking of the probe to the 
active metalloprotease and a biotin group for future 
visualisation and pull-down using biotin-streptavidin 
interaction. This chapter will also discuss the rationale 
as well as an overview of methodological prospects. Chapter 
3 encompasses a detailed retrosynthetic strategy followed 
by a synthetic discussion of the preparation of the 
described ABPP’s is presented.  
 
The importance of ACE in pathophysiology as well as its 
mechanism has been briefly described in Chapter 1. This 
enzyme is particularly interesting because it is a two-
domain enzyme, an N- and a C-domain each with its own 
active site. It has been implicated in the control of 
hypertension and is an important therapeutic target. Since 
the 1950’s ACE inhibitors have been used for its control. 
However this treatment has been associated with unpleasant 
side effects attributed to the lack of selectivity of these 
inhibitors for the hypertension controlling C-domain. 
Current generation ACE inhibitors inhibit both domains 
resulting in the disturbance of other homeostatic functions 
perfomed by the N-domain resulting in various side effects 
precipitated by the accumulation of substrates and 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Chapter 1: Introduction and Literature Review 
 
3 
metabolites. From the foregoing, it is clear that the next 
generation of ACE inhibitors should be C-domain specific.  
So apart from the synthesis of probes for future study of 
the behaviour of ACE, one other objective of this research 
was to design, synthesise and biologically evaluate a new 
series of potential novel C-domain specific inhibitors. 
Previous research has focused mainly on variations in the 
peptidomimetic carbon chain backbone whilst maintaining a 
strong zinc-binding group(ZBG) presence. This research will 
consider the effect on domain selectivity of an attenuated 
ZBG with a varied backbone. Our hypothesis is that the lack 
of domain selectivity exhibited by inhibitors, both 
existing and new ones synthesized in research, is because 
of the presence of a ZBG. The latter suppresses the 
influence of the more subtle but more specific interactions 
of the inhibitor backbone which have higher chances of 
achieving domain selectivity. Accordingly, Chapter 4 
elaborates on the structural ACE featuresas well as the 
need to achieve domain selective inhibition of this enzyme. 
It then proceeds to describe the design and synthesis of a 
small exploratory number of potential novel C-domain 
selective phosphinic acid based ACE inhibitors with an 
attenuated zinc-binding group. This part of the research 
will seek to investigate the effect attenuation would have 
on ACE-domain selectivity, utilizing structural features of 
the most C-domain selective inhibitor known, RXPA380. 
Current knowledge suggests that the domain selectivity of 
RXPA380 is attributed to the tryptophan residue in the 
P2’position. This chapter will therefore also explore 
briefly the C-domain specificity-imparting effect of 
tryptophan by incorporating the residue into the P2’-
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position of two of the most commonly prescribed ACE-
inhibitors, namely, captopril and enalaprilat. Chapter 4 
will further describe the synthesis of “serendipitous” 
compounds synthesized from synthetic intermediates from 
Chapter 1 coupled to tryptophan. 
In Chapter 5 the biological results of the assays are 
summarized. In Chapter 6 a conclusion of the results 
obtained as well as gives future perspectives are 
presented. Finally, Chapter 7 gives detailed experimental 
procedures used in the synthesis and biological evaluation 
of the probes and inhibitors reported herein.  
1.1 Literature Review 
1.1.1 Metalloproteases 
Proteases can be classified into four major classes: 
serine-, cysteine-, aspartic- and metalloproteases based on 
their residue or co-factor crucial in catalysis. 
Metalloproteases (MP’s)are proteases where the water 
molecule that is used for hydrolysis is complexed to a 
metal ion in the catalytic centre of the enzyme. The metal 
ion is itself held in position by several amino acid 
residues. Proteases can be categorized into 15 different 
clans based on the structural diversity of their sub-sites. 
Ten of these are given in Table 1 below where one of the 
major families is the zinc metalloprotease superfamily. The 
latter are the zinc containing metalloproteases most of 
which exhibit a characteristic Histidine-Glutamic Acid-X-X-
Histidine (HEXXH, single letter amino acid code, with X 
being any residue) consensus sequence. The two histidine 
(H) residues serve as zinc ligands and the glutamic acid 
(E) residue polarizes a water molecule involved in 
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nucleophilic attack at the scissile peptide bond of the 
substrate. 
--------~( )~--------
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Clan/Sub-Clan MEROPS 
Family Name 
General Family name Typical human Family members 
MA (E) 
“Gluzincins” 
M1 Aminopeptidase Aminopeptidase N, Aminopeptidase A, Insulin-regulated 
aminopeptidase, Pyroglutamylaminopeptidase II 
 M2 Angiotensin-Converting Enzyme 
(ACE) family 
ACE, ACE2 
 M3 ThimetOligopeptidase family Thymetoligopeptidase (EP24.15), Neurolysin (EP24.16), 
Mitochondrial intermediate peptidase 
 M13 Neprilysin family Neprilysin, NEP2, Endothelin-converting enzyme (ECE-1), 
ECE-2, Damage-Induced neuronal peptidase (DINE). 
 M41 FtsHendopeptidase family i-AAA protease 
MA (M) 
“Metzincins”  
M8 Leishmanolysin family Leishmanolysin-2 
 M10A Matrix metalloproteases Collagenases. Gellatinases, stromelysins, matrilysin, 
membrane-type MMPs 
 M12A Astacin Subfamily Meprin-α, β, Mammalian tolloid-like 1 protein 
 M12B Adamalysin Subfamily ADAM proteases, AMADTS proteases 
MC M14A Carboxypeptidas  A subfamily Carboxypeptidase A & B 
 M14B Carboxypeptidase E subfamily Carboxypeptidase E & N 
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ME M16A 
“Inverzincins” 
Pitrilysin Subfamily Insulysin, nardilysin, (NRD convertase) 
 M16B  Mitochondrial processing peptidase-β subunit 
 M16C  Eupitrilysin 
MF M17 Leucylaminopeptidase Leucylaminopeptidase 
MG M24A Methionylaminopeptidase 
subfamily 
Methionyl aminopeptidase-1, -2 
 M24B Aminopeptidase P subfamily Aminopeptidase P1 (solube), Aminopeptiase P2 (membrane bound), 
χ-Pro-dipeptidase 
MH M18  Aspartylaminopeptidase 
 M20A  Ytosolic non-specific dipeptidase 
 M28B  Glutamate carboxypeptidase !! 
 M28D  Plasma Glutamate carboxypeptidase 
MJ M19 Membrane Dipeptidase family Membrane Dipeptidase 
MM M50A  S2P protease 
M- M48A Ste24 endopeptidase family Farnesylated-protein-converting enzyme 1 
 M49 Dipeptidyl-peptidase III 
family 
Dipeptidyl-peptidase III 
 M67  Pohl peptidase 
Table 1.1: Classification of metallopeptidases. 1 
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1.1.2 Zinc Metalloproteases  
Zinc metalloproteases are a large and diverse class of 
enzymes involved and implicated in numerous and important 
biological phenomena both physiological and pathological. 
These are cell proliferation, signalisation, multiplication 
and migration, hormonal processing, angiogenesis, pathogen 
growth, tissue remodelling, hypertension and cancer.Their 
classification is based on the catalytic mechanism and the 
critical amino acid residues involved. In metalloproteases, 
an activated water molecule complexed to the divalent 
cation, usually Zn2+, serves as the nucleophile, attacking 
the carbonyl group of the targeted peptide bond. Ten years 
ago, Rawlings and Barrett2 proposed a classification system 
based not only on the catalytic mechanism, but also the 
evolutionary links between enzymes. According to this 
scheme, which has been updated in light of recent genomic 
and structural information and is now maintained on-line in 
the MEROPS peptidase database3 most of the mammalian 
metalloproteases fall into one of 4 clans or sub-clans 
(Table 1.1). 
 
By far the largest group, Clan MA, is distinguished by the 
active site motif HEXXH, where the two histidine residues, 
together with a third distant residue, bind the zinc atom. 
This clan is divided into two major sub-clans: MA(E), the 
“gluzincins,” where the third ligand is a glutamate, and 
MA(M), “metzincins,” which have a third histidine or an 
aspartate residue in this position.. This latter group is 
typified by the matrix metalloproteases and their relatives, 
including the “a disintegrinand metalloprotease” family 
(ADAMs). The gluzincins are further divided into families 
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based on homology. The families most relevant to mammalian 
signalling systems are M1 (aminopeptidases), M2 (angiotensin 
converting enzyme family), M3 (EP24.15/thimetoligopeptidase 
and EP24.16/neurolysin), and M13 (neutral endopeptidase 
family). The metallo-carboxyproteases belong to the clan MC, 
while a smaller group of peptidases, in which the active 
site motif is reversed (HXXEH; the so-called “inverzincins”) 
and typified by insulin-degrading enzyme (insulysin), belong 
to the M16 family within the clan ME. 
 
1.1.3 Angiotensin Converting Enzyme (ACE) as an example 
of a Zinc metalloprotease implicated in Hypertension 
Gluzincins characterized to date include thermolysin-like 
enzymes in gram-positive and –negative bacteria (M4 family), 
mycolysin from streptomyces (M5), botulinum neurotoxin 
(M27), a family of aminopeptidases (M1), neprilysin-like 
enzymes (M13), and ACE (M2).Angiotensin-converting enzyme 
(ACE4, EC 3.4.15.1) is a well-characterized membrane-bound 
zinc metalloprotease of the “gluzincins” family known to 
play a crucial role in cardiovascular homeostasis. It is an 
exopeptidase that cleaves dipeptides from the carboxyl-
terminal end of various peptide substrates.5 Like the 
similar carboxypeptidases, it is a zinc containing enzyme. 
Two reactions catalyzed by angiotensin-converting enzyme 
play a key role in blood pressure regulation. Firstly, it is 
the conversion of the inactive decapeptide angiotensin I 
(Ang I) to the potent vasopressor octapeptide angiotensin 
II6 (Ang II) and secondly, inactivation of the vasodepressor 
nonapeptide  bradykinin (BK).7 The central role that ACE 
plays in the Renin-Angiotensin System (RAS) renders it a 
major drug target for cardiovascular disease and blood 
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pressure control. Apart from Ang I and BK, ACE is also 
involved with other substrates such as peptide N-acetyl-
seryl-aspartyl-lysyl-proline (AcSDKP), a peptide known for 
its haemoregulatory roles. Even in this case, ACE functions 
as a dipeptidyl carboxypeptidase, releasing the KP fragment 
in the plasma.8 This indicates that ACE plays a role in 
several other physiological systems apart from the RAS. 
 
ACE is interesting not only because of its physiological and 
pathological characteristics, but also because it is the 
only known metalloprotease with two active-sites, attributed 
undoubtedly to gene duplication.9 The two active-sites are 
subtly different, with each site displaying distinct 
substrate and inhibitor affinities, a phenomenon 
successfully exploited in the design of site-specific 
inhibitors which limit the formation of the vasoconstrictor 
angiotensin II with minimal effects on BK degradation.10  In 
addition to its membrane-bound form, ACE also exists as two 
distinct soluble forms; a testis-specific, single active 
site ACE, arising from an alternate splice variant expressed 
in germ cells and required for male fertility. This isoform 
was recently used to solve the structure of the enzyme and 
is comparative to the C-domain of sACE11 and a secreted form 
of the somatic enzyme, released from the extracellular 
membrane by a specific proteolytic event. The possible ADAM 
proteases involved in this “shedding” event, as well as the 
physiological consequences of ACE secretion have been 
described.12,13 
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1.1.4 P. falciparum A – M1 as an example of a Zinc 
Metalloprotease implicated in Malaria  
Neutral aminopeptidases are ubiquitous in mammalian cells 
and are generally involved in protein processing by clipping 
N-terminal amino acids, such as the trimming of peptides to 
achieve optimal binding to major histo-compatibility complex 
class I molecules,14 or in the final stages of protein 
degradation. Malaria parasites express two such enzymes, a 
122 kDa M1- family alanyl aminopeptidase and a 67.8 kDa M17-
family leucyl aminopeptidase, termed PfA-M1 (MAL13P1.56) and 
PfA-M17 (Pf14_0439), respectively).15,16, 17,18,19, 20 PfA-M1 
functions in the blood stage of malaria infection and is 
responsible for regulating the intracellular amino acid pool 
within malaria cells, most likely by releasing amino acids 
from host-derived haemoglobin. In addition to providing 
essential nutrients for parasite growth and development, 
digestion of haemoglobin is important for maintaining the 
osmotic integrity of infected red blood cells.21 PfA-M1 and 
PfA-M17 are chemically validated therapeutic targets for a 
unique class of antimalarial drugs. Blocking the activity of 
these aminopeptidases by dipeptide analogs prevents growth 
of P. falciparum in culture and kills P. Chabaudi malaria in 
vivo.22 PfA-M1 is able to efficiently cleave N-terminal 
amino acids from peptide substrates; it exhibits substrate 
specificity and rapidly hydrolyses substrates containing 
Leu, Ala, Arg, and Lys but can also cleave substrates 
containing Phe, Tyr, Ser, and Asn (but not Glu or Asp).23,24  
PfA-M1 binds a single, tightly-bound Zn2+ metal ion.25 Its 
active site is buried deep in the structure, providing a 
solution to the problem of controlling appropriate substrate 
entry, as well as preventing hydrolysis of unwanted 
substrates.26 
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1.2 Mechanism of Proteolysis by Zinc Metalloproteases 
The mechanism of action of both ACE and PfA-M1 is thought to 
mimic that of the prototypical zinc metalloprotease 
thermolysin, whose mechanism of action was elucidated in 
several studies and summarised by Matthews27 (Fig. 1.1). 
Briefly, the reaction proceeds as a fairly typical general-
base catalysis. A water molecule associated with the zinc 
attacks the carbonyl carbon of the scissile bond of the 
substrate. The glutamic acid (E384) of the metalloprotease 
HEXXH motif acts as the acceptor of a proton from the water. 
The negatively charged oxygen resulting from the binding of 
-OH is stabilized by the zinc, as well as tyrosine (Y523) 
and water in this intermediate (in thermolysin these 
correspond to a histidine and tyrosine, respectively). As 
the reaction proceeds, the E384 releases its proton to the 
amine nitrogen, thus destabilizing the scissile bond. This 
bond’s nitrogen atom is stabilized by electrostatic 
interactions with the backbone carbonyls of A354 and S355. 
The consequent charge repulsion between the new amino 
terminal and zinc, as well as the stabilization of the C-
terminal by the same, leads to separation of the products. 
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Figure 1.1: Catalytic mechanism of thermolysin.27 
 
1.3 The Need to Study Enzymes utilizing new techniques 
The majority of hypotheses associating gluzincins to disease 
states have been focussed on disregulation of the catalytic 
activity in vivo. This poses a challenge to the analysis of 
these enzymes, since the strict regulation of proteolytic 
activity means that traditional protein analysis techniques 
may not provide the required information. Since any given 
sample can contain three different forms of the 
metalloproteinase, the inactive zymogen, the inactivated 
TIMP-proteinase complex and the activated mature enzyme, a 
mere determination of gene expression by quantitative 
polymerase chain reaction (PCR) or protein amount by 
immunochemical techniques or conventional proteomics may be 
of limited diagnostic value. 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Chapter 1: Introduction and Literature Review 
 
14 
Gluzincins are tightly regulated by multiple post-
translational mechanisms in vivo, hindering their functional 
analysis by conventional genomic and proteomic methods. This 
thesis will describe a general strategy for creating 
activity-based proteomic probes for MPs by coupling a zinc-
chelating reactive group to a benzophenone photo-crosslinker 
via a PEG linker. It was envisaged that this will promote 
selective binding and modification of MP active sites, in 
the malaria and hypertension disease models respectively. 
 
1.4 Traditional Methods used to determine 
metalloprotease activity 
Several analytical techniques to determine metalloprotease 
activity have been under development since the late 1980’s 
whilst the earliest methods were described as early as the 
1950’s. These were based quite simply on conversion of a 
known (protein) substrate of the metalloprotease and are 
described below. 
 
1.4.1 Substrate degradation 
This is a technique used to monitor substrate conversion. A 
radiolabeled endogenous protein or substrate of interest is 
incubated with the protease and degradation is measured by 
gel electrophoresis, HPLC or Mass spectrometry. This is a 
simple technique that allows for continuous monitoring of 
enzyme activity. However, it depends on the availability of 
an appropriate substrate. It is further limited by the 
overlapping substrate specificity of metzincin subfamilies 
rendering quantification of individual proteases 
impossible.28 
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1.4.2 Gelatine or Collagen Zymography 
This technique is a variation of substrate degradation but 
includes zymography. A substrate such as gelatine is co-
polymerized into a polyacrylamide gel (SDS-PAG). The enzymes 
are then renatured and the incorporated subtrate is 
degraded. Visualization is then achieved using Coomassie 
staining yielding bright blue gel with transparent bands 
indicating gelatinase or collaginase activity. This is able 
to discriminate the zymogen and the active enzyme form by 
molecular size resolution through electrophoresis. However, 
gelatine zymography shows very few gelatinases and thus 
limited profiling. Furthermore, it does not give a 
confirmation of proteinase identity, or discriminate between 
free and tissue inhibitorof metalloproteases (TIMP) 
inhibited mature enzymes and although quantification is 
possible with densitometry, it has been described as not 
very accurate.29 
 
1.4.3 Conversion of Biotinylated Gelatine 
 
For improved quantification several reporter molecules have 
been incorporated into substrates, being either whole 
protein or small synthetic peptide sequences with internally 
quenched fluorophores. A biotinylated gelatine yields singly 
biotinylated fragments after proteolytic degradation that 
can be distinguished from the multiply biotinylated original 
substrate containing multiple biotin moieties by capture on 
immobilized streptavidin and incubated with horse radish 
peroxidise incubated streptavidin. The resulting signal is 
inversely proportional to the enzymatic activity. 30 This is 
a quantitative technique with good linearity and determines 
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the actual active enzyme in a sample. It is however limited 
by substrate specificity and gives only total gelatinase 
activity in the sample. 
 
1.4.4 Fluorogenic Substrate Conversion 
This technique utilizes an internally quenched approach 
which yields a fluorescent product after degradation by the 
active protease. The substrate is usually a small peptide 
containing the recognition sequence of the protease (or 
protease family) of interest. It is also a quantitative 
technique with good linearity giving a read out of the 
amount of active enzyme in a sample. However, it is reported 
to have limited substrate specificity and does not give 
information on the identity of individual 
metalloproteases.31 
 
1.4.5 Activity-Based Enzyme Linked Immunosorbent Assay 
(ELISA) 
The technique involves the activation of pro-urokinase which 
is modified for cleavage by a protease of interest. The 
latter is captured by an immobilized antibody and incubated 
with the modified pro-urokinase which is then activated. 
This activation is measured by monitoring conversion of a 
chromogenic substrate. This is a quantitative technique with 
good linearity and determines the actual active enzyme in 
the sample. The antibody-capture step is related to the 
protease of interest. However, it has been reported to have 
poor determination of single proteases rendering it limited 
with respect to profiling possibilities.32,33 
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1.4.6 Enzyme and Tissue Inhibitor of Metalloproteinase 
ratio (TIMP) 
 
Activity-based analysis of metalloproteases may be based on 
the hypothesis that protease-related diseases are caused by 
an imbalance between proteolytic activity and the TIMP-based 
inhibition system. An excess of activated protease may over 
time deplete the pool of available TIMP and cause unwanted 
degradation of tissue since the protease is no longer 
controlled. This technique, however, may yield results of 
limited value since it depends on accurate quantification of 
the amount of active, mature protease that is present in a 
complex biological sample. A second difficulty is that the 
enzyme activities play a role within a tissue therefore 
quantities of enzyme and TIMPs measured in the soluble 
biological sample may not reflect the situation in the 
tissue. Often therefore, parallel studies are performed 
using tissue samples and histological staining techniques. 
This problem is particularly important in case of ADAMs, 
since many of the ADAMs are strong cell surface bound 
molecules that are not easily released into biological 
fluids. Another problem is the lack of specificity of TIMPs 
for individual MMPs, which may lead to incorrect 
conclusions. 34,35 
 
1.5 Proteomics 
Since the analytical methods described above each have their 
shortcomings when applied to the family-wide profiling of 
metalloprotease activity, investigators have searched for 
alternatives. Proteomics is the study of proteins, their 
structure, localizations, functions, interactions and post-
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translational mechanisms. Critical to modern drug discovery 
is the need to map protein structure-function as this is 
keyfor better understanding of cellular functions under both 
normal and diseased states.  
 
The completion of the human genome project has no doubt been 
a major achievement in scientific research, opening up new 
and exciting possibilities to fully map and characterize all 
proteins expressed in cells.36 However, the study of human 
proteome presents scientists with a task much more daunting 
than the human genome project. Functional assignment to 
these immense numbers of novel genes and gene products has 
become essential. In fact, the estimated > 100,000 different 
proteins expressed from 30000-40000 human genes make it 
extremely challenging, if not impossible with existing 
protein analysis techniques, to map the entire cellular 
functions at the translational level. Consequently, there 
have been rapid advances in the techniques and methods 
capable of large-scale proteomic studies. Among them, the 
recently developed high-throughput screening methods have 
enabled scientists to analyze proteins quickly and 
efficiently at an organism-wide scale. In the last couple of 
years various researchers have focused on the development or 
fine-tuning of the various methods for protein 
profiling,37,38,39  a handful of which will be described in 
the coming sections of this thesis. 
 
1.5.1 Conventional techniques for protein profiling 
The conventional two-dimensional gel electrophoresis (2D-
GE), in combination with advanced mass spectrometric 
techniques, has facilitated the rapid characterization of 
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thousands of proteins in a single polyacrylamide gel. The 
technique has the ability to separate thousands of proteins 
in a specific cell or tissue, including their post-
translational modified forms. Thus the method is well suited 
for the global analysis of protein expression in an 
organism. This, together with the newly developed activity-
based profiling approaches that target different classes of 
proteins, has now allowed the study of protein functions 
based on their intrinsic enzymatic activities.40, 41 However, 
2D-GE suffers from a number of long-standing problems, 
including low throughput, a limited dynamic detection range, 
poor reproducibility, low sensitivity, as well as its 
difficulties in analyzing hydrophobic, small, and very basic 
or acidic proteins. Incremental improvements in the 2D-GE 
technology, including the use of sensitive staining methods 
and higher-resolving gels, and sample fractionation prior to 
2D-GE, have alleviated some of these problems.42,43 
Differential gel electrophoresis (DIGE)44 and multiplexed 
proteomics approach45 are some other recent developments 
related to 2D-GE. Yates and co-workers introduced a 
multidimensional protein identification technology 
(MudPIT).46 In th s technique, multiple types of columns are 
coupled together to separate proteins using different 
physiochemical properties in addition to molecular weights 
and charges, thereby extending the analytical range to 
proteins having high or low molecular weights, as well as 
low-abundance and insoluble proteins. MudPIT also allows the 
flexibility of incorporating a suitable affinity column to 
enable selective analysis of protein complexes and protein-
protein interactions. 
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Isotope-coded affinity tagging (ICAT) is another chemical 
method developed for quantitative proteomics. It utilizes 
stable-isotope labelling to perform quantitative analysis of 
paired protein samples, followed by separation and 
identification of proteins within the complex mixtures with 
liquid chromatography and mass spectrometry.47 The method 
relies on the use of an affinity based approach which 
permits the quantitative comparison of protein abundances 
between complex proteomes by MS analysis. It employs a 
chemical probe composed of a reactive group capable of 
covalently binding to a defined subset of amino acid side 
chains, an isotopically coded linker and an affinity tag for 
the isolation of reactive peptides. More recently, the gel-
based ICAT has also been reported.48  However, the strategy 
is limited to probing known proteins containing cysteine 
residues and depends on non-specific binding to ICAT 
reagents.  
 
From the very beginning of the proteomic era, mass 
spectrometry (MS) has played a major role in the high-
throughput identification of proteins following separation 
techniques such as 2D-GE and ICAT to name a few. With the 
advent of the ‘soft’ ionization techniques such as ESI and 
MALDI coupled with various mass analyzers including the ion 
trap, time-of-flight (TOF), quadrupole and Fourier transform 
ion cyclotron (FT-MS), the analysis of large intact protein 
complexes is now possible49 thus providing complementary 
data to that obtained by well-established methods in 
structural biology such as electron microscopy, X-ray 
crystallography and NMR. Another MS-based technology for 
quantitative analysis of protein mixtures is known as the 
surface-enhanced laser desorption ionization-time of flight 
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(SELDI-TOF).50  This technique utilizes stainless steel or 
aluminum-based supports, or chips, engineered with chemical 
or biological bait surfaces that allow differential capture 
of proteins. After the removal of non-specifically adhered 
proteins, the bound proteins are laser-desorbed and ionized 
for MS analysis. This field is currently being developed as 
a prominent technique when combined with advances in protein 
chip technology.  
 
1.6 Activity Based Protein Profiling 
As far as most enzymes are concerned, the overall protein 
expression levels do not strictly compare to their activity 
profiles. Different enzymes have intrinsically different 
catalytic activities. Moreover, various post translational 
modifications such as phosphorylation, glycosylation, 
acetylation, action of endogeneous activators/inhibitors, 
factors like pH and other native conditions significantly 
influence catalytic activity of enzymes. Most of the 
aforementioned methods, like 2DE-MS, still focus on 
measuring the changes in protein abundance and hence provide 
only an indirect estimate of dynamics in protein function. 
Undeniably, several important forms of post-translational 
regulation, as well as protein–protein and protein–small-
molecule interactions,51 may escape detection by these 
proteomic methods. In order to accomplish the functional 
analysis of proteins, a number of proteomic methods have 
been introduced in the past few years aiming to characterize 
the activity of proteins on a global scale. Large-scale 
yeast two-hybrid screens52, 53 and epitope-tagging immuno-
precipitation54, 55 are some of the methods which are widely 
used to study protein-protein interactions. Although these 
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methods do have the benefit of assigning specific molecular 
functions to individual protein products, they normally 
depend on recombinant expression of proteins in non-natural 
environments and, therefore, do not directly evaluate the 
functional state of these bio-molecules in their native 
settings.  
 
Recently developed activity-based protein profiling (ABPP) 
has opened up new ways of answering some of the challenges 
associated with proteomic research. The activity/affinity-
based methods make use of small molecule/peptide based 
chemical probes to profile the functional state of enzyme 
families directly within a complex proteome. These probes 
are developed using tools of synthetic organic chemistry and 
have become a major attraction in the field of high-
throughput functional proteomics. Originally developed by 
Cravattet al., ABPP allows the proteases present in a crude 
proteome to be studied on the basis of their enzymatic 
activities rather than their relative abundance.56, 57, 58, 59, 
60, 61
 The major advantage of the protein activity-based 
chemical approaches for profiling proteins includes the 
ability to target low abundance and membrane associated 
proteins within samples of high complexity. The strategy is 
able to bridge the gap between technologies such as the 
protein microarray and 2D-GE based techniques which study 
endogenous proteins by their expression, and combine the 
high throughput feature of 2D-GE with the ability of 
function-based protein studies. The general strategy in 
activity-based profiling typically involves a small 
molecule-based, active site-directed probe which targets a 
specific class of enzymes based on their enzymatic activity. 
Thus, the activity-based approach can potentially filter out 
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proteins that are not of interest and focus on certain 
classes of proteins. For example, Fig. 1.2 below shows a 
general approach to activity-based enzyme profiling using a 
fluorescent activity-based probe.  Among the different 
enzymes present in a complex proteome, the probe selectively 
labels a particular class of active enzymes. The labelled 
enzymes can be separated by SDS-PAGE and visualized by 
fluorescent imaging, which could be further characterized by 
mass spectrometry. 
 
 
 
 
Figure 1.2: Schematic representation of labelling of active proteases in a 
complex proteome by activity based probes. The probe selectively 
recognizes the active site of the active enzyme. Incorporation of a 
reporter molecule such as a fluorescent dye or biotin, the labelled 
protease can be visualized after gel electrophoresis,or enriched on 
affinity beads for further analysis.57 
 
1.7 Activity-based probes 
 
Activity-based probes are designed based on their potential 
application in proteomics. The design of these probes 
depends largely on the nature/complexity of the system under 
consideration as well as the type of information intended to 
be gathered. Highly specific probes offer invaluable 
insights into the topology of the enzyme active site and the 
catalytic mechanism of a particular enzyme or sub-class of 
enzymes. Hence they are very useful in the design of 
specific inhibitors. On the contrary, broad-spectrum probes 
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can label most proteins having the same kind(s) of activity 
and hence find more application in high-throughput activity 
based profiling of different classes of enzymes on a global 
scale. They typically are activity-, mechanism or affinity-
based chemical probes which get attached to particular 
classes of enzymes, thus allowing for the large-scale 
protease identification, characterization, as well as 
fingerprinting experiments62,63,64 Although affinity based 
probes are not strictly activity-based, their function in 
enzyme profiling is however intimately associated with the 
catalytic activity. The design template for activity-based 
probes generally comprises of a reactive unit, a linker 
unit, and a reporter unit. (Figure 1.3 below) 
 
 
Figure 1.3: General Structure of an Activity-based protein profiling probe 
 
ABPs are generally classified into two types: directed ABP 
and non-directed ABP. Fordirected ABP, the reactive group 
usually derives from a well-characterizedirreversible enzyme 
inhibitor. This mechanism-based inhibitor holds an 
electrophilewhich can selectively and covalently react with 
the active-site nucleophilic residue of a family of enzymes. 
Based on the inhibitor, it is conceptually straight forward 
todesign a directed ABP by incorporating the inhibitor 
moiety with a linker and areporter tag. This type of ABPs 
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includes fluorophosphonate probes derived fromserine 
protease inhibitor diisopropyl fluorophosphonate (DFP) for 
serine hydrolases,and epoxide probes derived from papain-
like cysteine protease (PLCP) inhibitor E-64for PLCPs65. All 
directed ABP’s haveexcellent target selectivity within a 
family of enzymes sharing cognate mechanismand function, and 
minimal interfamily cross-reactivity. For example, epoxide 
probeDCG-04 derived from E-64 only targets papain subfamily 
but not other cysteine protease subfamilies, or serine 
proteases or metalloproteases.66 Due to a limited number of 
dedicated irreversible inhibitors, directed ABPs only covera 
small fraction of the active proteomes. Many enzymes 
including proteases, esterases and phosphatases catalyze 
hydrolytic reactions by acting on the substrates through a 
nucleophilic attack mechanism. Therefore, theoretically an 
ABP carrying amoderately reactive electrophile can 
covalently react with the nucleophile of the enzymes. Carbon 
electrophiles, including those present in reactive natural 
products, become the resource of choice as reactive groups 
of non-directed ABPs. Examples are sulfonate ester probes, 
and the spiro epoxide probes derived from the bioactive 
natural compounds fumagillin and luminacin D.67 
1.7.1 Reactive unit 
 
The reactive unit can be an activity or mechanism-based 
inhibitor of one particular class of enzymes. By reacting 
with the target enzymes in an activity-dependent manner, the 
reactive unit serves as a “guiding warhead” attaching the 
whole probe to the enzyme rendering the resulting probe-
enzyme adducts easily distinguishable from other unmodified 
proteins. The chemical groups on reactive units may be fine 
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tuned to target different classes of enzymes based on their 
intrinsic activity even in the complex cellular environment. 
The reactive units used in ABPP are mostly derived from 
enzyme inhibitors. For cysteine proteases, a number of 
probes containing reactive units such as vinyl sulfones68,69,70 
epoxides 71, 72,73, α-halo or (acyloxy) methyl ketone 
substituents74, 75 have been reported. Probes with sulfonate 
esters as reactive units can target different classes of 
enzymes such as thiolases, aldehyde dehydrogenases, epoxide 
hydrolases and so on. Probes conjugated to p-hydroxymandelic 
acid specifically label protein phosphatases76,77 and 
hydroxamate based probes target metalloproteases.78 
Fluorophosphonate/fluorophosphate derivatives have been 
developed for selectively profiling serine hydrolases.79,80 
Typical reactive groups as described above are given in fig. 
1.4 below. 
 
 
Figure 1.4: Examples of reactive groups used in Activity based protein 
profiling 
1.7.2 The linker unit 
The linker unit (Fig. 1.5 below) forms a bridge between the 
reactive group and the reporter tag unit. The main purpose 
of having a linker is to minimize the binding interference 
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of the tag to the enzyme. In other words, the linker unit 
functions as a spacer of appropriate length which allows the 
reactive unit to access the active site freely without 
considerable steric hindrance from the big reporter unit. 
Different types of linkers can be used based on the polarity 
of the active site of the target enzyme. Enzymes having 
hydrophobic residues in their active site are easily 
accessed by probes with a long alkyl chain as linker. 
Similarly a PEG linker may be used when polar residues are 
present in the active site. Thus the linker can actually 
enhance reactive unit-enzyme binding. The linker can also 
convey specificity elements to target the probe for a 
particular family of enzymes. A linker may function as a 
recognition unit when it is a peptide fragment which could 
define differential specificity of the probe towards 
different enzymes of the same class. Since an alkyl chain 
does not impart this kind of specificity, it is often found 
to be useful in the design of activity based probes for 
general profiling experiments such as those targeting all 
the enzymes in the same class. The non-specific linkers are 
more commonly used in large-scale protein profiling 
experiments whereby many different enzymes in the same class 
are analyzed simultaneously. Photo-cleavable linkers have 
been reported which facilitate quantitative proteome 
analysis.81 Upon irradiation, the linker gets cleaved, 
releasing the labelled proteins, which could be easily 
isolated and purified by standard solid-phase methods. 
 
Figure 1.5: Typical linkers utilized in probes 
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1.7.3 The reporter unit 
 
The reporter unit in the probe is either a fluorescent tag 
for sensitive and quantitative detection of labelled enzymes 
or an affinity tag which facilitates further protein 
enrichment, purification and identification. The tags must 
be compatible with standard SDS-PAGE techniques which allow 
for the simplest and inexpensive methods for protein 
separation and analysis. Biotin and its derivatives are the 
most commonly used affinity tags. Biotin facilitates 
detection by simple Western blot approaches using a reporter 
avidin molecule in place of a standard antibody. After 
biotin labelling, the protein can also be isolated from the 
crude cell lysate, enriched and purified by streptavidin 
agarose beads and subsequently identified by Mass 
Spectrometry. This strategy is well suited for the isolation 
of active enzymes that are present only in low abundance. 
When compared to affinity tags, fluorescent tags and 
radioactive tags offer high sensitivity for the detection 
experiments and are also much faster. They can be visualized 
by direct scanning of gels under a fluorescent scanner or 
phosphor-imager. The commonly used fluorescent tags are 
cyanine dyes such as Cy3 and Cy5, fluorescein and rhodamine 
examples of which are given in figure 1.5 below. These tags 
have a distinct colour which makes them suitable for 
potential multi-colour labelling experiments where a mixture 
of probes with different fluorescent units can be used to 
target different classes of enzymes in the same proteome, or 
the same class of enzymes from different proteome samples. 
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Figure 1.6:Typical reporter tags used in ABPP 
 
1.7.3.1 Trifunctional Probe 
 
ABPs may have a fluorescent or affinity tag. Another 
reported option is the combination of both fluorophore and 
biotin into one reporter tag. The resulting ABP is called a 
trifunctional ABP: a reactive group for activity-based 
labeling, and a fluorophore and a biotin for simultaneous 
in-gel detection and affinity purification.82 Fluorescence 
scanning is a lot more sensitive than protein staining to 
locate and select enriched targets for MS analysis, and 
excludes co-isolated endogenously biotinylated proteins as 
background. However, trifunctional ABPs can have reduced 
probe reactivity due to a bulkier tag causing steric 
hindrance, and theseprobes are more challenging to 
synthesize. 
 
1.7.3.2 Click-chemistry probe 
 
The function of an ABP principally relies on the inhibitor 
moiety. However, thereporter tag inevitably modifies the 
structure and physicochemical features of theinhibitor, 
leading to changes in e.g. size and hydrophobicity. This may 
cause reducedcellular uptake or biased sub-cellular 
distribution of the ABP, particularly hamperingits 
application for in vivo profiling. The click-chemistry probe 
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is an untagged ABP,with a small chemical adapter for the 
attachment of a reporter tag after labeling. This “tag-free” 
ABP maximally resembles the prototype inhibitor and 
minimally affects itstarget binding, especially in vivo. 
Alkyne and azide are two such adapters. Following covalent 
labeling of protein targets, the probe is ligated to the 
reporter tag in vitro, through Cu(I)-catalyzed cycloaddition 
reaction (“click chemistry”).83 In aqueous solution of 
biological samples, either adapter molecule is inertwhile 
their coupling is quick, efficient and specific under mild 
conditions. This two-step labeling strategy also allows one 
probe to accept diverse reporter tags, andsimplifies probe 
design and synthesis. Click-chemistry ABPs facilitate 
profiling protein activities in living cells and even in 
whole animals, and have a deep impact on ABPP techniques.84 
 
 
 
1.8 Applications of ABPP 
 
Directed activity-based probes have been developed for the 
profiling of various enzyme classesincluding cysteine 
proteases, serine hydrolases, catalytic β-subunits of 
proteasome, metalloproteases, histone deacetylases, kinases 
and nucleotide-binding proteins, phosphotases, ubiquitin-
specific proteases, glycosidases and cytochrome P450s, and 
non-directed ABPs for several other enzymes classes, many of 
which are implicatedin important biological processes from 
normal metabolism to patho-physiology.85 The rapidly-
expanding ABP toolbox has been applied to both basic 
research on function and regulation of individual proteins, 
and medical research from pharmacological studies to 
clinical practices. 
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1.8.1 Applications in mammalian studies 
 
1.8.1.2 Activity-based proteomics and enzyme mechanism 
studies 
Genome-sequencing projects successfully deciphered genetic 
codes on an overwhelming scale, but unfortunately, it gives 
no information with regards to structure, function, 
regulation and interaction of proteins. Proteomics and ABPP 
promises to be the answer to the latter challenges. ABPs can 
not only be used to detect and measure activities at 
individual protein or on a proteomic scale. ABPP gives an 
activity readout of enzymes only in active forms for 
functional analysis. 86 ABPs are undoubtedly a powerful tool 
to study enzyme mechanisms,including the catalytic mode, 
substrate selectivity and molecular function.  
 
 
1.8.1.3 Comparative ABPP and biomarkers/drug targets 
discovery 
By comparing prot in activity profiles of two or more 
proteomes under normal and diseased conditions or at 
different pathological stages, comparative ABPP identifies 
proteins whose activity level differs. These differential 
activities may be caused bydifferent protein accumulation 
levels, or by a higher order of regulation, e.g. presence 
of inhibitors. Differential protein activities can serve as 
biomarkers for diagnosis and/or drug targets for treatment. 
Cravatt et al reported the profiling of 33 human specimen 
proteomes from 28 breast tumours and 5 healthy breast 
tissues using APBs and identified 7 membrane-associated 
serine hydrolases with differential activities common to 
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breast cancer samples.87 Notably, a cDNA microarray on the 
same samples provided a direct comparison of protein 
transcript and activity levels, and showed a negative 
correlation for thrombin and KIAA1363. This reveals that 
KIAA1363 is a potential breast cancer biomarker and drug 
target that would not have been recognized by molecular 
profiling methods other than ABPP. Another example is when 
profiling of the life cycle of P. falciprum, the causative 
agent of human malaria, with DCG-04 identified that a 
pathogen PLCP falcipain 1, but not falcipain 2 or 3, is up-
regulated in invasive merozoites. 88 This implies that 
falcipan-1 plays a role in host cell invasion and that it is 
an anti-malaria drug target. 
 
1.8.1.4 Competitive ABPP and inhibitor screening 
 
A competitive version of ABPP allows screening of small 
molecule libraries and evaluation of inhibitors, since most 
inhibitors compete with the ABP for the same active site of 
a target protein. In a typical experiment, the model 
proteome is pre-treated with candidate inhibitors, and then 
labeled with ABP for the remaining active, not inhibited 
target proteins. Inhibitory efficacy is indirectly 
interpreted by the decrease in ABP labelling compared to 
inhibitor-untreated control, and is usually quantified and 
clustered into a heat-map for assessment. Screening of 
reversible inhibitors requires kinetically controlled 
conditions, because the end-point readout of ABPP is 
determined by both the affinity of the inhibitor and the 
rate of the probe reactivity. For this reason, labelling 
time must be optimized and restricted to the period before 
labelling with ABP reaches saturation.89 
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Competitive ABPP facilitates the selection of potent and 
specific inhibitors of known drug targets to generate novel 
drugs, and for proteins with unknown function to carry 
out chemical knockout assays. It offers several advantages 
over conventional substrate-based inhibitor screening. 
First, it takes place directly in physiologically relevant 
complex proteomes with no requisite for purified recombinant 
target protein. Second, it is “substrate-free”, which makes 
the inhibitor selection for the target protein with unknown 
substrates possible. Third, the candidate inhibitors are 
examined against not only the target protein, but also many 
other family members with similar enzymatic mechanism, 
therefore, the selectivity of the inhibitors is evaluated 
simultaneously.90 
  
1.9 Research objective 
One of the major advantages of the ABPP method is that it 
allows the selective detecti n of targeted proteins from a 
group of unknown proteins spotted as arrays when incubated 
with potential ligands. Thus the whole process of separating 
and identifying proteins in a complex mixture can be 
simplified, by focusing on specific targeted proteins. 
Several types of probes have been reported that target 
different classes of proteins on the basis of their 
enzymatic activities.91,92,93, 94 
 
The objective of this part of the project is to introduce 
ABPs in hypertension research by designing probes that can 
successfully bind and robustly label ACE as well as  
synthesise new probes for future use in malaria research. As 
an example, a summary of the rationale for the target 
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structure of the probes in the malaria model is given in 
figure 1.7 below. 
 
 
 
Figure 1.7: General structure of the target probes. 
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Chapter 2 
Rationale and Design of Activity Based Probes 
2.1 Introduction 
 
This chapter illustrates efforts towards the design of 
hydroxamate, carboxylate and sufhydryl based probes to 
potentially target the metalloproteases involved in 
hypertension and malaria such as Angiotensin Converting 
Enzyme (ACE) and P. faliciparum A – M1(PfA-M1). 
2.2 Affinity tag approach to develop a metalloprotease 
probe for an in vitro proteomic experiment in 
Hypertension and Malaria 
 
As described in detail in Chapter 1 a number of methods 
have been developed for identification of new 
metalloproteases and their interacting proteins (e.g. 
metalloprotease substrates)1,2,3 including cDNA pool 
expression strategies, two-hybrid approaches and two-
dimensional gel electrophoresis (2D-GE), just to name a 
few. Among them, the 2-D approach, in which global 
proteomic profiles of normal and diseased cells were 
compared, often generates a few hundreds of candidate 
protein spots, the majority of which are proteins unrelated 
to disease. This thus makes it difficult, as well as 
impractical, to be used in large-scale studies of proteins 
interacting/associating with proteases during the diseased 
state. Already researchers are developing new methods to 
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simplify protein analysis and allow high-throughput 
screenings. The activity-based protein profiling tag 
approach can potentially filter out proteins that are not 
of interest and focus on certain classes of proteins (e.g. 
based on activity)4, 5, 6, 7, 8 while protein chips and 
microarrays offer the attractive prospect of screening 
thousands of proteins simultaneously.9, 10 Unknown proteins 
could be spotted on arrays and incubated with potential 
ligands, which bind and allow the detection of the target 
proteins. The whole process of separating and identifying 
proteins in a complex mixture hence may be simplified, by 
zooming in only onto specific target proteins. Our 
metalloprotease probes are intended and hypothesized to 
selectively target all zinc metalloproteases in a single 
proteomic experiment for the targeted hypertension and 
malaria disease models.  
2.3 Design of Malaria ABPP probes for use in malaria 
disease model 
Generally, as described in Chapter 1, our probe is made up 
of four parts. Firstly, it has a hydroxamate, carboxylate 
or sulfhydril reactive group, secondly a simple 
polyethylene glycol linker as spacer, thirdly a 
benzophenone photocrosslinker and finally a fluorescent tag 
for easy visualization and purification of target proteins. 
 
2.3.1 Reactive group 
 
Gluzincins such as ACE and Aminopeptidases are potentially 
highly interesting targets for therapeutic intervention.11, 
12
 Successful production of synthetic inhibitors with 
therapeutic value has been achieved, especially in the 
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field of cardiovascular disease with several inhibitors and 
chemical entities currently on the market. However, many of 
these, especially inhibitors of ACE have been associated 
with undesirable side-effects due to their lack of domain 
selectivity.13, 14, 15, 16 Most ACE inhibitors synthesized to 
date are based on a Zn2+-chelating group fitted onto a 
peptide-like backbone mimicking the endogenous protein 
substrate of the protease. Following the Schechter and 
Berger nomenclature17 three distinct inhibitor types can be 
distinguished: inhibitors with a peptide sequence N-
terminal (P1-P2) or C-terminal (P1’-P2’) of the scissile 
peptide bond (i.e. the Zn2+ ion in the catalytic site) and 
compounds with a zinc binding group (ZBG) located in the 
middle of the inhibitor with a backbone protruding on 
either side.  
 
Several functionalities such as carboxylic acid 
derivatives, thiol groups, phosphinates, ketones can be 
used as effective ZBGs but the most effective ZBG for 
producing high-affinity inhibitors has been the hydroxamate 
moiety. The latter have been found immensely suitable in 
elucidating the binding requirements and chemically 
reactive residues of the active sites of zinc 
metalloproteases and are a popular approach as zinc 
chelators.18 However, their failure in clinical trials has 
been, among other reasons, their lack of selectivity. This 
failure has been mainly due to the strong bidentate 
zinc(II)- binding capacity of hydroxamic acid group (Figure 
2.1). This strong ligation of the Zn2+ ion, which is the 
main determinant of the overall binding energy,19 
effectively replaces the water molecule and inhibits the 
catalytic mechanism. However, it suppresses the overall 
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effect of weaker but more specific non-covalent 
interactions of the inhibitor backbone with the substrate 
specific regions of enzymes18, 20 and as a result has led only 
to the development of a large number of highly efficient 
but broad spectrum zinc metalloproteases inhibitors with 
low nanomolar affinity.21   
 
Figure 2.1: Bidentate binding of hydroxamates with zinc 
metalloproteases. 
 
It is this lack of selectivity that has been exploited in 
the design of the probe reactive group structure. 
Hydroxamates as a class have been reported to inhibit PfA-
M1 a zinc aminopeptidase found in the malaria parasite 
Plasmodium falciparum22 as well as exhibit in vitro 
schizontocidal activity.23  They are also reported as 
inhibitors of ACE in hypertension.24 There also exists a 
plethora of literature on their success in closely related 
matrix-metalloproteases.25 Generally, therefore, their 
promiscuity  renders them as an optimal binding scaffold 
which accommodates a broad range of active-site structures 
found in metalloproteases and were thus proposed as the 
zinc-chelator or “war head” in this research. 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Chapter 2: Rationale and Design of Activity Based Probes  
 
 
46 
2.3.2 Polyethylene Glycol (PEG) Linker 
PEGylation is a procedure of growing interest for enhancing 
the therapeutic and biotechnological potential of peptides 
and non-peptides.26 When a PEG is properly linked to a 
polypeptide, it modifies many of its features while the 
main biological functions, such as enzymatic activity or 
receptor recognition, may be maintained. The potential of 
the conjugation of PEG’s to proteins emerged in the 
1970’s.27 PEGylation produces alterations in the 
physiochemical properties including changes in 
conformation, electrostatic binding and hydrophobicity 
improving solubility. Several authors have reviewed 
different aspects of PEGylation with emphasis on the 
polypeptide and protein conjugation and also on the 
modification of peptides and non-peptide moieties.28, 29, 30, 
31,
 
32,
 
33,
 
34
 
 
The use of this PEG linker was proposed due to its 
hydrophilicity which would potentially minimize non-
specific interactions that can arise from the spacer group 
becoming buried in the hydrophobic pocket of proteins. 
Secondly, this spacer restricts hindrance between the 
peptide and reporter group, hence better avidin-biotin 
binding during affinity purification. The PEGylation 
process would involve the preparation of suitable homo-
bifunctionalization of the polymer at the terminals. 
 
Figure 2.2: Homo-bifunctional linker for PEGylation to probe 
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2.3.3 Benzophenone Photocrosslinker 
Taking into account the fact that in the catalytic 
mechanism of metalloproteases the nucleophile is not part 
of the protein itself but rather an active-site bound water 
molecule, the development of covalent inhibitor probes for 
these enzymes has to rely on a different principle. 
Described probes for MMPs35, 36 and for ADAM proteases37 all 
rely on inhibitor probes that have an interaction with the 
catalytic zinc ion (usually a hydroxamate zinc-chelating 
group) combined with a reactive photo-crosslinking group 
that forms a covalent bond with the enzyme after uv 
irradiation. Given that the active site is located at least 
32 Å deep inside the protein, a probe with sufficient 
length spanning the active site and outside regions of the 
protein is ideal to ensure the photocrosslinker and biotin 
remain on the outside for photocrosslinking, visualization 
and affinity purification. 
 
2.3.4 Reporter Group 
Biotin 2.3a (Fig. 2.3) is an entity utilized in cell 
growth, fatty acid production, fat and amino acid 
metabolism as well as participates in the citric acid 
cycle. It is also important in the maintenance of steady 
blood sugar levels as well as a co-factor responsible for 
carbon dioxide transfer in several carboxylase enzymes.38 
The attachment of biotin to various chemical sites, a 
process called biotinylation, is used as an important 
laboratory technique to study various processes including 
protein localization, protein interactions, DNA 
transcription and replication. Biotin binds very tightly to 
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the tetrameric protein avidin, streptavidin and 
neutravidin.39, 40 Biotin may be covalently linked, or tagged, 
to a molecule for biochemical assays in biotinylation. 
Since avidins bind preferentially to biotin, biotin-tagged 
molecules can be extracted from a sample by mixing them 
with beads with covalently-attached avidin, and washing 
away anything unbound to the beads. 
Biotin was thus the choice for the activity based probes in 
this research to allow for future avidin-based purification 
of target structures. The method would enable the 
enrichment and purification of labelled proteins by 
affinity capture with streptavidin beads. This biotin-
streptavidin interaction can be broken using various 
methodologies, freeing the biotinylated structure for 
further analytical purposes.41  
 
Figure 2.3: Structure of Biotin 
 
2.4 Methodological prospects 
 
The analytical use of small molecule inhibitors of 
metalloproteases has the potential to greatly improve our 
understanding of the roles of these proteases in malaria 
and hypertension disease conditions. By employing this 
functional proteomics technique described schematically in 
steps 1 to 6 (figures 2.5 to 2.10) below, the analysis may 
move from correlating the well known and well-described ACE 
and aminopeptidases in disease towards profiling of all 
active metalloproteases. This may lead to new insights, and 
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potentially to new targets for pharmaceutical intervention 
and the opportunity for a better follow-up of therapy. On 
the other hand, this methodology may also be used to 
identify unknown protein targets that interact with newly 
developed as well as existing inhibitors thus allowing 
better optimization of inhibitors prior to entering 
clinical trials. 
 
 
Figure 2. 4: Step 1. Selection of a suitable available inhibitor, or 
synthesis of novel inhibitors 
 
 
Figure 2. 5: Step 2. Screening of the inhibitory profile using a 
relevant metalloproteases 
 
 
Figure 2.6:  Step 3. Selection of best-suited inhibitor for profiling. 
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Figure 2.7: Step 4. Conversion of inhibitor into suitable structure for 
future activity-based proteomics via synthesis of activity-based probe 
by introducing spacer, photo-crosslinker and a reporter molecule 
 
 
     
 
Figure 2. 8: Step 5. In-vitro testing of newly synthesized probes for 
activity-based proteomics with proteases by labelling of samples of 
interest with the activity based probe and visualisation of active 
metalloproteases after gel electrophoresis 
 
 
Figure 2.9: Step 6. Isolation and enrichment of active proteases from 
biological samples by enrichment of photo-labelled proteins with 
immobilized streptavidin. This is then followed by a tryptic digestion 
of enriched proteins and mass spectrometric identification. 
 
Similar methodology have been reported by several authors 
and applied extensively in MMPs which are related to Zinc 
metalloproteases. However, this thesis describes that 
synthesis of novel probes with PEG linkers which have 
incorporated the use of a benzophenone photocrosslinker. 
This is the first time that such probes targeting future 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Chapter 2: Rationale and Design of Activity Based Probes  
 
 
51 
analysis of protease activity in the malaria and 
hypertension disease models specifically targeting ACE and 
PfA-M1 have been synthesized. It is also the first time 
that the known ACE inhibitors namely suflhydril captopril 
as well as the carboxylate enalaprilat have been employed 
as reactive groups in such probes. Successful binding of 
the probe molecule would lead to insight into the 
interaction of these known inhibitors with other active 
enzymes in proteomes. From the X-ray crystal structure, the 
active-site of ACE is known to be located 32Å deep inside 
the 32kda enzyme.42 Application of the PEG8 probe which is 
sufficiently long is expected to access this active-site. 
However, we envisaged and hypothesized that if the shorter 
PEG3 probes were able to access the active-site and label 
active ACE, we would be able to have further insight into 
the conformation and positioning of the active-site when 
ACE is in action. 
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Chapter 3 
3.0 Introduction to Chemical synthesis 
Chapter two described the design of the probes to be employed 
in future for both the hypertension and malaria disease 
models. Furthermore, it described the rationale behind the 
synthesis of such probes. It also looked briefly at the 
methodological prospects to be employed in the application of 
these probes. Chapter 3 will give a retro-synthetic strategy 
followed by a detailed synthetic discussion which culminated 
into the synthesis of the targeted probes with general 
structure 3.1a below(Figure 3.1).  
 
Figure 3.1: Probes general structure 
3.1 Retrosynthetic strategy 
3.2.1 Overall restrosynthetic strategy 
To determine the best possible synthetic route to the targeted 
probes, a retrosynthetic strategy was conducted. 
Retrosynthesis involves working backwards from the target 
molecule in order to devise a suitable synthetic route. In the 
case of the present study, the retrosynthetic analysis 
revealed that a convergent route, involving several basic 
‘building blocks’ joined together relatively late on in the 
synthesis to give the final product was the best strategy.  
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C-N peptide bond disconnection of the designed probe general 
structure 3.1a leads to four sub-units.(Scheme 3.1 below) The 
four adducts being the o-benzyl protected reactive group, the 
PEG spacer,(S)-2-amino-3-(4-benzoylphenyl)propanoic acid 
(Benzophenone) photo-crosslinker and 5-((3aS,4S,6aR)-2-
oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanoic acid 
(biotin) tag identified as 1, 2, 3 and 4 respectively. Sub-
units 3 and 4 are commercially available whereas 1 and 2 had 
to be synthesized. 
 
Scheme 3.1:Retrosynthetic strategy for the complete probe showing sub-units 
1,2, 3, and4. 
3.2.2 Retrosynthesis of the reactive group 
The O-benzyl protected reactive group 1(scheme 3.1) is a 
succinic acid derivative. The stereochemistry at the 
steroegenic centre could be either the S- or R- and resolution 
was thus not important. Succinate hydroxamates have been 
reported to have been synthesized utilizing several strategies 
including malonate esters as starting material.1 
Retrosynthetically, we envisaged an initial functional group 
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interconversion of the carboxylate 3.2a to the ester 
3.2b.(Scheme 3.2)A C-N disconnection at the benzyl protected 
hydroxamateof 3.2b would give the carboxylic acid 3.2c which 
can be prepared from 3.2d by a functional group 
interconversion (FGI).Intermediate 3.2d itself may easily be 
formed from carboxylic intermediate 3.2e. The latter is a 
product of 1,3-dicarboxylic acid 3.2f. 3.2g is a dialkylated 
derivative of 2,2-dimethyl-1,3-dioxane-4,6-dione 3.2i commonly 
known as Meldrum’s acid and this was chosen as the starting 
material. 
 
Scheme 3.2: Retrosynthetic strategy for the reactive group. 
3.2.3 Synthetic Strategy 
3.2.3.1 Introduction 
Synthesis started with 2,2-dimethyl-1,3-dioxane-4,6-dione3.2i 
(Meldrum’s Acid). The latter is an active methylene compound 
with a rigid cyclic structure, high acidity (pKa  = 4.9) and 
can undergo hydrolysis very easily.2 It is well known that 
Meldrum’s acid can undergo Knoevenagel condensation.3, 4Reports 
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on alkylation studies reveal that unlike dialkyl malonates it 
has a strong tendency to undergo bis-alkylation even with one 
mole equivalent of alkyl halide5 and only in exceptional cases  
does mono-alkylation result.6,7 The interest in the synthesis 
of monoalkylated Meldrum’s acid as well as mixed dialkylated 
Meldrum’s acid continues to evolve due to their use in the 
synthesis of dialkylated malonates as well as barbiturates. 
The difficulties in preparing dialkylated Meldrum’s acid 
wherein the two alkyl substituents are different can be 
overcome by alkylation of mono-alkylated Meldrum’s acid, which 
in turn can be prepared by several described methods. Firstly, 
they may be prepared by a Knoevenagel condensation of 
Meldrum’s acid with carbonyl compounds to ylidene Meldrum’s 
acid followed by conjugate reduction with sodium borohydride8 
or sodium tellurohydride9 or by cuprous chloride catalyzed 
conjugate Grignard addition to ylidene Meldrum’s acid.10 The 
second reported option is by condensation of Meldrum’s acid 
with aromatic aldehydes in the presence of formic acid and 
triethylamine,11or thirdly by the reduction of acylated 
Meldrum’s acid with sodium cyanoborohydride.12A fourth option 
is the reductive alkylation of Meldrum’s acid with carbonyl 
compounds using boranetriethylamine.13 
All these methods, however, require a multi-step reaction 
sequence to be carried out. Therefore a simple, one pot method 
for the preparation of monoalkylated as well as mixed 
dialkylated Meldrum’s acids was preferred.14 It involved the 
Knoevenagel condensation of Meldrum’s acid with various 
aldehydes utilizing K3PO4 as a catalytic base. 
3.2.3.2 Preparation of the Mono-alkylated Meldrum’s acid 
The reaction sequence depicted in scheme 3.3 below was carried 
out in ethanol medium by K3PO4 as base catalyst giving the 
various Knoevenagel condensation products in situ. This 
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specific solvent-base combination not only effected 
Knoevenagel condensation of Meldrum’s acid 3.2i with aromatic 
and some aliphatic aldehydes to give arylidene Meldrum’s acids 
3.3a, but also permited the reduction of 3.3a with NaBH4 in the 
same pot to furnish monoalkylated Meldrum’s acid derivatives 
3.3b. The sequence of reactions was carried out at room 
temperature and were monitored easily by TLC.   
 
Compound 3.3b-3 3.3b-4 3.3b-5 3.3b-6 
R – Group CH2CH(CH3)2 CH2Cyclohexyl CH2Ph CH2Naphthyl 
Yield 88 79 91 90 
Scheme 3.3: Reagents and conditons. (i) RCHO, K3PO4EtOH, RT, 4 h (ii) NaBH4 , 
3 h. 
Mechanistically, the Knoevenagel condensation proceeds via the 
enolate ion generated by the catalytic base. K3PO4 is a strong 
enough base to form a significant concentration from the 1,3-
dicarbonyl compound 3.2i but not strong enough to form the 
enolate from the aldehyde. The formation of the enolate 3.4a 
in scheme 3.4 below can be from either tautomer of 3.2i. The 
enolate ion 3.4a attacks the electrophilic carbonyl of the 
aldehyde and the resulting intermediate 3.4b captures the 
initially abstracted proton which is in the reaction mixture 
resulting in the aldol 3.4c. However, there is still one 
acidic proton between the two carbonyl groups in 3.4c so 
enolate anion formation is again easy and dehydration of 3.4d 
follows to give the unsaturated product 3.3a. It is at this 
point that 1,4-conjugate reduction of the unsaturated 
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alkylidene product 3.3ais conveniently achieved with NaBH4, 
resulting in 3.4e. Acidification with dilute HCl then gives 
way to the mono-substituted Meldrum’s acid 3.3b. 
O O
OO
H
O O
OO
H R
O
O O
OO
RO
H
O O
OO
RHO
H
-H
O O
OO
RHO
O O
OO
RH
+ H
O O
OO
R
3.2i 3.4a 3.4b
3.3a 3.4d
3.4c
B B
O O
OO
R
3.4e3.3b
 
Scheme 3.4: Mechanism of Knoevenagel condensation and conjugate reduction. 
A section of the typical 1H NMR of the monosubstituted 
Meldrum’s acid, namely 5-benzyl-2,2-dimethyl-1,3-dioxane-4,6-
dione 3.3b-5. (Fig. 3.2,Phenyl region not shown) 
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Figure 3.2: A section of a typical 1H NMR of mono-substituted Meldrum’s acid 
3.3b-5 in CDCl3. 
From the foregoing, a singlet was observed in the region ~1.65 
ppm integrating for six C-1 and C-3 protons. Secondly, the C-5 
protons were each revealed as doublet around 3.35 ppm and 
finally the C-4 proton came as a triplet at ~3.95 ppm.  
3.2.3.3 Preparation of the disubstituted Meldrum’s acid 
The desired unsymmetrical 5-benzyl-5-substituted Meldrum’s 
acids 3.5a were prepared in one-step by reacting the mono-
substituted Meldrum’s acid 3.3b with 2 equivalents of allyl 
bromide using K2CO3 in DMF. (Scheme 3.5)
O O
O O
R
O O
O OR(i)
3.5a3.2i
OH OH
O OR(ii)
3.5b  
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Compound 3.5a-3 3.5a-4 3.5a-5 3.5a-6 
R – Group CH2CH(CH3)2 CH2Cyclohexyl CH2Ph CH2Naphthyl 
Yield 88 80 75 90 
Scheme 3.5: Reagents and Conditions (i) Allyl Bromide, K2CO3, DMF, 0 ºC - 
rt., overnight (ii) 4M NaOH, 1,4-Dioxane (1:1) reflux 100°C,5 h. 
Mechanistic details of the di-substitution reaction are shown 
in scheme 3.6.It proceeds via a typical SN2 reaction mechanism. 
Allyl compounds react rapidly by this mechanism because the 
double bond can stabilize the transition state 3.6b by 
conjugation with the allylic pi-bond.  
 
O O
OO
HR
B
O O
OO
R
Br
O O
OO
R
O O
OO
R
Br
H
H
Transition state 3.6b
3.2i 3.5a3.6a
 
Scheme 3.6: Mechanism of SN2 reaction with allyl bromide. 
The quaternized Meldrum’s acid derivatives 3.5a were easily 
isolated in an analytically pure form by extraction and 
further purified by recrystallization from MeOH. Substrate 
isolation was facilitated by the exceptional crystallinity of 
Meldrum’s acid derivatives. A typical 1H NMR for this 
disubstituted structure, 5-allyl-5-benzyl-2,2-dimethyl-1,3-
dioxane-4,6-dione 3.5a-5.  (Fig. 3.3) 
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Figure 3.3: Section of typical 1H NMR of 5-allyl-5-benzyl-2,2-dimethyl-1,3-
dioxane-4,6-dione 3.5a-5. 
Amongst this group of intermediates, the common diagnostic 
features in the 1H NMR were the appearance of the 
characteristic vinylic proton signals downfield doublet of 
doublets at ~4.95 ppm and a multiplet at ~5.50 ppm integrating 
for the two C-5 protons and one C-4 proton respectively. The 
H-3 protons typically came as a doublet around ~2.55 ppm. 
3.2.3.4 Preparation of the benzyl protected hydroxamates 
Hydrolysis of the acetonide ring of 3.5a was achieved by 
treatment with sodium hydroxide in H2O:1,4-dioxane 
(1:1)affording diacid 3.5b (Scheme 3.5) in yields as per table 
3.1. 
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Compound 3.5b-3 3.5b-4 3.5b-5 3.5b-6 
R – Group CH2CH(CH3)2 CH2Cyclohexyl CH2Ph CH2Naphthyl 
Yield 77 70 88 80 
Table 3.1: Yields for compound series 3.b. 
Subsequent thermal decarboxylation in DMSO resulted in 3.7a 
and condensation with methanol in the presence of SOCl2 
afforded the ester 3.7b (Scheme 3.7). Ruthenium catalyzed 
oxidation of the terminal olefin gave the scission product 
carboxylic acid 3.7c. RuO4 was generated by vigorously stirring 
the required (stoichiometric) amount of RuO2.2H20 and a 6 molar 
excess of NaIO4 in the tri-phasic system CH3CN-CCl4-H20 (2:1:1) 
and the organic layer added portion-wise to the olefin 3.7b 
dissolved in CCl4. 
Peptide coupling of the resultant carboxylic acid 3.7c with 
commercially available benzyl hydroxylamine was achieved using 
molar equivalents of commercially available N-(3-
dimethylamonipropyl)-N’-ethylcarbodiimide hydrochloride salt 
(EDC-HCl) in the presence of 1-hydroxybenzotriazole (1-HOBt) 
and iPr2NEt in DMF. The mixture was stirred at room temperature 
for 18h giving the fully protected precursor 3.2b. Alkaline 
hydrolysis of the methoxy-ester isolated products yielded the 
desired benzyl protected succinic acid based reactive group 
compound series 3.2a-1 to 3.2a-6. 
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Scheme 3.7: Reagents and conditions. (i) DMSO, 130 °C, 3 h, (40 – 65%) (ii) 
SOCl2, MeOH, 0 °C - rt, 3 h, quant. (iii) RuO2(cat.), NaIO4, Acetonitrile-
CCl4-water (2:1:1), rt, 48 h (45 – 65%);  (iv) BnONH2-HCl, EDC-HCl, DIEA, 
HOBt, DMF, RT, 18 h (60 – 84%). 
Compound 3.2a-1 3.2a-2 3.2a-3 3.2a-4 3.2a-5 3.2a-6 
R – Group H CH3 CH2CH(CH3)2 CH2Cyclohexyl CH2Ph CH2Naphthyl 
Yield 90 70 70 72 75 84 
 
3.2.3.5 Mechanistic details of decarboxylation 
Decarboxylation is an elimination type reaction resulting in 
the loss of a carbon dioxide molecule. Simple carboxylic acids 
rarely undergo decarboxylation. However, carboxylic acids with 
a carbonyl group at the 3- (or β-) position readily undergo 
thermal decarboxylation and a typical example are the 
derivatives of malonic acid. Structure 3.5b is a malonic acid 
derivative. The reaction proceeds via a cyclic transition 
state. The mechanism begins with the protonation of the 
carbonyl, followed by breaking of the O-H bond then formation 
of the pi-bond as the carbon-carbon bond breaks all in a 
rearrangement of six electrons in a cyclic six-membered 
transition state 3.8a(scheme 3.8). Tautomerisation of the enol 
3.8b leads to the carboxylic acid product 3.8c (2-benzylpent-
4-enoic acid 3.7a-5 1HNMR given in Fig.3.4). 
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Scheme 3.8: Mechanism of thermal decarboxylation of the malonic acid 
derivatives. 
 
 
Figure  3.4: A section of 1H NMR of 2-benzylpent-4-enoic acid 3.7a-5in 
CDCl3(phenyl region not shown). 
3.2.3.6 Mechanism of methoxyester protection 
The carboxylate group with general structure 3.9a (Scheme 3.9) 
is the effective nucleophile. A substitution onto SOCl2 takes 
place in a similar fashion as nucleophilic acyl substitution, 
with the loss of a chloride anion as a good leaving group 
resulting in transition intermediate 3.9b. This is then 
CO2H1
2
3
4
5H-2 H-1 H-4 H-3a/b H-5a/b
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followed by the loss of a second chloride as well as 
abstraction of a proton by the first chloride leading to 
formation of HCl. The second chloride then serves as the 
nucleophile in the nucleophilic acyl substitution of 3.9c. The 
next step 3.9d driven primarily by the loss of sulfur dioxide 
then gives rise to a very reactive acid chloride intermediate 
3.9e that is sufficiently electrophilic to be attacked by the 
methanol oxygen lone pair to ultimately form the desired 
methyl ester 3.9g after the departure of HCl in 3.9f.  
R
O
Cl
HOMe
R
O
Cl-
R
O
OMe
H
O
3.9a 3.9c
3.9e 3.9f 3.9g
R OH
O Cl S Cl
O
R O S Cl
O
H
O Cl
R O S Cl
O O
Cl
Cl
R O S Cl
O O
Cl
3.9b 3.9d
HCl
HCl
Cl
 
Scheme 3.9: Mechanism for methoxy-protection of the carboxylic group 
3.2.3.7 Ruthenium tetraoxide catalyzed cleavage mechanism 
 
Ruthenium tetroxide is a powerful oxidizing agent classically 
used for oxidative C–C-bond cleavage.15,16 It is a diamagnetic 
tetrahedral ruthenium compound. It may be generated from 
RuCl3·xH2O or RuO2 as pre-catalyst with NaIO4. A plausible 
mechanistic cycle for the cleavage of alkenes with ruthenium 
dioxide and sodium periodate17 is given in scheme 3.10. The 
pre-catalyst RuO2.xH2O is converted into the catalytically 
active RuO4 3.10a in situ. Subsequently, the tetraoxide 
converts the alkene 3.10b into a vicinal diol 3.10c, which is 
oxidatively cleaved by periodate into an aldehyde 3.10d with 
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the release of carbon dioxide. The aldehyde is subsequently 
oxidized with RuO4 to afford the desired carboxylic acid 3.10e. 
Ruthenium(VI) species that are produced during the oxidations, 
are oxidized back to RuO4 through periodate. 
 
Scheme 3.10: Proposed mechanism for the Ruthenium tetra-oxide catalyzed 
cleavage of terminal alkenes.18 
A typical 1H NMR of the hemi-succinate product 3.10e-5 is given 
below (Fig. 3.5). 
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Figure 3.5: A section of 1H NMR of hemisuccinate3.10e-5the RuO4 catalyzed 
scission product in CDCl3. (Phenyl region not shown). 
All the 1HNMR spectra of these intermediates displayed common 
diagnostic features. The most notable features, compared to 
the spectrum for the precursor showing successful cleavage of 
the terminal alkene and formation of 3.10e-5 included the 
disappearance of the signals for the vinylic protons in the 
1HNMR. This was corroborated by the loss of one carbon peak in 
the 13C NMR spectra and the appearance of a second carboxylic 
acid peak at ~177.8ppm. 
3.2.3.8 Mechanistic details of the peptide crosslinking 
In the peptide cross-coupling mechanism, a lone electron pair 
from a nitrogen of the zero crosslinker EDC (scheme 3.11) 
abstracts the most acidic proton from the substrate 3.11a 
forming the carboxylate anion 3.11b. Subsequent attack by this 
anion on the sp carbon of the protonated EDC species results 
in the formation of an O-acylisourea intermediate 3.11c. The 
latter rapidly undergoes a nucleophilic acyl substitution 
reaction releasing the urea by-product which is water soluble 
HO2C * CO2CH31 2
3
4
H-3 H-2 H-4a H-4b H-1
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and ends up in the aqueous layer during workup, resulting in 
3.11d. HOBt is an auxiliary which enhances the reaction. It is 
a strong nucleophile owing to the destabilizing effect of the 
nitrogen lone pair electrons on the negatively charged oxygen. 
This results in a very fast substitution reaction which 
reduces the concentration of O-acylisourea, and ultimately the 
extent to which racemisation can occur. The short lifespan of 
the activated O-acylisourea intermediate reduces the 
occurrence of O- to N-acyl migration leading to N-acyl ureas. 
HOBt’s weakly acidic character prevents racemisation. A 
nucleophilic acyl substitution couples the benzyl 
hydroxylamine to the carboxylic acid moiety resulting in an 
amide bond formation and product 3.2b via intermediate 3.11e 
and regeneration of the auxiliary HOBt (scheme 3.11). 
 
Scheme 3.11: Mechanism of the peptide coupling reaction. 
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Fig. 3.6 below shows the typical 1H NMR of 2-benzyl-4-
((benzyloxy)amino)-4-oxobutanoic acid 3.2a-5 below which is 
representative of the protected reactive group series of 
compounds. 
 
Figure  3.6: A section of a typical 1HNMR of 2-benzyl-4-((benzyloxy)amino)-4-
oxobutanoic acid 3.2a-5. 
Key diagnostic features for this spectrum were the doublet for 
C-2 proton pair at ~2.20 ppm and another in the region of 2.7 
ppm, the pair of C-4 proton doublet of doublets at ~3.1 ppm 
and ~3.2 ppm respectively followed by a multiplet for C-3 
protons at ~3.3ppm. The C-1 diastereotopic methylene proton 
pair were revealed as a singlet around ~4.8 ppm.  
3.2.3.9 Preparation of the Succinate derivatives from 
anhydrides 
Several methods have been reported for the preparation of 
monoalkylidene derivatives 3.3a (scheme 3.3) of Meldrum's acid 
3.2i by reaction with aldehydes. The method of Cope19 and that 
Ph-H
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was used in this research gives fair-to-good yields with 
aromatic or hindered aliphatic aldehydes. However, with 
straight-chain aliphatic aldehydes, it is reported to give 
polymers. The major disadvantage of this normal base- or 
Lewis-acid catalysed20 Knoevenagel condensation is that the 
rate of Michael addition of 3.2i to the product 3.12a is, 
unfortunately, often comparable to the rate of formation of 
3.3a itself, leading to extensive formation of the double 
condensation product such as 5,5'-methylenebis(6-hydroxy-2,2-
dimethyl-4H-1,3-dioxin-4-one) 3.12b (scheme 3.12 below). 
O
O
HO
O
O
O
OH
O
3.12b
O O
OO
HCHO
3.2i
O O
OO
3.12a
O O
OO
3.2i
 
Scheme 3.12: Scheme depicting formation of 5,5'-methylenebis(6-hydroxy-2,2-
dimethyl-4H-1,3-dioxin-4-one) 
To circumvent the problem of formation of the undesired 
polymer, a procedure employed by Gullotti et al21 for the 
preparation of the glycine and alanine succinic acid 
derivatives 3.2a-1 and 3.2a-2 was utilized. This involved a 
simple alcoholysis of succinic anhydride 3.13a with an 
equimolar amount of methanol. However, in the case of the 2-
methyl succinate, as expected, the reaction proceeded with low 
regioselectivity and resulted in two products namely the 
desired 3.13b and 3.13c (35:65% respectively). These two 
products were easily isolated on silica gel with 20% EtOAc in 
hexane (rf 0.3 and 0.35). The desired regeoisomer 3.13b was 
the minor product due to steric crowding around the carbonyl 
carbon adjacent to the methyl group restricting nucleophilic 
attack. The relative percentages of the regioisomer found were 
in agreement with the literature.22 The usual coupling and 
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deprotection procedures were then employed resulting in 3.2b 
and 3.2a respectively. 
 
Scheme 3.13: Reagents and Conditions. (i) MeOH, Reflux 
110 ºC, 5 h, (quant.) (ii) BnONH2-HCl, EDC-HCl, 
DIEA, HOBt, DMF, RT, 18 h (60 – 90%). 
 
The mechanism for the ring opening reaction of the anhydrides 
enroute to the succinyl derivatives is shown in scheme 3.14 
below. The RCOO- moiety is not a very good leaving group (pka  
= about 5) and does not leave on its own and thus a second-
order mechanism applies. Under these circumstances the 
kinetics are bimolecular (rate = k[(RCO)2O][MeOH]) and the rate 
determining step is formation of a tetrahedral intermediate. 
The methanol oxygen lone pair attacks either one of the 
electrophilic carbonyls of 3.14a resulting in 3.14b. A 
subsequent proton transfer leads to unstable tetrahedral 
intermediate 3.14c. The oxygen lone pair of the latter then 
attacks leading to ring opening giving way to the alkoxide 
species 3.14c. Finally, a proton transfer leads to the 
formation of product 4-methoxy-3-methyl-4-oxobutanoic acid 
3.14d.( 1HNMR in Fig 3.7) 
Compound 3.2a-1 3.2a-2 
R – Group H CH3 
Yield 90 60 
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Scheme 3.14: Mechanism for the ring opening for the anhydride 3-
methyldihydrofuran-2,5-dione 3.14a. 
 
Figure 3.7: A section of a typical 1H NMR in CDCl3 of synthesized compound 
product 4-methoxy-3-methyl-4-oxobutanoic acid 3.13b-1. 
3.2.4 Preparation of hydroxamate reactive groups for screening 
with ACE 
Before attempting the synthesis of probes for the hypertension 
model where ACE is one of the target enzymes, and according to 
our methodological prospects (Chapter 2) biological assays 
MeO2C
*
CO2H
23
4
5
H-5 H-3/2 H-2a H-4
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were performed with the reactive group series 3.15-1 to 3.15-
2(Scheme 3.15). 
 
Scheme 3.15: General structure of reactive group with unmasked hydroxamate. 
This series were prepared by deprotection of the precursor 
series 3.2a by hydrogenolysis in EtOH/Pd-C after conversion to 
the respective HCl salt. The general scheme is given in 3.16 
below and a representative 1H NMR of 2-benzyl-4-(hydroxyamino)-
4-oxobutanoic acid 3.16f is given in figure 3.8. 
 
Compound 3.16b 3.16c 3.16d 3.16e 3.16f 3.16g 
R – Group H CH3 CH2CH(CH3)2 CH2Cyclohexyl CH2Ph CH2Naphthyl 
Yield 55 60 58 60 41 60 
Scheme 3.16:Preparation of hydroxamate reactive groups for 
biological assays. Reagents and conditions.: (i) NaOH, H2O (ii) 
HCl(aq) (iii) H2/Pd-C, MeOH, rt, 3atm. 
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Figure 3.8:A section of the typical 1HNMR of the free reactive group2-benzyl-4-
(hydroxyamino)-4-oxobutanoic acid 3.16f in CDCl3. 
Mechanistically, the hydrogenolysis is believed to involve the 
cleavage of a C-O bond by addition of hydrogen in the presence 
of a metal catalyst. Plausibly, the hydrogen becomes adsorbed 
onto the metal catalyst surface. The hydroxybenzyl 3.17a 
(scheme 3.17) then coordinates to the metal catalyst via the 
electron-rich aromatic ring. The C-O bond as depicted in 3.17b 
now comes into close proximity with the palladium bound 
hydrogen atoms and is subsequently reduced. This leads to the 
free hydroxamate group of 3.17c as well as a toluene molecule.
O
NHR
3.17a
H H
O
NHR
Aromatic ring
coordniates to catalyst
H H
O
NHR
H
HO NHR
3.17b
3.17c
 
Scheme 3.17: Plausible mechanism of hydrogenolysis.23 
H-3b H-3a H-1b/2 H-1a
HO
N
H
CO2H
O
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3.2.5 Preparation of (2S)-3-(4-benzoylphenyl)-2-(5-((4S)-2-
oxohexahydro-1H-thieno[3,4-d]imidazol-4-
yl)pentanamido)propanoic acid (Benzophenone-Biotin). 
D-Biotin 3.18a was activated with 1,1’-carbonyldiimidazole 
(CDI) 3.18b in dry N,N-dimethylformamide (DMF) to give the 
imidazolide 3.18c.(Scheme 15). Moisture and amines in DMF are 
deleterious as they lead to hydrolysis and aminolysis, 
respectively, of the reactive intermediate 3.18c. Hence the 
use of dry, freshly distilled DMF is crucial to the success of 
the reaction. The activated biotin may be isolated and is 
stable under dry, inert conditions. However, without 
isolation, compound 3.18c was coupled to 4-benzoyl 
phenylalanine 3.18d in the same pot to give 3.18e in 60% 
yield.  
 
Scheme 3.18: Reagents and conditions. (i) DMF,DIEA, 70 ºC, 30 min (ii) DMF, 
70 ºC-rt-50 ºC, overnight, 60 %. 
3.2.6 Mechanistic details of the cross-linking involving 
carbonyl diimidazole (CDI) 
In a biomimetic fashion, the mechanism begins with the 
carboxylic acid 3.19a lone pair attacking the carbonyl group 
of the CDI 3.19b. A proton transfer results in the departure 
of one imidazole ring. The nucleophilic electron pair on this 
departed imidazole then returns and attacks the carboxylic 
carbonyl group of 3.19c. Release of carbon dioxide and 
departure of an imidazole gives imidazolide 3.19d. 
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Scheme 3.19: Mechanism of amide bond formation via the imidazolide 
At the appropriate time, the amino group of the p-benzoyl 
phenylalanine then launches a nucleophilic attack on the 
carbonyl group of the imidazolide 3.19d which culminates in 
the departure of the imidazole, a good leaving group, giving 
the product 3.19f. Although theoretically, the carboxyl group 
of the p-benzoyl phenylalanine is also nucleophilic, the amino 
group is clearly a better nucleophile. Evidence of the 
successful synthesis of the intermediate (2S)-3-(4-
benzoylphenyl)-2-(5-((4S)-2-oxohexahydro-1H-thieno[3,4-
d]imidazol-4-yl)pentanamido)propanoic acid 3.18e is given by 
the 1H NMR spectrum in figure 3.9. 
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Figure 3.9: 1H NMR of (2S)-3-(4-benzoylphenyl)-2-(5-((4S)-2-oxohexahydro-1H-
thieno[3,4-d]imidazol-4-yl)pentanamido)propanoic acid 3.18e in CDCl3. 
Diagnostic features for this intermediate included a 
doublet of triplets at ~4.7 ppm and a doublets of 
doublets signal at ~4.3 ppm for the C-1 and C-4 protons 
respectively. Other key features were the doublet at ~3.1 
ppm integrating for two protons assigned to the C-10 
while a pair of doublets at 3.3 ppm and 3.2 ppm was 
assigned to each of the C-2 protons. The 6 protons on C-
5,6 and 7 were assigned to the three multiplets appearing 
between 1.7 and 1.3 ppm. 
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3.2.7 Synthesis of 2,2'-(ethane-1,2-
diylbis(oxy))diethanamine(PEG)3 and 3,6,9,12,15,18,21-
heptaoxatricosane-1,23-diamine (PEG)8 Linkers 
 
The improved pharmacological and biological properties that 
are associated with the covalent attachment of poly (ethylene 
glycol) (PEG) to therapeutically useful polypeptides is now an 
established fact. For this research and as described in 
Chapter 2, triethylene glycol and octaethylene glycol were 
chosen for probes to be deployed in the malaria and 
hypertension disease models respectively. The rationale for 
the choice of PEG spacers as well as the difference in chain 
length was discussed in more detail in chapter two of this 
thesis. The longer chain was desired in the hypertension model 
because for ACE, the active site is located at least 32 Å deep 
inside the protein. Therefore a probe with sufficient length 
spanning the active site and outside regions of the protein is 
ideal to ensure the photocrosslinker and biotin remain on the 
outside for photocrosslinking, visualization and affinity 
purification. 
The polyethylene glycol linker is hydrophilic in nature which 
potentially minimiz s non-specific interactions that could 
arise from the spacer group becoming buried in the hydrophobic 
pocket of proteins. Secondly, this spacer restricts hindrance 
between the peptide and reporter group, hence better avidin-
biotin binding during affinity purification.  
3.2.8 Retrosynthetic Strategy 
Retrosynthetically, a functional group interconversion was 
planned to give way to the mono-boc protected 
homobifunctionalized PEG diamine adduct 3.20a (Scheme 3.20). 
Commercially available polyethylene glycol 3.20c was to be 
converted to the di-tosylate which would undergo SN2 
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transformations because the tosylate is a good leaving group 
due to its ability to form a stable anion. This strategy would 
create an opportunity for substitution of the tosylate with an 
amine group which would be installed by an appropriate vehicle 
such as a pthalimide salt. 
 
Scheme 3.20: Retrosynthetic strategy for the PEG linker 3.20a 
Synthetically therefore, a modified Gabriel synthesis was used 
for the transformation of 3.20c to the homobifunctionalized 
triethylene linker 3.20b. This commenced with the activation 
of the terminal hydroxyl groups of PEG 3.20c into the 
corresponding tosylate 3.21a using tosyl chloride in the 
presence of pyridine. Tosylates are a good leaving group (the 
conjugate base of tosic acid has pKa = 2.8). This was then 
followed by an SN2 reaction with potassium pthalamide in DMF 
forming the di-N-alkylphthalimide 3.21b. The potassium 
phthalimide is a protected-NH2 synthon which allows the 
preparation of primary amines by reaction with alkyls that 
have a good leaving group. After N-alkylation, the amine 
product may be unmasked by a cleavage reaction with a base or 
hydrazine. Hydrazinolysis was thus employed to liberate the 
diamine PEG linker 3.21b in a typical Ing-Mnske procedure.24 
The product was isolated in 64% yield. 
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Scheme  3.21: Reagents and Conditions (i) TsCl, Pyridine, DCM 88% (ii) 
Potassium Pthalamide 68% (iii) Hydrazine monohydrate, 64%. 
 
Scheme 3.22: Mechanistic details of tosylate ester formation 
Mechanistically,the alcohol 3.20c (Scheme 3.22) lone pair 
nucleophilically attacks the electrophilic centre of the tosyl 
chloride 3.22a displacing the chloride giving way to the 
intermediate 3.22b. The base, pyridine, is there to “mop up” 
the HCl by-product leading to the tosylate 3.22c.   
In the next step (Scheme 3.22) the tosylate 3.22c reacts with 
the potassium phthalimide 3.23a (Scheme 3.23 below) leading to 
the departure of the tosyl group and the desired N-alkylated 
resonance stabilized intermediate 3.23b.  
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Scheme 3.23: Mechanistic details of nucleophilic N-phthalimide alkylation 
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To liberate the amine 3.24c from the phthalyl residue 3.23b, 
(scheme 3.24) the hydrazinolysis mechanism begins with a 
nucleophilic attack on the electrophilic carbonyl-carbon of 
3.23b by the hydrazine. This is followed by a proton transfer 
and ring opening resulting in intermediate 3.24a. The second 
amine of the hydrazine also attacks on the other carbonyl 
carbon of 3.24a and a proton-transfer culminates in the 
production of the phthalylhydrazide precipitate 3.24b along 
with the primary amine 3.24c.   
 
Scheme 3.24: Mechanistic details of hydrazinolysis 
                                     
 
Figure 3.10: 1H NMR of 3.25a diamino product (n = 3) in CDCl3 
H2N O O NH2
3.25a
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The multiplet at ~3.04 ppm was assigned to C-6 and C-1 
protons, the singlet at 3.60 ppm to C-3 and C-4 protons 
whereas a multiplet at 3.63 ppm was for the C-2 and C-5 
protons (Fig 3.10).  
3.2.9 Mono-Boc-protectionof 2,2'-(ethane-1,2-
diylbis(oxy))diethanamine(PEG)3and 3,6,9,12,15,18,21,24-
octaoxahexacosane-1,26-diamine  (PEG)8 Linker using a two-step 
fractional extraction. 
Mono-functionalization of symmetrical or unsymmetrical 
diamines is an essential step for the synthesis of 
biologically important pharmacophores and materials.25  Mono-
functionalized diamines hold functional molecules at the one 
end while the other end is free to be attached to other 
entities.26 Among the various amine protecting groups, Boc- is 
the most popular, and its protected form is normally in a good 
physical state to be handled for the next reaction.27 
Subsequently, a reported facile route for mono-BOC protection 
of symmetrical diamines was employed to access the mono-
protected diamine PEG linker 3.25c from 3.25a.28(Scheme 3.25) 
 
Scheme 3.25: Reagents and Conditions (i) HCl (g), MeOH aq., rt. 30 min 
(ii)(BOC)2O 
Using this route, the two amine groups are differentiated as 
an acid salt and a free base, which is ready for further 
functionalization. One molar equivalent of HCl gas was bubbled 
through a 50% aqueous ethanol solution of diamine 3.25a 
bearing two basic amino groups. The solution was stirred for 
30 min to reach full equilibrium. Mechanistically, three 
different species exist including starting diamine 3.25a with 
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two free amines, 3.25b as one free amine and one HCl salt as 
the dominant species, and 3.26a with two amine salts in 
aqueous methanol (Scheme 3.26). Addition of 1 mol of (BOC)2O 
into this solution led to the reaction of the free amines in 
the species 3.25a and 3.25b giving way to possibly four 
different species 3.25a, 3.26a, 3.22b and 3.22c in the 
reaction as per the TLC. (Scheme 3.26) 
 
Scheme 3.26: Reagents and Conditions (i) 1 mol (BOC)2O, rt. 1h (ii) Et2O/H2O 
extraction (iii) Amberlyst A21 ion-exchange resin, 74%. 
After the reaction was completed, an optimized two-step 
fractional extraction was employed. The MeOH was removed in 
vacuo and the remaining aqueous mixture was separated with 
diethyl ether removing the unreacted diamine as well as any 
di-Boc product 3.25a and 3.26b respectively. The freebase 
amines are then obtained by scavenging the crude reaction 
mixture with the basic Amberlyst A-21 ion-exchange resin 
giving crude mono-BOC product tert-butyl 2-(2-(2-
aminoethoxy)ethoxy)ethylcarbamate 3.26d in 74% yield. This was 
used in the next step without further purification because the 
TLC showed negligible amounts of the starting material 3.25a. 
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A typical 1HNMR of the mono-Boc species 3.26d is given (fig. 
3.11). 
    
 
Figure 3.11: 1H NMR of t-butyl 2-(2-(2-aminoethoxy) ethoxy) ethylcarbamate in 
CDCl3 3.26d 
3.2.10 Synthesis of PEG3 hydroxamate probe  
At this stage, all the sub-units or their respective 
appropriately protected derivatives proposed in the 
retrosynthetic strategy (Scheme 3.1) for the preparation of 
the hydroxamate probes were ready. The next step was the 
coupling of mono-Boc protected diamine 3.26d to the 3.18e. 
Typically, 3.26d was crosslinked to 3-(4-benzoylphenyl)-2-(5-
((4S)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-
yl)pentanamido)propanoic acid 3.18e resulting in 3.27a. The 
latter was then deprotected using TFA in DCM (1:1) which was 
followed by removal of the volatiles in vacuo. However, 
NH 2 5 4 3/1b 1a 6
4 5
6
O ON
H
NH2O
O
32
1
Boc-H
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although the deprotection appeared clean by TLC, the product 
yields after aqueous extraction to remove the residual TFA 
were poor. Aqueous workup was thus avoided by using a 
literature procedure29 where the crude residue is dissolved in 
DCM and treated with amberlystA-21® ion-exchange resin giving 
freebase amine 3.27b. The latter was used in the next step 
without further purification. A representative 1HNMR of this 
intermediate is given in figure 3.12.                                                                  
 
Figure 3.12: A section of 1H NMR for 3.27b in CDCl3 
The next step was a peptide coupling of 3.27b to 3.2a 
performed under standard conditions followed by unmasking of 
the hydroxamate “war head” in the final step by hydrogenolysis 
using H2 in the presence of Pd-C in ethanol. This resulted in 
the probe series 3.27c-2, 3.27c-3, 3.27c-4, 3.27c-5 and 3.27c-
6(Scheme 3.27). 
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Scheme 3.27: Reagents and Condit ons (i) EDC-HCl, DIEA, HOBt, DCM, rt. 
Overnight. 47% (ii) TFA, DCM, rt. 3h, quant. (iii) EDC, DMAP, HOBt, DCM, 
rt. Overnight, (iv) Pd-C/H2, 3 atm, rt. 
As expected, it proved difficult to fully characterize the 
probes 3.27c-2,3, 4, 5 and 6 using 1HNMR due to the number of 
protons and overlapping of peaks. A typical 1H NMR is given in 
Fig. 3.14a. The respective M+ peak was observed at 795.53amu 
(Fig. 3.14) and thus successful synthesis was concluded. After 
deprotection with H2/Pd-C in methanol, the final product sample 
was immediately sealed in a dry sample vial to avoid chelation 
of the free hydroxamate to any metals. 
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HK3.27c-3
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Figure 3.13:Electrospray ionization MS M+ peak for probe structure 3.27c-3. 
 
Figure 3.14: A section of 1HNMR for 3.27c-3 in CDCl3. 
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3.2.11 Synthesis of PEG8 hydroxamate probe  
According to Cravatt et al.,30(Fig. 3.15) probes may be 
employed in selective inhibitor, substrate metabolic or enzyme 
discovery in order to achieve functional characterization. 
With the failure of our proposed hydroxamates (3.16b to 3.16g) 
to inhibit ACE to satisfactory levels (discussed in detail in 
Chapter 5), we envisaged that replacement of the reactive 
group with known inhibitors Captopril and Enalaprilat would be 
a viable option with regards to studying their specificity. 
Therefore, their application in the hypertension disease model 
proteome would give an insight into whether they are specific 
to ACE or inhibit other related or unrelated enzymes as well 
which could explain some of the observed contra-indications. 
 
Figure 3.15:Schematic summary of the importance of ABPP in drug discovery30 
Subsequently, an Enalaprilat as well as Captopril based probe 
were synthesized.  
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3.2.12 Synthesis of N-((R)-1-amino-27-(4-benzoylphenyl)-25-
oxo-3,6,9,12,15,18,21-heptaoxa-24-azaheptacosan-26-yl)-5-
((4R)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamide 
3.24b 
t-butyl(23-amino-3,6,9,12,15,18,21-heptaoxatricosyl)carbamate 
(N-Boc PEG8) 3.28a prepared in a similar fashion to 3.26d 
(Scheme 3.26) was linked to the Biotin-Benzophenylalanine 
3.18e substructure under standard peptide coupling conditions 
using EDC-HCl and HOBt. Subsequent deprotection with 35% TFA 
in DCM, followed by treatment with Amberlyst A-21 ion exchange 
resin unmasked the free-base amine to give intermediate 3.28b. 
 
 
Scheme 3.28:Reagents and Conditions (i) EDC-HCl, DIEA, HOBt, TEA, DCM, rt. 
Overnight. 47% (ii) TFA, DCM, rt. 3h, quant. 
3.2.13 Synthesis of (S)-1-((S)-3-(acetylthio)-2-
methylpropanoyl)pyrrolidine-2-carboxylic acid 3.29d 
The strategy for the preparation of S)-1-((S)-3-(acetylthio)-
2-methylpropanoyl)pyrrolidine-2-carboxylic acid (Acetylthio-
Captopril) 3.29d was to leave the prolyl carboxylic acid free 
for coupling to 3.28b. Subsequently, the commercially 
available starting material(S)-3-(acetylthio)-2-
methylpropanoic acid 3.29a was activated to form an acyl 
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chloride 3.29b using SOCl2 in DCM. Nucleophilic acylation at 
the carbonyl of 3.29b by the commercially available amino acid 
proline 3.29c then gave the adduct 3.29d (Scheme 3.29). 
S OH
O
S Cl
O
HN
CO2H S N
O CO2H
O O
O3.29a 3.29b
3.29c
3.29d
 
Scheme 3.29.:Reagents and Conditions: (i) SOCl2, DCM, rt, on (ii) Proline, 
NaHCO3, H2O : Dioxane (1:1), 3h, 60%. 
Mechanistically, the carboxylic acid activation is identical 
to that in methoxyester protection given in scheme 3.9 above. 
The only difference is that the attacking nucleophile is the 
prolyl amine.  
3.2.14 Synthesis of (S)-1-((S)-2-(((S)-1-ethoxy-1-oxo-4-
phenylbutan-2-yl)amino)propanoyl)pyrrolidine-2-carboxylic acid 
(Enalapril) 3.30c 
In a similar fashion, but utilizing PCl5 commercially available 
3.30a was activated to the acid chloride 3.30b. (S)-1-((S)-2-
(((S)-1-ethoxy-1-oxo-4-phenylbutan-2-
yl)amino)propanoyl)pyrrolidine-2-carboxylic acid (Enalapril) 
3.30c was then synthesized by acylation of 3.30b with proline. 
(Scheme 3.30) The pure product was isolated on silica gel. 
 
Scheme 3.30: Reagents and conditions: (i) PCl5, DCM, rt, on (ii) Proline, 
NaHCO3, H2O :Dioxane (1:1), 3h, 54%. 
The mechanism of chloride activation by PCl5 proceeds via a 
substitutive chlorination replacing the -OH of the carboxylate 
with the chloride. As depicted in scheme 3.31, an oxygen lone 
pair from acid 3.31a attacks the phosphorous of PCl5 leading to 
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the dissociation of one Cl-. The latter then attacks the 
electrophilic carbonyl carbon of intermediate 3.31b leading to 
3.31c. 
 
Scheme 3.31: Mechanism of PCl5 activation and subsequent acylation 
The next step from 3.31c to 3.31d is driven primarily by the 
formation of POCl3 and also leads to the loss of HCl. The very 
reactive acid chloride intermediate 3.31d is sufficiently 
electrophilic and is attacked by the amino-NH2 lone pair to 
ultimately form the desired acylated product 3.31f with the 
loss of HCl. 
The 1HNMR data of enalapril and acylthio-captopril were in 
agreement with the literature.31,32 These were then coupled to 
intermediate 3.28b respectively, and thereafter deprotected by 
saponification using NaOH to give target probes 3.32a and 
3.32b. (Scheme 3.32) 
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HK 3.32a 
m/z
100 200 300 400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900
%
0
100
HK_UCT_100901_03  16 (0.170) Cn (Cen,4, 70.00, Ar); Sm (SG, 1x5.00); Sb (1,40.00 ); Cm (16:24-115:136) TOF MS ES+ 
7.80e31174.1
699.4
391.3
225.2 
366.2 
261.2 
681.3 
470.2 679.3 
470.7 552.3
828.4 794.4
701.4 
845.8
1032.5
331.3
 
Scheme 3.32: Synthesis of probes 3.23a and 3.23b. Reagents and conditions: 
EDC-HCl, DIEA, HOBt, DCM, rt. 72 hrs. 27% (ii) 2M NaOH aq. 3h, 88%. 
Peak assignment for the 1HNMR of probe 3.32a and 3.32b also 
proved to be a challenge due to overlapping and multiple 
peaks. Confirmation of the successful synthesis was observed 
by MS. Accordingly, molecular ion peaks for the compounds were 
observed at 1044.2 and 1174.1 amu (Fig.3.15a & b) 
respectively. 
 
 
 
 
 
 
 
 
 
Figure 3.16a: Electrospray ionization MS M+ of enalaprilat probe 3.32a. 
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Henry  3.32b
m/z
100 200 300 400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900
%
0
100
HK_UCT_100901_02  19 (0.200) Cn (Cen,4, 70.00, Ar); Sm (SG, 1x5.00); Sb (1,40.00 ); Cm (19:30-119:140) TOF MS ES+ 
7.57e3
                                                                                                1011.2
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226.2 
391.3
247.2
295.1
315.1 
                                                                                                1044.1
553.3
450.4
477.2 624.3 
583.3 625.3 
845.6493.2 
 
 
 
 
 
 
 
Figure 3.17b: Electrospray ionization MS M+ of enalaprilat probe 3.32b. 
 
3.2.15 Summary  
Following on from Chapter 2, this chapter has given a detailed 
retrosynthetic strategy followed by a synthetic discussion of 
the synthesis of the targeted probes structures. As stated in 
Chapters 1 and 2, the hydroxamate probes were synthesized for 
future application in malaria disease model whilst the 
sulfhydril (Captopril) and carboxylate (Enalapril) based ones 
were assayed in the hypertension disease model the results of 
which are described in Chapter 5. The latter will also present 
a discussion of the biological results of all the other 
compounds synthesized in this research.  
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CHAPTER 4 
 
Potential Novel antihypertension agents with an 
Attenuated Zinc Binding Group 
4.0 Introduction 
 
The introduction in chapter one of this thesis described in 
brief the importance of the enzyme ACE in hypertension 
pathophysiology. This chapter will elaborate the full 
details as well as describe a novel approach towards 
potential new antihypertensive agents. 
 
Playing a key role in the Renin Angiotensin system (RAS) 
cascade in the control of hypertension, ACE has been a 
therapeutic drug target. Treatment of hypertension via 
inhibition of this enzyme has been achieved quite 
successfully since the 1950’s. However, this treatment has 
been associated with a panel of unpleasant side effects. 
These inhibitors were designed before the discovery of ACE 
as a two-domain enzyme, N- and C-domain and that each of 
these possesses an independent active site with different 
activation requirements. Current inhibitors inhibit both 
domains completely halting other important homeostatic 
functions of the enzyme.  Consequently, an accumulation of 
substrates occurs leading to an array of side effects. 
Research has now established that only the C-domain of ACE 
is responsible for hypertension control. Inhibition of only 
the C-domain allowing the N-domain to continue its activity 
could possibly improve the side effect profiles and  
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provides a platform for research towards the next 
generation of antihypertensive ACE inhibitor drugs. 
 
In the past few years, research towards C-domain specific 
inhibitors has focused on changes to the peptidomimetic 
backbone of existing as well as potential inhibitors whilst 
maintaining a strong Zinc-binding group (ZBG) with very 
little success. This part of the thesis, however, seeks to 
explore, using a small series of compounds, the effect of 
attenuating the characteristic ACE inhibitor ZBG. The 
hypothesis is that this effect will allow the more subtle 
and more specific interactions of the peptidomimetic 
backbone of potential inhibitors with the enzyme active 
site and may lead to the next generation of ACE inhibitors. 
4.1 Hypertension 
 
Hypertension, or elevated arterial blood pressure, is a 
condition that affects approximately 26% of the world’s 
adult population. This figure, with its major socio-
economic implications, is expected to increase to 29% by 
the year 2025, with at least two thirds of these patients 
having been shown to originate from economically developing 
countries. 1   This precipitates the urgent need to 
effectively treat such a condition with particular 
attention on the needs for treatment in sub-Saharan Africa.  
The treatment of hypertension also results in control of 
downstream cardiovascular conditions such as myocardial 
infarction and stroke.  
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4.2 The Renin Angiotensin System 
The Renin-angiotensin system (Figure 4.1) is a complex, 
highly regulated pathway that is integral in the regulation 
of blood volume, electrolyte balance, and arterial blood 
pressure. This system consists of several enzymes that are 
responsible for the conversion of substrates into active 
peptides that play an important role in regulating blood 
pressure.  
 
Renin, secreted from the kidney, is responsible for the 
cleavage of angiotensinogen to produce angiotensinI. 
Angiotensin I (Ang I), a decapeptide, is subsequently 
converted into angiotensin II (Ang II), an active 
octapeptide, by Angiotensin-converting Enzyme (ACE). 2 
Binding of Ang II to appropriate receptors causes systemic 
vasoconstriction 3that increases total peripheral resistance 
through a variety of mechanisms. Furthermore, it results in 
increased aldosterone secretion and water retention in the 
kidney.2 Yet another substrate of ACE is the potent 
vasodilator bradykinin (BK), an intermediate in the 
Kallikrein-Kinin System. ACE cleaves the C-teminal 
dipeptide unit Phe-Arg inactivating BK resulting in 
decreased vasodilation. The plasma kallikrein-kinin system 
counterbalances the RAS.4 
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Figure 4.1: The interaction between the plasma KKS and RAS. Angiotensin-
converting enzyme (ACE) converts inactive angiotensin I to the 
vasoconstrictor angiotensin II. At the same time ACE degrades active 
vasodilator bradykinin into bradykinin(1–7).4 
4.3 Angiotensin-converting Enzyme (ACE) and its role in 
the RAS and KKS 
 
ACE (EC 3.4.15.1) is a zinc dipeptidyl carboxypeptidase 
and, as described above, is responsible for the crucial 
conversion of Ang I to Ang II in the RAS. More 
specifically, this enzyme is responsible for the cleavage 
of a dipeptide C-terminal unit (HL) from the decapeptide 
substrate (DRVYIHPFHL) into the octapeptide form. From this 
stage, the cleaved product is subjected to further  
conversions of the RAS including ACE2 and aminopeptidases.5 
The various products of catalysis are capable of binding to 
their respective receptors and regulate cardiac function. 
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ACE is involved in another critical conversion, although 
not part of the RAS, whereby bradykinin (BK, RPPGFSPFR), a 
peptide part of the Kallikrein-Kinin System (KKS) with 
vasodilator characteristics, into its inactive form, 
bradykinin1-7 (BK1-7). (Figure 4.1) This serves as a 
complementary control for the increase in arterial blood 
pressure, whereby the peptides responsible for 
vasoconstriction (Ang II) are introduced and the peptides 
with vasodilation properties are degraded or inactivated.  
 
Apart from Ang I and BK, ACE is also involved with other 
substrates such as peptide N-acetyl-seryl-aspartyl-lysyl-
proline (AcSDKP), a peptide known for its haemoregulatory 
roles. Even in this case, ACE functions as a dipeptidyl 
carboxypeptidase, releasing the KP fragment in the plasma6 . 
This together with others indicates that ACE plays a role 
in several other physiological systems apart from the RAS. 
4.4 ACE characteristics 
 
ACE has two isoforms, depending on tissue localisation. 
Somatic ACE (sACE) is ubiquitously expressed but 
predominantly on the plasma membrane of endothelial and 
epithelial cells.5 Molecular cloning revealed interesting  
characteristics of this enzyme. It has been shown that the 
cDNA consists of 1,306 residues, including the signal 
peptide, with a transmembrane domain near the C-terminal of 
sACE. The sACE gene consists of 26 exons which are 
translated 1 through to 26 excluding exon 13.  Further, 
sACE was shown to have two domains, namely N- and C- 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Chapter 4: Synthetic Discussion – Potential Novel 
Inhibitors with an Attenuated Zinc Binding Group 
 105 
 
domains, that have high sequence similarities and both 
containing active sites.7 
 
tACE is an isoform that is expressed exclusively in male 
germinal cells and is comparable to the C-domain of sACE. 8 
The shortened protein results from the presence of a tissue 
specific promoter present in intron 12 of the sACE gene 
giving rise to a 2 435 nucleotide (732 amino acids) 
fragment. With the exception of a unique 36 amino acid 
residue region on the N-terminal, tACE is identical to the 
C-domain region of sACE.9 
 
sACE consists of two catalytic domains, as described by the 
characteristic HEMGH zinc binding site. tACE is encoded by 
the same gene but transcribed with a tissue specific 
promoter present in intron 12. Hence tACE can be viewed as 
truncated relative to sACE. Both catalytic sites have a 
conserved Zn2+ but differs both in substrate specificities 
and in chloride activation profiles. 10 , 11  It has also been 
shown that the C-domain is more dependent on chloride ion 
for activation and subsequent substrate conversion, 
compared to the N-domain and both domains show similar 
kinetics for bradykinin breakdown.10 
 
4.5 Three dimensional structure of ACE 
4.5.1 Testis ACE  
In 2003, the three dimensional crystal structure of tACE 
mutant (tACE∆36NJ) co-crystallized with Lisinopril was  
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published. 12 The basic structural observations included the 
presence of a large abundance of α-helices and a 30Å 
central groove that divides the molecule approximately in 
half into designated sub-domains I and II (Figure 4.2). N-
terminal helices α1, α2 and α3 form a cap-like structure 
that appears to partially cover the active site. This 
observation is interesting since it suggests that, in order 
for ACE to accommodate either substrate or inhibitor, a 
conformational change is required.5 The catalytic zinc ion 
is located in the active site, coordinated by residues 
His383 and His387 as predicted by the characteristic zinc 
binding motif.12 
 
 
 
 
 
 
 
 
Figure 4.2: A structural view of testis ACE (tACE). The sub-domains (I 
and II) are given in green and purple respectively. Chloride ions are 
indicated and shown in red. Lisinopril and the catalytic zinc ion are 
shown in yellow and green respectively. The structure assumes an 
ellipsoid shape overall. 12 
In 2007, the three dimensional crystal structure of tACE 
mutant (tACE∆36NJ) co-crytallized with RXPA380 (the only 
known C-domain specific inhibitor) was also solved. This  
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Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Chapter 4: Synthetic Discussion – Potential Novel 
Inhibitors with an Attenuated Zinc Binding Group 
 107 
 
phosphinic peptide is a long molecule whose residues were 
revealed occupying S2, S1, S1’ and S2’.13 (Figure 4.3) 
 
Figure 4.3: Cartoon of tACE (pink) showing RXPA380 (yellow)bound in the 
active site. Zinc and chloride ions are shown in grean and yellow 
respectively.  
RXPA380 is reported to bind in the active site in an 
elongated conformation with the phosphinyl oxygens 
coordinating with the zinc. (Figure 4.4) 
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Figure 4.4: Stick representation of RXPA380 (orange) within the active 
site of tACE.14 
 
The crystal structure revealed that despite the differences 
in zinc coordinating moieties in the different ACE 
inhibitors (carboxyl and sulfhydril) the inhibitor 
coordinating atoms are similarly positioned. The phosphinyl 
oxygens overlap almost precisely the same as those of 
carboxylate groups of enalaprilat and lisinopril with a 
distance of between 2-2.5Å away from the zinc atom. 
Furthermore, RXPA380 follows a conformation similar to 
captopril on the C-terminal side of the ZBG and four of the 
eight hydrogen bonding interactions in the active site 
being the same as both enalaprilat and captopril. 
Significant among these are the C-terminal carboxylate and 
the adjacent carbonyl oxygen moiety interaction with Lys511 
and Tyr 520 and with His353 and His513 respectively. 
Chemical structures of RXPA380, enalaprilat and captopril 
with residue positions P2, P1, P1’ and P2’ in  
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the S2, S1, S1’ and S2’ subsites respectively are given in 
figure 4.5. 
 
Figure 4.5: Chemical structures of RXPA380, enalaprilat and captopril with residue 
positions in the P2, P1, P1’ and P2’ 
 
4.5.2 N-domain  
The crystal structure of the N-domain of sACE has recently 
been solved. Many similarities can be observed when 
comparing the overall structures of the two domains, with 
the N-domain also being abundant in helices and having an 
equivalent topology to that of the C-domain.15 The molecule 
consists of 18 α-helices and six short β-strands. The 
catalytic Zn2+ ion was found to be in the active site with 
the characteristic zinc binding motif found in the C-
domain. Glycosylation sites and amount of glycosylation of  
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the protein also differ. Nevertheless, the overall 
conformational considerations between the two domains 
remain. A structural comparison of the two domains is given 
in figure 4.6. 
 
 
 
 
 
 
 
 
 
 
Figure 4.6: A structural comparison of the C- and N-domains. The domains, 
in overall structure, are very similar. The C-domain sequence is shown 
in pink while the N-domain is shown in blue. The catalytic zinc ion is 
shown in green.15 
The tACE residues that form hydrogen bonds with RXPA380 are 
all conserved in the N-domain. However, the aromatic 
interaction with Phe391 is lost because it is replaced by 
Tyr369 suggesting a possibly different orientation of the 
inhibitor in this domain. The C-domain selectivity in 
RXPA380 is thus attributed to the lack of this interaction 
as well as reduced hydrophobicity in the S2’ subsite.15 
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4.5.3 Comparison of N- and C-domain active sites and 
inhibitor binding 
The active site of the two ACE domains can be considered to 
be made up of four subsites (S1, S2, S1’, S2’) each 
containing different amino acid residues.12  Comparisons can 
be drawn and made use of from the above crystal structure 
determinations, both in the binding of lisinopril in the 
active site and the interactions of this inhibitor with 
active site residues. Differences exist between the 
residues of the active sites of the N- and C-domains, with 
a larger number of differences existing particularly in the 
S1’ and S2’ subsites.15 A summary of differences between the 
residues of the S2’ subsites in each domain are given in 
table 4.1. 
 
Table 4.1: Summary of the differences between the S2’ residues of the 
active site 
 S2 subsite   
C-domain 
(tACE) E403 F391 V518      
N-domain R381 Y369 T496      
 S1subsite   
C-domain 
(tACE) V518 S516 E413         
N-domain T496 N494 S119        
 S1' subsite 
C-domain 
(tACE) E162 N277 S284 E372 N374 E376 D377 V380 
N-domain D140 D255 E262 R350 T352 D354 N355 T358 
 S2' subsite   
C-domain 
(tACE) T282 S284 E376 V379 V380 D453   
N-domain S260 D262 D354 S357 T358 E431   
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4.6 Historical Perspective of ACE Inhibitors and 
Inhibition 
 
The story of the design and synthesis of the first orally 
active and potent inhibitors of ACE has been described as 
one of the first examples of rational drug design. 16 
Involvement of a metal in the catalytic mechanism of ACE 
had been suspected from its discovery. 17  Confirmation of 
this fact in the 1970’s 18 led to the mechanistic similarity 
assumption of ACE to Carboxypeptidase A (CPA). 19  The next 
breakthrough came with the discovery that bradykinin-
potentiating peptides isolated from the venom of the 
Brazilian pit viper Bothropsjararaca 20 could specifically 
inhibit ACE.21 Subsequent structural-activity studies showed 
optimal inhibitory capability of  C-terminal sequence of 
Phe-Ala-Pro 22  and led to the proposal that venom peptides 
were competitive substrate analogues. The next step was 
then to find orally active non-peptide analogues of the 
venom peptides.  
 
A new by-product analogue concept based on work by Byers 
and Wolfenden 23 for CPA inhibitors led Cushman and Ondetti 
into recognizing the important role of active-site zinc 
coordination in binding affinity of inhibitors. 
Subsequently, their search for superior zinc-binding 
capabilities led to the replacement of the carboxyl group, 
typical in CPA inhibitors based on benzylsuccinic acid, 
with a sulfhydryl group, yielding Captopril 24 as the first 
orally active and clinically approved therapeutic agent for 
the treatment of hypertension and its related disorders.  
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Side effect related short-comings of Captopril, connected 
to the sulfhydryl moiety, led to reversion to carboxyl 
compounds and research into alternative functionalities. 
This led to the discovery of Enalaprilat, Lisinopril and 
all current generation ACE inhibitors as variations on the 
original theme, with most of the differences residing in 
the functionalities that bind the active site zinc and the 
subsite pockets.25 
4.7 Classification of known ACE Inhibitors 
 
Some current generation ACE inhibitors (Fig. 4.7) include 
sulfhydrils, ketones, carboxylates and phosphinates.  
 
Figure 4.7: Current-generation ACE inhibitors 
 
These compounds are tripeptide substrate analogs in which 
the C-terminal and penultimate amino acids are retained 
like in Captopril but the third amino acid is isosterically 
replaced by a substituted N-carboxymethyl group. The search 
for ACE inhibitors which lacked the sulfhydryl group also 
led to the investigation of phosphorous containing 
compounds.26 
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Generally, the mechanism of action of ACE inhibitors 
involves attenuating the effects of the Renin-angiotensin 
system (RAS) by inhibiting the conversion of angiotensin I 
to angiotensin II. They are selective in that they do not 
directly interfere with any other components of the RAS and 
have thus been a huge success clinically.27 
4.8 Selectivity Profiles of Current generation ACE 
inhibitors 
 
Table 4.2 below shows the selectivity profiles, with 
respect to the two ACE-domains of some inhibitors currently 
used in blood pressure treatment as well as research. 
 
Table 4.2: Domain selectivity of some ACE inhibitors.28 
Inhibitor Residues N-domain (nM) C-domain (nM) 
Enalaprilat Phe-Ala-Pro 26.0 6.3 
Captopril Ala-Pro 8.9 14.0 
Lisinopril Phe-Lys-Pro 44 2.4 
RXPA380 
Phe-Phe-Pro-
Trp 
10,000.00 3.0 
RXP407 
Asp-Phe-Ala-
Ala 
2.0 2500 
 
It is clear that the ACE inhibitors Captopril, Lisinopril 
and Enalaprilat show very modest degrees of domain-
selectivity. The most C-selective inhibitor currently is 
the tetrapeptide RXPA380.(Figure 4.8) It is 3,000 times  
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more selective for the C- rather than the N-domain. 29  In 
designing this inhibitor, Divéet al exploited the known 
differences in the active site composition of the C- and N-
domains.  However, the challenges with regard to size (high 
molecular weight) and synthesis render the tetrapeptide not 
a good drug candidate. RXP407 on the other hand is 1000 
times more N-domain selective.  
 
 
Figure 4.8: Structure of RXPA380 the most C-domain selective inhibitor 
known 
4.9 Adverse effects and the need for “second 
generation” ACE inhibitors 
Current generation ACE-inhibitors have been contraindicated 
in many patients. 30  Clearly, the large number of 
contraindications underscores the need for newer and safer 
antihypertension drugs with better side effect profiles.  
Current generation ACE inhibitors inhibit both the N- and 
C-domains. Therefore, taking the side effect profiles and 
the recent elucidation of the 3-D structure of ACE into 
consideration, highly specific single C-domain specific 
inhibitors of ACE offer an attractive alternative as 
antihypertension agents. The N- and C-domain active sites 
of ACE hydrolyze Ang I and BK at comparable rates in vitro, 
but in vivo it seems that the C-domain is primarily  
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responsible for regulating blood pressure. 31 This might 
indicate that a C-selective inhibitor would have an 
inhibitory profile comparable to current mixed inhibitors. 
 
Whereas Ang I is hydrolyzed predominantly by the C-domain 
in vivo, BK is hydrolyzed by both domains32,33 and therefore 
we envisage selective inhibition of the C-domain site will 
allow BK degradation to continue, catalyzed by the N-
domain. This could be sufficient to prevent the excessive 
BK accumulation that has been observed during attacks of 
angioedema.34 Thus a highly selective C-domain inhibitor has 
the potential for effective blood pressure control with 
reduced vasodilator-related side effects. 
4.10 Study justification 
 
The aim of this study therefore, was to pursue our proposed 
hypothesis with regards to achieving domain-selective ACE-
inhibition. This hypothesis is based on the notion than an 
attenuated zinc-binding group (ZBG) may achieve C-domain 
selectivity.  
 
Countless attempts have been made to synthesize novel C-
domain specific ACE inhibitors based on changes in the 
inhibitor backbones surrounding a ZBG with little or no 
success in achieving the selectivity. This part of the 
research therefore focused on the synthesis of a small 
number of potential novel inhibitors with an attenuated 
ZBG. These were utilized in investigating the effect on 
selectivity and were based on structural features derived 
from the most C-domain selective inhibitor known, RXPA 380. 
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Current knowledge suggests that the remarkable selectivity 
of RXPA380 for this domain is due to the bulky tryptophan 
residue situated in its P2’position.  
 
Therefore, apart from attenuating the ZBG, the research 
investigated a simple structure activity relationship study 
of this tryptophan moiety effect by incorporating the 
residue into the P2’position of two of the most commonly 
prescribed ACE-inhibitors, namely, Captopril and 
Enalaprilat. We envisaged that this study could give 
insight into whether the tryptophan moiety is the only 
determinant of the domain selectivity in RXPA380. 
 
It is further envisaged that derivatization of current 
generation ACE inhibitors that show little or no 
selectivity for the two ACE domains as templates would be a 
good point to start in inhibitor selectivity studies.  
 
4.11 ACE Zinc Binding Group 
 
As observed in the above discussion, a prominent feature in 
current generation ACE inhibitors is the zinc binding group 
(ZBG).The main challenge presented by these drugs is the 
lack of selectivity between the two domains of ACE namely, 
N- and C- domain, the latter which is the only domain 
responsible for the control of hypertension and thus the 
therapeutic target. 35 Current generation ACEIs inhibit both 
domains, blocking the other homeostatic functions carried 
out by the N-domain, resulting in adverse side effects.36 
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ACE is a zinc metalloprotease enzyme which is closely 
related to matrix metalloproteases (MMPs). 37 ZBGs have been 
found to modulate selective inhibition of MMPs. Several 
novel MMP inhibitors have been reported and studies show 
that their selectivity is dependent on the nature of the 
ZBG. This is in contrast to most current matrix 
metalloprotease inhibitors (MMPI’s), which obtain isoform 
selectivity solely from the peptidomimetic backbone portion 
of the compound. Different ZBGs have been appended to a 
common backbone and the inhibition efficiency of each 
inhibitor determined. These results show that the 
selectivity profile of each inhibitor is different as a 
result of the various ZBGs. 38  This study further 
demonstrated that the choice of ZBG can have a significant 
effect in a relevant patho-physiological endpoint. 
 
Other studies have also demonstrated that strong ZBGs such 
as hydroxamates lack selectivity. 39 Their strong zinc (II)- 
binding capacity suppresses the overall effect of the 
weaker but more specific non-covalent interactions of the 
inhibitor backbone with the substrate specificity regions 
of the enzyme.40 
 
MMPIs bearing the weak ZBG phosphinic acid have been found 
to efficiently discriminate between the different enzymes, 
especially through the increasedinteraction with both the 
primed and unprimed subsites of the protease active 
sites. 41 Furthermore, the placement of the ZBG is in the 
middle of a pseudopeptidic scaffold and not at its N- or C-
terminus, as is the cases with hydroxamate and carboxylate 
inhibitors.  
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Therefore, specific, non-covalent interactions between a 
phosphinic peptide and a protease with the S2, S1, S1’ and 
S2’ can be significantly increased which can result in 
enhanced selectivity if these interactions are properly 
tuned. 42 Over the last several years, numerous MMPI’s 
havebeen reportedthat actually do not possess a ZBG and 
hence do not bind the catalytic Zn2+ ion.43, 44, 45, 46 
 
Current generation ACE inhibitors have ZBGs such as 
sulhydryl, carboxylates, hydroxamates 47 , ketones and 
phosphinic acids.48 A plethora of other ZBGs exist for other 
members of the metalloprotease family.46 Quantum chemistry 
calculations performed on simple models of interaction 
between the zinc ion and the various zinc-binding groups 
mentioned above predict that the hydroxamate function is 
the strongest ZBG group in this series, while the 
phosphoryl is the weakest.49 These predictions fit with the 
extremely high potency displayed by many hydroxamates 
developed towards MMPs, as compared with the potency 
displayed by some phosphinic peptide inhibitors.39 
 
This remarkable selectivity is attributed to the bulky 
backbone of the molecule and specifically on the tryptophan 
residue in the P2’position. The molecule is more easily 
accommodated by the deeper and more hydrophobic C-domain S1’ 
and S2’ subsites than those in the N-domain.15 Furthermore, 
in the position α- to the ZBG, there is a bulky five-
membered cyclopentane structure which further conceals the 
ZBG and restricts free rotation about the Cα-Cβ bond. Domain 
selectivity assays of the analogues synthesized enroute to 
RXPA380 (Figure 4.9) revealed that there was significant C- 
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domain selectivity amongst the analogues with a group in 
the α’-position to the ZBG compared to those without. 50 
These potency studies therefore strongly suggest that the 
selectivity of RXPA380 for the C-domain may not only be due 
to the tryptophan residue in the P2’, but the prolyl moiety 
in the P1’ as well. Studies have been performed before in 
this research group where bulkier hydrophobic residues 
inserted in the P2’did not effect domain selectivity in 
either the C- or N-domain.51,52 
 
Compound Amino Acid Selectivity Ki for 
the C-domain 
 
 
 
PheProTrp 
 
3300 
PheProAla 22 
PheProPro 15 
PheProArg 22 
 
PheAlaTrp 90 
PheAlaAla 1 
 
AlaProTrp 130 
 
HomoPheProTrp 138 
 
Figure 4.9: Domain selectivity potency studies of RXPA380 and its 
analogues 
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Our hypothesis is therefore that a weaker and/or concealed 
zinc-binding group could present an opportunity for coming 
up with a C-domain selective ACE inhibitor resulting from 
enhanced contribution from the usually suppressed weaker 
but more specific non-covalent interactions. 
 
It is also clear that the ZBG could have a significant 
effect on the selectivity of ACE inhibitors. From the 
plethora of evidence gathered in the study of the closely 
related MMPI’s, a burning question to ask at this point is 
to what extent the ZBG affects domain-selectivity in ACE. A 
further and future question to consider for the next 
generation of domain-selective ACE inhibitors iswhether 
they should or should not have a ZBG. Consequently, a 
follow-up aspect of our hypothesis is to investigate 
whether the tryptophan residue in the RXPA380 structure is 
the only determinant of C-domain selectivity. 
4.12 Summary of Rationale 
 
The rationale for this strategy revolves around minimizing 
or eliminating the interaction with the catalytic Zn2+ ionto 
achieve domain selectivity, as the metal site is the most 
conserved feature between the N- and C-domain of ACE. 
Phophinates were thus chosen because of the advantageous 
placement of the ZBG in the middle of a pseudopeptidic 
scaffold and not at its N- or C-terminus, as in the cases 
of hydroxamate, carboxylate and sulfhydryl inhibitors. Less 
synthetically challenging phophinates were thus proposed 
and synthesized, including a varied R-group in the position  
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α- to the phosphinic acid, to investigate the effect on 
domain-selectivity. (Figure 4.10) It should be noted 
however, that compared to the ordinary phosphinic acids, 
the molecules have the NH group two bonds closer to the 
phosphinic group. This is a major backbone modification 
with possible implications on the overall alignment of the 
molecule in the active site bringing the proposed P2’ 
residue closer to the P1’ region. 
 
 
 
Figure 4.10: General structure for the design of target compounds 
depicted in the active site  
Figures 4.10 gives the general structure for the design of 
target phosphinic acid based compounds depicted in the ACE-
active site. The R-groups were selected from a different 
sized substituents ranging from methyl to benzyl groups 
with careful consideration of Lipinski’s rule-of-five 
analysis. This analysis/guidelines predict that poor 
absorption or permeation of a orally administered compound 
are more likely if the compound meets the following 
criteria,  molecular mass greater than 500 amu, high 
lipophilicity (expressed as cLogP greater than 5), more 
than 5 hydrogen bond donors, more than 10 hydrogen bond. 
These rules are based on the observation that most drugs 
are relatively small and lipophilic molecules.53Although the  
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molecular weights of the compounds ranges from 499 to 623 
amuthey have 5 hydrogen bond donors and/or acceptors and 
generally, the compounds have cLogP’s of less than 5. 
Moreover, the compound, RXPA380 on which the design was 
based itself has a molecular weight of 617 amu.  
 
 
Given that an attenuated ZBG may influence domain 
selectivity and specificity, a further hypothesis was that 
the tryptophan residue of RXPA380 may not be the only 
structural determinant of C-domain selectivity. We 
therefore envisaged that replacement of the prolyl moiety 
of known ACE inhibitors with the bulkier tryptophan residue 
would provide insight into this domain selective-
behaviour.A good precedence for this is the enhanced ACE C-
domain selectivity observed with Keto-ACE analogues (Figure 
4.11) whose structure also involved a ZBG in the middle of 
a pseudo-peptidomimetic scaffold.54 
 
 
Figure 4. 11: KetoAce and its tryptophan based analogue 
4.13 Objectives 
The objectives for this part of the research were: 
 
 To synthesize novel phosphinic acid-based ACE 
inhibitors with a substituent in the α-position 
relative to the phosphinate ZBG as potential novel 
antihypertension agents 
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 To synthesise new potential ACE-inhibitors 
incorporating a tryptophan residue in the P2’of the 
captopril and enalaprilat scaffold 
 To evaluate the domain selectivity of these 
synthesised compounds in vitro using appropriate ACE 
inhibitory assays. 
 
4.14 Synthetic Discussion 
4.14.1 Retro-synthetic Strategy 
 
Retrosynthetically, target molecule 4.2i is synthesized in 
one pot from the amino acid tryptophan 4.2h and an 
appropriate aldehyde 4.2g. The latter is the protected 
derivative of α-aminophosphinic acid 4.2e which is prepared 
from the deprotection of 4.2d. 
 
Scheme 4. 1: Retro-synthetic strategy for the preparation of the target 
compounds   
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A double disconnection across C-N and P-N bonds leads back 
to commercially available diphenylmethylamine 4.2a, 
aldehyde 4.2b and hypophosphorous acid 4.2c. 
4.14.2 Synthesis of (1-amino-2-phenylethyl)phosphinic 
acid 4.2e 
Preparation of phosphinic acid 4.2d was thus achieved using 
a well known literature procedure 55 by refluxing equimolar 
amounts of commercially available diphenylmethylamine 
hydrochloride 4.2a, 50% aqueous hypophosphorous acid and an 
aldehyde in ethanol for 3h. The resulting 
diphenylmethylaminophosphonous acid 4.2d precipitate was 
filtered off, dried and immediately dissolved in 48% 
hydrobromic acid and heated for 1 hour at 100 oC resulting 
in the cleavage of the diphenylmethyl group unmasking the 
amine group of α-amino-phosphinic acid 4.2e. (Scheme 4.3) 
 
Scheme 4.2:Reagents and conditions. (i) R1CHO, H3PO2, EtOH, H2O, reflux, 
3h, 88% (ii) 48% HBr, H2O, 100oC, 1h, quant. (iii) CBz-Cl, NaOH, NaHCO3, 
H2O, 4oC (iv)(a)R2CHO, TrpOMe, 1,4-Dioxane, 5h (b) 4M NaOH, MeOH. 
 
 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Chapter 4: Synthetic Discussion – Potential Novel 
Inhibitors with an Attenuated Zinc Binding Group 
 126 
 
Precipitation was induced by dissolution in ethanol and the 
drop-wise addition of propylene oxide until complete. 
Purity was confirmed using melting point. 
 
4.14.3 Preparation of 2-((1-((1-
(((benzyloxy)carbonyl)amino)-2-
phenylethyl)(hydroxy)phosphoryl)ethyl)amino)-3-(1H-
indol-3-yl)propanoic acid 4.2i. 
The amine was then reacted with benzyl chloroformate in 
basic medium to yield 4.2f. A reported one-step, three 
component reaction involving an appropriate aldehyde,(1-
(((benzyloxy)carbonyl)amino)-2-phenylethyl)phosphinic acid 
4.2f (or its analogues) as well as methoxy-protected 
tryptophan gave way to 2-((1-((1-
(((benzyloxy)carbonyl)amino)-2- 
phenylethyl)(hydroxy)phosphoryl)ethyl)amino)-3-(1H-indol-3-
yl)propanoic acid 4.2i-4 (or its analogues).56 
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Table 4. 3: Percentage yields of 4.2i analogues 
Compound R1 R2 % Yield 
4.2i - 1 CH3 CH3 ND* (Crude 81%) 
4.2i - 2 C(CH3)3 CH3 75 
4.2i - 3 CH2Ph CH3 ND* (Crude 43%) 
4.2i - 4 CH2CH2CH3 CH3 66 
4.2i - 5 CH3 CH2CH2CH3 68 
4.2i - 6 C(CH3)3 CH2CH2CH3 70 
4.2i - 7 CH2Ph CH2CH2CH3 72 
4.2i - 8 CH2CH2CH3 CH2CH2CH3 68 
4.2i - 9 CH3 C(CH3)3 79 
4.2i - 10 C(CH3)3 C(CH3)3 79 
4.2i - 11 CH2Ph (CH3)3 88 
4.2i - 12 CH2CH2CH3 (CH3)3 82 
4.2i - 13 CH3 CH2Ph 80 
4.2i - 14 C(CH3)3 CH2Ph 60 
4.2i - 15 CH2Ph CH2Ph 54 
4.2i - 16 CH2CH2CH3 CH2Ph 50 
ND* - Yield not determined. M+ ion observed but compound extremely 
impure (HPLC). Very low yield and not enough material to isolate. 
4.14.4 Mechanistic details for the preparation of 1-
diphenylmethyl aminophophonous acid 4.4g. 
 
There are two postulated mechanisms for this reaction. In 
the first one, it is said to proceed via the nucleophilic 
addition of hypophosphorous acid to the azomethine bond of 
1,1-diphenyl-N-(2-phenylethylidene)methanamine Schiff base 
of phenyl acetaldehyde leading to the formation of 1-
diphenylmethyl aminophophonous acid. The second possible 
mechanism includes attack of hypophosphorous acid on an 
aldehyde leading to α- hydroxyphosphonous acid, which  
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undergoes the nucleophilic substitution and it converts 
into the desired α-aminophosphonous acid. It is not known 
which mechanism is operative in this case but the more 
plausible one is the first. (Scheme 4.3) 
The acidic media provides the carbonyl oxygen of 4.3a with 
the catalytic proton resulting in the attack of the 
nucleophilic amine 4.3b on the electrophilic carbonyl 
carbon followed by the loss of an H+ from the now positively 
charged nitrogen. The hydroxyl oxygen of 4.3c is protonated 
again forming an oxonium ion 4.3d which then results in the 
departure of an H2O, the driving force being formation of a 
resonance stabilized intermediate 4.3e. Departure of a 
proton restores the nitrogen lone pair and forms the Schiff 
base 4.3f. Nucleophilic addition of hypophosphorous acid to 
the azomethine position follows resulting in 4.3g. 
 
Scheme 4. 3: Mechanism for the preparation of diphenylmethyl aminophophonous 
acid 4.4g. 
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A typical H NMR for 4.2i-1 is given in figure 4.12. 
 
 
Figure 4.12: A section of the typical 1H NMR for compound 4.2i-1 in 
CDCl3 
4.14.5Preparation of Enalaprilat and its analogues 
 
The carboxylic acid (S)-2-(((S)-1-ethoxy-1-oxo-4-
phenylbutan-2-yl)amino)propanoic acid 4.4a was activated by 
conversion to (S)-2-(((S)-1-ethoxy-1-oxo-4-phenylbutan-2-
yl)amino)propanoic hypochlorous anhydride 4.4b using 
phosphorous pentachloride.  Acyl chloride 4.4b was then 
elaborated to compounds 4.4c, (S)-2-(((S)-1-(((R)-1-
carboxy-2-phenylethyl)amino)-1-oxopropan-2-yl)amino)-4-
phenylbutanoic acid 4.4d and (S)-2-(((S)-1-(((R)-1-carboxy-
2-(1H-indol-3-yl)ethyl)amino)-1-oxopropan-2-yl)amino)-4-
phenylbutanoic acid 4.4e via a reaction with proline,  
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phenylalanine and tryptophan respectively each followed by 
saponification using 4M NaOH (Scheme 4.4).  
 
 
 
Compound Amino Acid Residue % Yield 
4.4c Pro 54 
4.4d Phe 60 
4.4e Trp 69 
 
Scheme 4.4. General Reagents and Conditions: (i) PCl5, DCM, rt. 
Overnight (ii) NaHCO3, H2O 1,4-Dioxane, Amino Acid(ii) NaOH, H2O 
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Figure 4.13: Typical HNMR for (S)-2-(((S)-1-(((R)-1-carboxy-2-(1H-
indol-3-yl)ethyl)amino)-1-oxopropan-2-yl)amino)-4-phenylbutanoic acid 
(tryptophan analogue)4.4e in CDCl3. 
 
4.14.6 Preparation of (S)-1-((S)-3-mercapto-2-
methylpropanoyl)pyrrolidine-2-carboxylicacid 
(Captopril)and its analogues 
In a similar fashion to Enalaprilat and its analogues, the 
carboxylic acid of 4.5a was activated by conversion to the 
acyl chloride 4.5b using thionyl chloride.  Acyl chloride 
4.5b was then elaborated to compounds 4.5c, 4.5d and 4.5e 
via a reaction with the proline, phenylalanine and 
tryptophan respectively, followed by saponification using 
4M NaOH. (Scheme 4.5). A typical 1HNMR of this series of 
(R)-2-((S)-3-mercapto-2-methylpropanamido)-3-
phenylpropanoic acid 4.5d is given in Fig 4.14. 
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Compound Amino Acid Residue % Yield 
4.5c Pro 80 
4.5d Phe 64 
4.5e Trp 70 
 
Scheme 4.5:General Reagents and Conditions: (i) SOCl2, DCM, rt. 
Overnight (ii) NaHCO3, H2O 1,4-Dioxane, Amino Acid.HCl(ii) NaOH, H2O. 
 
Figure 4.14: 1HNMR of (R)-2-((S)-3-mercapto-2-methylpropanamido)-3-
phenylpropanoic acid 4.5d in Phenylalanine analogue) in CDCl3 
 
Mechanistically, intermediate 4.5b is an active acid 
chloride that can easily undergo nucleophilic acyl  
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substitution (Scheme 4.8).  An equivalent of base destroys 
the hydrochloride salt of phenylalanine 4.6a and frees the 
nitrogen lone pair of electrons as depicted in 4.6b. This 
lone pair then nucleophilically attacks the acyl carbonyl 
of 4.5b resulting in the departure of a chloride anion. The 
amide bond results in adduct 4.6c and the resulting 
hydrochloric acid formed in the reaction is taken care of 
by the excess sodium bicarbonate base leaving the product 
4.6d. 
 
Scheme 4. 6: Mechanism of acyl substitution 
4.14.7 Preparation of Tryptophan hydroxamates 
 
The protected hydroxamates 3.2a-3 to 3.2a-6 were coupled to 
L-tryptophan methoxy-ester under standard coupling 
conditions followed sequentially by saponification and 
hydrogenolysis giving rise to a series 4.7a to 4.7e. 
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Compound R-group % Yield 
4.7a CH2Cyclohexyl 66 
4.7b CH2CH(CH3)2 71 
4.7c CH2Ph 70 
4.7d CH2Napthyl  75 
4.7e CH3 ND 
ND: Sample difficult to purify 
Scheme 4. 7: Reagents and conditions (i) AA-Methyl ester, EDC-HCl, HOBt, DIEA (ii) 
NaOH, MeOH (iii) H2/Pd-C, 3h. 
 
A typical 1HNMR for the compound 4.7c is given in figure 
4.15 below. 
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Figure 4.15:.A section of 1HNMR for compound 4.7c in CDCl3. 
 
4.15 Summary 
 
Chapter 4 has discussed a novel arena of research in the 
drive towards the next generation domain-selective ACE 
inhibitors. Currently, there exist no ACE inhibitors that 
do not rely on the ZBG for their activity. Synthesis of 
potential novel ACE inhibitors with an attenuated, or 
indeed with an excluded ZBG could be the answer to domain 
selectivity.  
 
The attenuated ZBG in this research is phosphinic acid 
which is a weak zinc binding group. Its zinc-binding 
ability is further inhibited by its being sterically  
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crowded with bulky groups in the α-position to the reactive 
group. Chapter 4 has presented how a series of inhibitors 
with an attenuated phosphinic acid ZBG have been 
synthesised. Chapter 5 will go on to discuss the biological 
results obtained from these compounds with respect to 
domain selectivity. 
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Chapter 5 
Biological Assays 
5.1 Introduction 
This thesis has thus far described the synthesis of various 
hydroxamate reactive groups and their respective probes. It 
has also given a synthesis of a series of new inhibitors 
with an attenuated phosphinic acid ZBG. Further, it has 
described the synthesis of analogues of current generation 
ACE inhibitors Captopril and Enalaprilat. As clearly 
outlined in Chapter 4, the discovery of current generation 
ACE inhibitor was not all rational but involved elements of 
serendipity. Another famous example of the latter was the 
discovery of penicillin in 1928 by Alexander Fleming1 and 
therefore, it remains an integral part of drug discovery. 
Consequently, a small number of hydroxamate inhibitors were 
synthesized as described in Chapter 4 from the condensation 
of the hydroxamate reactive groups meant for the probes to 
tryptophan.  The biological results for these compounds are 
also reported.  
 
As discussed in earlier Chapters, it should be noted that 
the biological assay results given herein include all 
except those for the hydroxamate based probes for the 
malaria disease model. Further, with the exception of the 
Captopril and Elalaprilat analogues, all the compounds were 
screened as stereoisomeric mixtures. Pure stereoisomers 
could not be obtained because there was no appropriate 
equipment to carry out the separations. However, this was 
not an isolated case as stereoisomers have been screened in 
assays in the literature. 
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The importance of ACE in human homeostasis as well as the 
relevance of ACE inhibitors has been discussed briefly in 
Chapter 1 and given in greater detail in Chapter 4. The 
biological results of all the assays carried out on the C- 
and N-domain constructs of this enzyme with all the 
synthesized compounds will be given in this Chapter in four 
sections beginning with screening of the suitability of the 
initially proposed hydroxamate reactive groups as well as 
those coupled to tryptophan. This will be followed by the 
assays carried out to establish whether the synthesized 
ABPs for the hypertension model would bind and inhibit ACE. 
Thirdly, an examination of the inhibitory and domain 
selectivity profiles of the new compounds in the attenuated 
phosphinic acid series will be carried out. Fourthly, the 
inhibitory and domain selectivity profiles of Enalaprilat 
and Captopril analogues modified by the replacement of the 
P2’ prolyl moiety with a tryptophan will examined.  
 
5.2 Preparation of the Inhibitor Compounds 
The inhibitors (approx. 1mg) were dissolved in an 
appropriate volume of DMSO to give a 20mM inhibitor stock 
solution. The solution was then further diluted with DMSO 
to yield a 50uM stock solution. An appropriate volume of 
Phosphate buffer pH 8.3 containing 0.1M K2HPO4/KH2PO4, 0.3M 
NaCl and 10 µM ZnSO4  was then added resulting in a working 
solution of 250nM of inhibitor.  
 
5.3 Enzymes and substrate 
For the evaluation of ACE selectivity and activity, the 
inhibitors were tested with tACE∆36-g13. 2 This is a variant 
of testis ACE lacking the 36 N-terminal residues unique to 
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this isoform as well as the transmembrane and cytosolic 
regions. Thus, it is identical to the C-domain of somatic 
ACE) and purified N-domain (a minimally glycosylated 
construct of the N-domain of somatic ACE generated by site-
directed mutagenesis)3 protein constructs.  Both these 
proteins used in this study were expressed and purified by 
Ms S.L.U. Schwager of the Zinc Metalloprotease Research 
Group. A 1.05mg/mL stock solution of N-domain enzyme was 
diluted in an appropriate volume of buffer to give a 10 nM 
enzyme working solution while the C-domain working solution 
was diluted in buffer to a working solution of 25nM 
concentration.  
 
5.4 Z-FHL Substrate Preparation 
ACE activity was assayed using the substrate 
benzyloxycarbonyl-phenylalanyl-histidyl-leucine (Z-FHL) 
(Bachem, Budendorf, Switzerland) as described previously. 4 
Z-FHL is a synthetic peptide, a substrate cleaved 
efficiently by both N- and C-domains. A 20mM stock solution 
of Z-FHL was made up by dissolving 110 mg of Z-FHL in 1ml 
0.28 M NaOH and 9 ml distilled water was added to make a 
final volume of 10ml. The working stock solution of 1mM was 
prepared by dilution with an appropriate volume of stock 
buffer solution (0.5M K2HPO4; 0.5M KH2PO4, pH 8.3; 1.5 M 
NaCl, 10 µM ZnSO4) and distilled water to which 2ml Z-FHL 
stock solution was added.   
 
5.5 ACE Assay 
ACE activity was determined using a spectrofluorimetric 
assay. It employs the tripeptide substrate Z-FHL. The assay 
is based on the principle that ACE cleaves penultimate 
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peptide bond to yield an HL moiety that forms a fluorescent 
adduct upon addition of o-pthaldialdehyde.4  The amount 
adduct produced is directly proportional to the amount of 
dipeptide cleaved by ACE and compared to activity of the 
enzyme with a known inhibitor as well as enzyme only with 
no inhibitor as controls. 
 
The screening assay at 250nM is a semi-highthroughput 
screen which gives a read-out of the percentage reduction 
of enzyme activity in the presence of the potential 
inhibitor compared to control experiments which are without 
any inhibitor as a negative control (100% control) as well 
as a positive control using a known inhibitor such as 
Captopril or Lisinopril for comparative purposes.  
Individual ACE domains namely C- and N-domain are incubated 
with a particular inhibitor 40uL of inhibitor working 
solution was pre-incubated with 40uL of individual ACE 
domains namely C- and N-domain of enzyme and incubated at 
room temperature for 15 minutes.   
 
Each experiment was done in triplicate by adding 20uL of 
the pre-incubated solution to each well. 20uL of the 1mM Z-
FHL was then added to each well. The plate was then 
incubated at 37oC in a water bath for 15 minutes. 
Thereafter, each reaction was stopped with 185uL stop 
solution (170uL 0.28M NaOH and 15uL o-pthaldialdehyde 
20mg/ml in methanol) and derivatised for 10 minutes at room 
temperature. Derivatisation was stopped with 25uL of 3N 
HCl. Fluorescent intensities were then measured using a 
Cary Eclipse Varian Fluorescence Spectrophotometer with 
excitation setting at 360 nm and emission at 485 nm (slit 
width 10x10).   
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5.6 Data Analysis 
Graphs of percentage remaining activity of each individual 
ACE domain in the presence of potential inhibitor were 
plotted and analyzed using GraphPad Prism 4.01 (GraphPad 
Software, La Jolla, CA) and/or Microsoft Excel®. The enzyme 
without inhibitor was used as a control and deemed to be 
100% enzyme activity. Experiments were repeated and each 
assay was performed in triplicate. The value resulting from 
the percentage activity remaining for the N-domain as 
numerator divided by that of the C-domain as denominator 
describes the selectivity for the C-domain for each 
inhibitor. The larger this figure is, the more C-domain 
selective the inhibitor appears to be. 
 
5.6.1 Introduction to Assay Results 
These assays served to determine the inhibitory profiles 
and/or C-domain selectivity of the synthesized compounds at 
a fixed 250nM compound concentration with each domain of 
ACE. Bar charts depicting percentage activity of control 
(with no inhibitor) compared with of the 250 nM of each 
compounds incubated with the enzyme were plotted. Here, a 
reduction in enzyme activity to 90% for instance is 
described as 10% inhibition. This provided comparison of 
the ACE inhibition potencies of the compounds as well as 
selectivity for either the C- or N-domain. Compounds 
exhibiting good inhibitory potency at this concentration 
were to then be carried through for IC50 determination with 
individual ACE-domains.  
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5.6.2 In Vitro Assay results for hydroxamate reactive 
groups 3.15-1 to 3.15-6. 
The title compounds have been evaluated for their 
biological activity competitively inhibiting ACE at 250 nM 
concentration with reference to incubation with no 
compound. The percentage remaining activity of the enzyme 
was calculated and is presented in Table 5.1. The results 
indicated that almost all these potential hydroxamate 
“warheads” had low to moderate inhibition of ACE at this 
screening concentration. The compound showing the best 
inhibition of enzyme activity was found to be 3.15-6 with 
30% inhibition of the N-domain activity (equal to 70% 
remaining enzyme activity)  and 15% of the C-domain 
compared to Captopril which had 97% control in the N- and 
98.5% in the C-domain. Compound 3.15-6 had a napthyl 
subtituent in the R-position. The rest of the compounds 
namely 3.15-1 to 3.15-5 (with Cyclohexyl, Isopropyl, methyl 
and phenyl R-substituent) all generally had less than 15% 
inhibition in both domains with no significant preference 
for either domain. This inhibition was not as robust as 
desired in a reactive group to be employed in a probe. It 
was concluded that although hydroxamate compounds with 
related structural features have been reported to be active 
against PfA-M1 (and were used in Malaria probes in this 
thesis) they would not be effective in the hypertension 
targeting ACE. 
 
 
 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Chapter 5: Biological results Discussion 
 
 149
Table 5.1: Effect of compounds 3.15-1 to 3.15-6 (250nM) on ACE 
percentage activity of control compared to no compound at all.  
Compound % Activity remaining 
   N          C 
Selectivity 
Enzyme only 100 100 1.0 
3.15-1 85 95 0.89 
3.15-2 95 95 1.0 
3.15-3 95 95 1.0 
3.15-4 90 90 1.0 
3.15-5 90 100 0.9 
3.15-6 70 85 0.82 
Captopril 3 1.45 0.5 
 
 
Figure 5.1: General structure of compounds 3.15-1 to 3.15-6 
 
5.6.3 In Vitro Assay results for hydroxamate series 4.7a to 
4.7d. 
The title compounds have been evaluated for their 
biological activity competitively inhibiting ACE at 250nM 
as well as 5uM concentration with reference to incubation 
of enzyme with no compound or with known ACE inhibitor 
Lisinopril as negative and positive controls respectively. 
The percentage remaining activity of the enzyme at this 
concentration for these hydroxamic acid derivatives were 
calculated and are presented in Tables 5.2 and 5.2b. For 
all the compounds the results indicated very low (less than 
25% inhibition) to moderate inhibition (more than 25 but 
less than 50%). Further, there was no significant 
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difference observed between results obtained in either the 
N- or C-domain. 
 
Table 5.2: Z-FHL assay of hydroxamate series cross-linked to tryptophan 
at 250nM inhibitor concentration 
 
Compound % Activity Remaining 
  N-Domain      C-domain 
Selectivity 
Lisinopril 3 1.8 1.67 
4.7a  95 88 1.08 
4.7b  90 100 0.9 
4.7c  95 80 1.19 
4.7d  95 60 1.58 
Enzyme 100 100 1 
 
Table 5.2b: Z-FHL assay of hydroxamate series crosslinked to tryptophan 
at 5uM inhibitor concentration 
 
Compound % Activity Remaining 
  N-Domain      C-domain 
Selectivity 
Lisinopril ND 1.8 ND 
4.7a  ND 82 ND 
4.7b  ND 100 ND 
4.7c  ND 91 ND 
4.7d  ND 14 ND 
Enzyme ND 100 ND 
ND: Not determined. 
 
The potential hydroxamate “war heads” 3.15-1 to 3.15-6 
presented poor biological results. This could possibly be 
due to their inability to interact effectively in the S1-, 
S1’- and S2’-subsite pockets of the inhibitors. The R-group 
present may only be interacting with the S1’ but the lack of 
any interaction especially with the all important S2’-
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subsite could have rendered them inactive. Prompted by 
these results, a tryptophan residue was cross-linked to 
these structure resulting in preparation of 4.7a, 4.7b, 
4.7c and 4.7d. We envisaged that the added S2’ interaction 
would result in better biological results which would then 
make them suitable for the preparation of future 
hydroxamate based probes to apply in the hypertension (ACE) 
model. The results obtained with these compounds however 
also presented a low to moderate inhibitory profile. 
Compound 4.7d showed the best promise with a 60 percent 
reduction in ACE activity at 250nM. As presented above, at 
a concentration of 5uM, this compound had a percentage 
reduction of activity of 86%. This compound 4.7d has a 
bulky Napthyl R-group in the P1 position where its analogues 
4.7a, 4.7b and 4.7c had a cyclohexyl, isoleucine, and a 
phenylalanine moiety in the same position. A recent study 
by Akif et al5 suggests that very bulky groups situated in 
the P1’ position are unexpectedly oriented towards the 
deeper S2’ pocket which may rationalize the accommodation of 
such a large side chain. In this case, 4.7d has a 
considerably bulkier R-group which could force its way into 
the S2’ explaining  why this compound exhibited slightly 
better control over the C-domain in the assay. However, the 
difference here is that Akif et al had a bicyclic structure 
with isoxazole heteroatoms nitrogen and oxygen. These were 
found to have interactions with an Asp415 and His383 
respectively.  
 
5.6.4 In Vitro Assay results for ABP’s 3.32a and 3.32b   
The title compounds have been evaluated for their 
biological activity competitively inhibiting C-domain at 5 
uM concentration with reference to incubation of enzyme 
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with no compound. The percentage remaining activity of the 
enzyme at this concentration for the Enalaprilat probe 
3.32a and Captopril probe 3.32b was calculated and is 
presented in Table 5.3. In this case, inhibitor Captopril, 
the enzyme on its own and a buffer only were also used as 
controls to observe change in activity. 
 
The results at 5 uM indicated that the Enalaprilat probe 
3.32a had very low inhibition of ACE (10%) whereas the 
Captopril probe 3.32b had moderate (60%)inhibition leaving 
an apparent 40% ACE activity after 90 minutes incubation. 
 
Table 5.3: Z-FHL assay of enalaprilat probe 3.32a and Captopril probe 
3.32b  at 5 uM 
 
Compound % Activity remaining 
 
 C-domain 
Enzyme Only 100 
Enalaprilat probe 3.32a 90 
Captopril Probe 3.32b 40 
Captopril 5 
 
From these results, the title compounds were further 
evaluated for their biological activity competitively 
inhibiting t-ACE at 250nM concentration with reference to 
appropriate negative and positive controls. The reduction 
in concentration was done mainly to investigate whether a 
similar inhibitory pattern would be observed at this lower 
concentration. The percentage remaining activity of the 
enzyme at this concentration for the Enalaprilat probe 
3.32a and Captopril probe 3.32b was calculated and is 
presented in Table 5.4. Like previously, inhibitor 
Captopril and the enzyme on its own with buffer only were 
also used as controls to observe change in activity. 
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The results indicated that the Enalaprilat probe 3.32a had 
completely no control of t-ACE whereas the Captopril probe 
3.32b had very low control leaving >90% ACE activity after 
90 minutes incubation. 
 
Table 5.4: Z-FHL assay of Enalaprilat probe 3.32a and Captopril probe 
3.32b at 250nM 
 
Compound % Activity remaining 
  C-domain 
Enzyme Only 100 
Enalaprilat probe 3.32a 100 
Captopril Probe 3.32b 90 
Captopril 5 
 
As highlighted in Chapter 1 of this thesis, principally, 
the function of an ABP relies on the inhibitor moiety. 
However, the linker chain, the benzophenone photo-
crosslinker and biotin reporter tag inevitably modify the 
structure and physicochemical features of the inhibitors 
Enalaprilat and Captopril, leading to obvious changes in 
size, bulk and hydrophobicity of the molecules. 
Furthermore, the linker was attached to the C-terminus of 
the inhibitor where a free carboxylate has been described 
to have an important interaction with enzyme active-site 
Lys511. The latter and the former may have reduced the 
inhibitor ability to access and bind the enzyme active-
site, hampering its application for in vitro binding 
resulting in low or no inhibition observed in the screening 
assay.  
 
To overcome this hurdle, it is proposed that a click-
chemistry probe be designed and would be more appropriate. 
This should be an inhibitor-linker combo ABP which is 
untagged but with a small chemical adapter for the 
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attachment of a reporter tag after labeling. This “tag-
free” ABP would maximally resemble the prototype inhibitor 
and minimally affects target binding in vitro. Alkyne and 
azide are two examples of such adapters. Following covalent 
labeling of protein targets, the probe may be ligated to 
the reporter tag in vitro, through appropriate chemical 
techniques.6,7 Chemical adapters such as those mentioned 
above are inert in assay aqueous media while their coupling 
is quick, efficient and specific under mild conditions in 
the presence of water. Another advantage of this two-step 
labeling strategy is that it would allow one probe to 
accept diverse reporter tags, and simplifies probe design 
and synthesis.  
 
L-fucose
glycoconjugate
substrateFucTs
O
N3
O
N3
O
N3
1-P
O
N3
GDP
O
N3
GDP
glycoconjugate O
N
glycoconjugateO
N3
NN
Golgi
 
Figure 5.2: An illustration of the application of a click chemistry 
probe.7 
 
5.6.5 In Vitro Assay results for Enalaprilat and Captopril 
analogues 4.4d, 4.4e, 4.5d and 4.5e. 
 
The title compounds have been evaluated for their 
biological activity competitively inhibiting the N- or C- 
domains of ACE at 250nM concentration with reference to a 
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negative and positive controls, enzyme with no compound and 
Captopril. The percentage remaining activity of the enzyme 
at this concentration for the Captopril and Enalaprilat 
analogues 4.4d, 4.4e, 4.5d and 4.5e were calculated and are 
presented in Table 5.5. All four compounds exhibited 
approximately 20% activity reduction in the N-domain at 
this concentration. In the C-domain however, the figures 
observed were 0, 30, 20, 0% percentage control of activity 
for 4.4d, 4.4e, 4.5d and 4.5e respectively. In terms of 
significance of inhibition, these results were very low 
compared to the control, Captopril. Furthermore, as 
highlighted above, there is no significant preference for 
either the N- or C-domain in all the compounds at 250nM 
concentration. 
Table 5.5: Percentage activity remaining of ACE compared to Captopril 
as a standard 
Compound % Activity remaining 
 N-domain  C-domain 
Selectivity 
Enzyme 100 100 1.0 
4.4d 80 100 0.8 
4.4e 80 70 1.14 
4.5d 80 80 1.0 
4.5e 80 100 0.8 
Captopril <1 <1 1 
 
One hypothesis of this research was that the tryptophan 
residue of RXPA380 may not be the only structural 
determinant of C-domain selectivity. Consequently, 
established ACE inhibitors Enalaprilat and Captopril were 
modified by replacement of the prolyl moiety with the 
bulkier tryptophan residues as is found in RXPA380 as well 
as replaced with a phenylalanine residue. Any change in 
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selectivity between the N- and C-domain would provide 
insight into this domain selective-behaviour and effect of 
these residues. A previous study in our group (Zinc 
Metalloprotease Group) on Lisinopril involved a similar 
strategy as well as molecular docking studies.8 It was found 
that the S2’ subsite of the enzyme readily accommodated the 
tryptophan moiety of the Lisinopril derivative a finding 
which confirmed earlier studies highlighting the importance 
of a deep S2’ pocket as a determinant of C-domain-
selectivity. 9 It was expected therefore that with the  
tryptophan moietiy, additional hydrophobic and hydrogen-
bonding interactions with S2’ residues Thr282, Val379, 
Val380, and Asp453 of the C-domain active site (Fig. 2), 
and may increase the C-domain-selectivity of these 
compounds as compared with Enalaprilat and Captopril. 
 
However, the results indicated very low to moderate 
inhibition and no significant difference between the N- or 
C-domain selectivity. These results could be attributed to 
the inevitable change  in the 3-dimensional structure and 
physicochemical properties of these compounds compared to 
Enalaprilat and Captopril. The latter could have caused 
different molecular orientation in the active site and sub-
site residues resulting in little or no inhibition.  
 
 
5.6.6 In Vitro Assay results for Phosphinic acids 4.2i-1 to 
4.2i-16. 
The rationale behind the design of these phosphinic acids 
was based on minimizing or eliminating the interaction with 
the catalytic Zn2+ ion to achieve domain selectivity. The 
metal site is the most conserved feature between the N- and 
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C-domains of ACE. Phosphinates were chosen because of the 
advantageous placement of the ZBG in the middle of a 
pseudopeptidic scaffold and not at its N- or C-terminus, as 
in the cases of hydroxamate, carboxylate and sulfhydryl 
inhibitors. Then R-groups were strategically placed in the 
positions adjacent to the ZBG to partially mask and 
consequently attenuating the ZBG. Structural diversity was 
introduced by placing various groups in the P1 and P1’ 
moeities of the potential inhibitors. The title compounds 
were evaluated for their biological activity competitively 
inhibiting ACE at a fixed concentration of 250nM with 
control reference to incubation of enzyme with no compound 
as negative control and Lisinopril being the positive 
control. The percentage remaining activity of the enzyme at 
this concentration for these phosphinic acid derivatives 
were calculated and are presented in Table 5.6.  
 
These inhibition studies for the compounds showed that 
4.2i-7 had the best efficiency to inhibit the C-domain at 
53%, and 21% in the N-domain.  Compounds 4.2i-4, 4.2i-10, 
4.2i-11, 4.2i-14, 4.2i-15 and 4.2i-16 exhibited 33, 34, 32, 
39, 36 and 36% inhibitory efficiency in the C-domain 
compared to 0, 4, 11, 22, 18 and 27% respectively in the N-
domain. Compounds 4.2i-5 and 4.2i-8 showed generally little 
or no activity exhibiting between 0 and 4 % inhibition in 
the C- and 0 and 8% in the N-domain. Others were compounds 
4.2i-6, 4.2i-9, 4.2i-12 which exhibited minimal inhibition 
(27, 19 and 25%) in the C-domain and completely no 
inhibition in the N-domain.  
 
It is worth noting that although all the compounds did not 
have excellent inhibitory potency, it was observed 
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generally that the compound with the best efficiency to 
inhibit the C-domain of ACE, namely, 4.2i-7 and those with 
efficiency closely related to it such as 4.2i-11 and 4.2i-
15 all have the phenylalanine moiety in the P1-position. 
From the X-ray crystalstructure of RXPA380 in the C-domain, 
this bulky group interacts with the S1 subsite of the C-
domain and possibly hydrophobic interactions occurring with 
the Val518 residue which is replaced by a Tyr496 in the N-
domain. Generally, the S1 in the C-domain construct is more 
hydrophobic than that in the N-domain. This phenylalanine 
feature of the molecule is therefore expected to be better 
accommodated by the C-domain. However, at best, only a 1.68 
preference was observed for the C- over the N-domain in 
4.2i-7. This could also explain the reason why compounds 
such as 4.2i-4, 4.2i-10, 4.2i-14 and 4.2i-16 also exhibited 
a slight preference of the C- over the N-domain. The latter 
compounds had either a propyl chain or a tert-butyl moiety 
which was possibly stretching more to the part of the S1 
subsite where the VAL518 is located. 4.2i-5 and 4.2i-9 
which both have only a methyl group in the same position 
showed the least measure of control as well as difference 
in domain preference. 
 
Both in terms of selectivity as well as inhibition, it 
seemed the best combination of R-groups was the phenyl 
alanine in the P1 position and a propyl moiety in the P1’ 
position. Generally however, bulky hydrophobic groups 
performed better than the smaller methyl groups in the P1-
position as was seen with compounds 4.2i-2, 4.2i-4, 4.2i-7, 
4.2i-11, 4.2i-10, 4.2i-14, 4.2i-16. Compounds with the 
smaller methyl groups in the P1 position such as 4.2i-5 and 
4.2i-9 had no inhibition in the N- domain and approximately 
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4% control in the C-domain. In the P1’ position however, no 
particular pattern was observed and both bulkier and 
smaller groups were reasonably accommodated with activity 
control in the C-domain of up to 40% at 250nM concentration 
being observed in compounds with both a small and/or larger 
moiety. Going by this observation, it may be suggested that 
the S1’subsite is able to tolerate a wider range of 
substituents and it would be worthwhile in future to 
conduct an SAR study with groups of diverse electronic 
configuration such as heteroatoms as well as electron 
donating and withdrawing group. 
 
Table 5.6: Z-FHL assay of phosphinic acid series at 250nM inhibitor 
concentration 
Compound R1 R2 % Activity 
Remaining 
N-   C-domain 
Selectivity 
Lisinopril   3.2 1.8 ~1.8 
4.2i-1 CH3 CH3 ND ND ND 
4.2i-2 C(CH3)3 CH3 100 60 1.67 
4.2i-3 CH2Ph CH3 ND ND ND 
4.2i-4 CH2CH2CH3 CH3 100 67 1.49 
4.2i-5 CH3 CH2CH2CH3 100 96 ~1 
4.2i-6 C(CH3)3 CH2CH2CH3 100 73 1.37 
4.2i-7 CH2Ph CH2CH2CH3 79 47 1.68 
4.2i-8 CH2CH2CH3 CH2CH2CH3 91 100 0.91 
4.2i-9 CH3 C(CH3)3 100 81 1.2 
4.2i-10 C(CH3)3 C(CH3)3 96 66 1.45 
4.2i-11 CH2Ph (CH3)3 89 68 1.31 
4.2i-12 CH2CH2CH3 (CH3)3 100 75 1.36 
4.2i-13 CH3 CH2Ph ND ND ND 
4.2i-14 C(CH3)3 CH2Ph 78 61 1.28 
4.2i-15 CH2Ph CH2Ph 82 64 1.28 
4.2i-16 CH2CH2CH3 CH2Ph 73 64 1.14 
Enzyme 
  
100 100 1 
ND: Not determined. Insufficient purity 
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Figure 5.3: General structure for the design of target compounds 
depicted in the active site with varied R-groups as per the Table 5.6. 
 
From the foregoing, it may further be suggested that ZBG is 
an essential feature for effective binding in the ACE 
active site. This being the case, it is proposed that in 
future, exploration and structure activity relationship 
studies be pursued with cyclic bioisosteres such as 1,2,4- 
and 1,3,4-Oxadiazoles and Oxathiazoles in attempts to 
retain the zinc binding capability while reducing the 
dependence on it for binding. Another angle would  be the 
inclusion of a non sterically hindered (or attenuated) 
analogue without groups in the positions adjacent to the 
ZBG  with an identical carbon chain backbone that is a good 
inhibitor as a positive control.   
 
Generally for existing ACE inhibitors, it would also be 
important to carry out an SAR investigation on the 
influence of heteroaromatic groups as well as a small 
variety of electron donating and withdrawing substituents 
in the R-groups as these would possibly pick up more 
interactions in the amino acid residues of the active site. 
Consideration of such changes are highly recommended in 
drug discovery. 10 Another proposal would be to carry out 
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high through-put biological screens of compound libraries 
with the separate domains of ACE. The latter has the 
potential of revealing possible domain selective compounds 
and/or resulting in completely new scaffolds on which to 
base future hypertension ACE-inhibitor drug discovery. 
Furthermore, carrying out a fragment based modelling may 
lead to identification of potential novel fragments.  
 
5.7 Future Biological Work 
Validation of assay results above was attempted at 
different concentrations. 5uM concentration was also 
attempted in order to try and observe enhanced inhibition 
of the enzyme by the inhibitors. The phosphinic acid 
derivatives were problematic in that they precipitated out 
of buffer solution at concentrations higher than 250nM. 
Care was taken to ensure not more that 1% DMSO was in the 
assay media and more of the buffer was used, but this 
generally resulted in the compounds precipitating out of 
solution. This work was not pursued further due to time 
constraints. However, as a way forward in the design of 
these and new inhibitors, appropriate solubility studies be 
carried out. The solubility problems faced in this research 
may be approached from several angles.  Firstly, 
appropriate modification of the dilution protocol can be 
made, or secondly detailed assessment of compound 
solubility can be conducted, thirdly, the ACE assay can be 
optimized for less soluble compounds such as these. Finally 
during the inhibitor design, moieties with hydrogen bond 
donors and acceptors or other groups that can enhance 
solubility should be incorporated in the scaffold.  
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Furthermore, an SAR study is recommended for the 
hydroxamates cross-linked to a tryptophan residue above and 
when compounds are identified that would reduce the 
percentage remaining activity to the region of 10% or 
lower, IC50 values would then be determined. The IC50 is a 
term used to describe the inhibitor concentration required 
to cause a 50% decrease in enzyme activity. The lower the 
IC50 value of a compound, the greater the inhibition. A 
sigmoidal-dose response curve analysis is used to determine 
the IC50 values.  
 
This chapter has given biological assay results as well as 
offered a biological discussion with regards to all 
compounds assayed. Although very good inhibition amy not 
have been observed, in-roads have been established on the 
design and synthesis of new probes for use in the 
hypertension disease model. Apart from this, new compounds 
have been synthesized and assayed and have revealed the 
effects of carrying out certain modifications on existing 
as well as new inhibitors. Furthermore, synthesized 
aminophosphinates have been employed successfully in 
biological evaluation of the C- and N-domain constructs of 
Angiotensin-converting enzyme.  
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Chapter 6 
 
Conclusion 
 
6.0 Conclusion 
The simplicity of the chemistry employed during the 
synthesis, coupled with the commercial availability of 
reagents in all synthetic areas makes the synthesis of the 
probes, phosphinic acids, hydroxamates, Enalaprilat and 
Captopril derivatives an attractive route in the 
development of domain-selective inhibitors.  
 
ABPs have been introduced in the arena of hypertension 
research through a captopril-linked probe among others that 
can be potentially employed to label whole proteomes in the 
elevated hypertension disease condition compared to the 
normal condition. These newly synthesized probes did not 
show significant inhibitory results probably due to altered 
physicochemical properties and bulk. Proposals for future 
work to cross these hurdles have been forwarded in the 
biological discussion given in Chapter 5 in the form of 
“click chemistry” probes. Synthetic routes for the 
synthesis of new probes for future use in malaria research 
have also been successfully developed.  
 
New phosphinic acid-based ACE inhibitors with a substituent 
in the α-position relative to the phosphinate ZBG as 
potential novel antihypertension agents have been 
synthesized via three-component pseudo-Kabachnik-Fields 
reaction involving an aldehyde, amine and phosphoryl 
compound. It should be noted however that the purification 
of the resultant phosphinate derivatives was challenging 
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because some of the reactions never went to completion and 
resulted in multiple products forming. The desired 
compounds had to be carefully isolated using prep TLC or 
reversed phase HPLC using appropriate solvent systems.  
 
New potential ACE-inhibitors incorporating a tryptophan 
residue in the P2’of the captopril and enalaprilat scaffold 
have also been prepared. Although the results ranged from 
low inhibition to no inhibition at all, biological assays 
have been carried out to evaluate the domain selectivity of 
all synthesised compounds in vitro using appropriate ACE 
inhibitory assays.  
 
The sulfhydryl and carboxylate ABP’s, hydroxamates as well 
as the phosphinic acids were evaluated with enzymatically 
active purified C- and N-domain constructs. Although the 
carboxylic acid probe 3.32a showed no inhibition, the 
sulfhydryl probe 3.32b exhibited an apparent IC50 of 25 µM.  
 
For the hydroxamate inhibitors, compound 4.7d was found to 
inhibit ACE by 86% at 5 µM. Amongst the phosphinic acid 
compounds with the attenuated zinc-binding group, 4.2i-7 
inhibited the C-domain construct by 53% whereas 4.2i-2, 
4.2i-14, and 4.2i-16 inhibited by 40, 39 and 36% 
respectively at 250 nM The different groups adjacent to the 
ZBG’s had varying degrees of effect on the activity of the 
compounds with the most active 4.2i-7 having a pseudo-
phenylalanine moiety in the α- and a propyl group in the 
α’-position relative to the phosphinic acid. On the other 
hand, compared to the 99% inhibition by Captopril in both 
domains, Enalaprilat analogue 4.4e inhibits by 30 and 20% 
in the C- and N domains where Captopril analogue 4.5d 
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inhibit both domains by 20% respectively at 250 nM. None of 
the compounds showed significant selectivity for the C- or 
N-domains. 
 
Finally, in retrospect, a lesson learnt from this research 
is that instead of carrying out biological assays at the 
end of the synthesis, an iterative cycle of synthesis and 
design, guided by biological results would have been more 
instructive. 
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Chapter 7 
General Experiment 
All commercially available chemicals were purchased from 
either Sigma-Aldrich or Merck, South Africa, unless 
otherwise stated. Reactions were monitored by thin layer 
chromatography using Merck F254aluminum-backed pre-coated 
silica gel plates and were visualized by ultraviolet light 
or iodine vapor. Silica gel chromatography was performed 
using Merck kieselgel 60: 70-230 mesh for gravity columns. 
Melting points were determined on a Reichert-Jung Thermovar 
hotstage microscope and are uncorrected. Microanalyses were 
determined using a FisonsEA 1108 CHNO-S instrument. Low 
Resolution Mass Spectra were recorded on an API 4000 triple 
quadropole (Applied Biosystems), fitted with a Turbo Ion 
spray source, samples were introduced via Harvard Syringe 
Pump at 10ul/min. High resolution MS data are not given as 
the facility was not available. 
 
Purity was routinely measured by HPLC on a Thermo 
Separation Products (Spectra Physics) reversed phase HPLC 
instrument with a P200 Gradient Pump and a UV2000 UV/VIS 
detector fitted with a Technokroma C18 semi-preparative 
Tracer EXcel 120 ODSB 5mm 20 x 1.0 column.Mobile phases: 
0.1% TFA in millipore purified water (A) and 0.1% TFA and 
75% HPLC grade acetonitrile in Millipore purified water 
(B). A gradient was formed from 80% of A in 5 minutes and 
held at 80% for 30 min, then 100 B for 3 minutes and back 
to 80% A for two minutes; flow rate was 0.3 mL/min and 
injection volume was 50 µL; retention times (HPLC, tR) are 
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given in minutes. Compound HPLC purity was determined by 
monitoring at 215 and 280 nm.  
 
1H NMR spectra were recorded on a Varian Mercury 
spectrometer at 300 MHz, a Varian Unity Spectrometer at 400 
MHz and a Bruker Systems Avance III 400MHz instrument. All 
spectra were recorded in deuterochloroform, 
deuterodimethylsulfoxide, deuteromethanol or D2O downfield 
from tetramethylsilane (TMS) as an internal standard. All 
chemical shifts are recorded in ppm. H-bonding between 
compounds containing NH2 or OH groups and the deuterated 
methanol or deuterated water resulted in a reduction of 
hydrogen signals observed in 1H NMR spectra.1HNMR coupling 
constants are measured in Hertz and are rounded off 
resulting in exactly the same coupling constants for 
coupling partners.  
 
13C NMR spectra were measured on a Varian Mercury 
spectrometer at 75 MHz or a Varian Unity spectrometer at 
100 MHz or a Bruker Systems Avance III 400MHz instrument. 
The format used for recording 13C NMR data is that accepted 
by most international journals (including American Chemical 
Society journals). In this format chemical shift values are 
simply listed without specific assignment to carbon atoms. 
 
Dry solvents were prepared by appropriate techniques. 
Tetrahydrofuran was dried over lithium aluminium hydride 
and subsequently distilled over sodium wire prior to using 
benzophenone as indicator. Methylene chloride was dried 
over phosphorous pentoxide and distilled prior to use. 
Unless otherwise stated, all other solvents used were AR 
grade solvents. 
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General procedure for the synthesis of compounds 3.3b-3, 
3.3b-4, 3.3b-5 and 3.3b-6 
To a stirred solution of 2,2-Dimethyl-1,3-dioxane-4,6-dione 
(2.16g, 15.0 mmol) in 40 ml EtOH was added K3PO4 (0.6 g, 
2.82 mmol) followed by a solution of the appropriate 
aldehyde (15.0 mmol) in 5 ml EtOH. Mechanical stirring was 
continued until completion of the reaction (TLC) and to it 
NaBH4 (1.2g, 31.50 mmol) was added. On completion of the 
reaction (TLC) the solvent was removed in vacuo. H2O (50 ml) 
was added and the mixture acidified to pH4 with 1NHCl. This 
mixture was then separated with EtOAc. The organic layer 
was washed several times with H2O (4 x 50 ml) and dried over 
MgSO4. After evaporation of the solvent in vacuo and 
recrystallization from EtOAc/Hexanes 5-substituted-2,2-
dimethyl-1,3-dioxane-4,6-dione’s 3.3b-3, 3.3b-4, 3.3b-5 and 
3.3b-6 were obtained. 
 
O O
O O
1 2
3
4
 
 
(±)5-Benzyl-2,2-dimethyl-1,3-dioxane-4,6-dione 3.3b-5 
Yield:91%; Colourless crystals from EtOAc-Hexane; m.p. 80-
81 oC (Lit.1 m.p. 82-84); 1H NMR (400 MHz, CDCl3) δH 1.7 (s, 
6H, H-1/2), 3.4 (d, J = 12 Hz, 2H, H-4), 4.0 (t, J = 7 Hz, 
1H, H-3), 7.25 (m, 5H, PhH). 
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O O
O O
1 2
3
4
 
 
(±)5-(Cyclohexylmethyl)-2,2-dimethyl-1,3-dioxane-4,6-dione 
3.3b-4  
Yield: 79 %; colourless crystals from EtOAc-Hexane; m.p. 
110-112 oC; 1H NMR (400 MHz, CDCl3) δH0.95 (m, 2H, Cyclo-CH), 
1.3 (m, 4H, Cyclo-CH), 1.7 (s, 6H, H-1/2), 1.8 (m, 5H, 
Cyclo-CH), 2.0 (dd, J = 11, 4 Hz, 2H, H-4), 3.6 (t, J = 7 
Hz, 1H, H-3); 13C NMR (100 MHz, CDCl3) δC 26.0, 26.3, 27.1, 
27.3, 28.6, 32.9, 33.3(2C), 33.8, 44.1, 104.5, 168.1, 
168.6; m.p. 110-112 ˚C. 
 
 
(±)2,2-Dimethyl-5-(naphthalen-1-ylmethyl)-1,3-dioxane-4,6-
dione 3.3b-6 
Yield: 90 %; Colourless crystals from EtOAc-Hexane; m.p. 91 
– 94 oC; 1H NMR (400 MHz, CDCl3) δH1.7 (s, 6H, H-1/2), 3.15 
(d, J = 9 Hz, 2H, H-4), 4.1 (t, J = 7 Hz, 1H, H-3), 7.3 (m, 
7H, Naphthyl-H); MS m/z 284.31. 
 
General procedure for the preparation of compounds 3.5a-3, 
3.5a-4, 3.5a-5 and 3.5a-6 
 
5-substituted-2,2-dimethyl-1,3-dioxane-4,6-dione (11.00 
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mmol) was dissolved in DMF (15 ml). K2CO3 (2.073, 15.00 
mmol) was then added and stirred for 10 min at r.t. Allyl 
bromide (1.3 ml, 1.815 g, 15.00 mmol) was added to the 
mixture and stirred overnight. H2O was added and the mixture 
separated with EtOAc. The organic layers were repeatedly 
washed with water (3 x 50 mL) and dried over MgSO4. The 
solvent was removed under reduced pressure and the crude 
product was purified on silica gel, eluting with 20% EtOAc-
Hexane giving 5-bis-substituted-2,2-dimethyl-1,3-dioxane-
4,6-dione derivatives 3.5a-3, 3.5a-4, 3.5a-5 and 3.5a-6. 
 
O O
O O
1 2
3
4 5
6
 
 
5-Allyl-5-benzyl-2,2-dimethyl-1,3-dioxane-4,6-dione 3.5a-5. 
Yield: 75 %; Pale yellow oil; 1H NMR (400 MHz, CDCl3) δH1.6 
(s, 6H, H-1/2), 2.6 (d, J = 7.6 Hz, 1H, H-3), 3.2 (s, 2H, 
H-6), 4.9 (dd, J = 12, 5 Hz, 2H, H-5), 5.5 (m, 1H, H-4), 
7.2 (m, 5H); Anal. Calcd. for C16H18O4: C, 70.06; H, 6.61. 
Found: C, 70.26; H, 6.64.; MS calculated for C16H18O4 m/z 
274.1 [M+1], found 274.2. 
 
 
O O
O O
1 2
3
4
5
6
 
 
5-Allyl-5-(cyclohexylmethyl)-2,2-dimethyl-1,3-dioxane-4,6-
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dione 3.5a-4. 
Yield: 80 %; Clear colourless oil; 1H NMR (400 MHz, CDCl3) 
δH0.8 (m, 2H, Cyclo-CH), 1.1 (m, 1H, Cyclo-CH), 1.3 (m, 2H, 
Cyclo-CH), 1.6 (s, 6H, H-1/2), 1.7 (m, 6H, Cyclo-CH),1.75 
(d, J = 9 Hz, 2H, H-6), 2.7 (d, J = 8 Hz, 2H, H-3), 5.0 (m, 
2H, H-5), 6.2 (m, 1H, H-4). 
 
O O
O O
1 2
3
4 5
6
 
 
5-Allyl-2,2-dimethyl-5-(naphthalen-1-ylmethyl)-1,3-dioxane-
4,6-dione 3.5a-6 
Yield:90 %; A light brown oil; 1H NMR (400 MHz, CDCl3) δH1.7 
(s, 6H, H-1/2)2.7 (d, J = 8 Hz, 1H, H-3), 3.7 (s, 2H, H-6), 
5.1 (dd, J = 12,5Hz, 2H, H-5), 6.2 (t, J = 7 Hz, 1H, H-4), 
7.3 (m, 7H); Anal. Calcd. for C20H20O4: C, 74.06; H, 6.21. 
Found: C, 74.26; H, 6.64.; MS calculated for C20H20O4m/z 
324.2 [M+], found 323.1. 
 
 
5-Allyl-5-isobutyl-2,2-dimethyl-1,3-dioxane-4,6-dione 3.5a-
3. 
Yield: 88 %; Light yellow solid m.p. 91-94 ˚C; 1H NMR (400 
MHz, CDCl3) δH 0.91 (s, 6H, H-8/9), 1.4 (m, 1H, H-7),  1.7 
(s, 6H, H-1/2) 2.0 (d, J = 9 Hz, 2H, H-6), 2.6 (d, J = 9 
Hz, 2H, H-3), 4.9 (m, 2H, H-5), 5.9 (m, 1H, H-4).  
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General Procedure for the preparation of compounds 3.7a-3, 
3.7a-4, 3.7a-5, 3.7a-6 
 
A suspension of 5-Allyl-5-substituted-2,2-dimethyl-1,3-
dioxane-4,6-dione (2.10 mmol) in NaOH (2M, 10 mL) and 1,4-
dioxane (5 mL) was stirred at 100 °C for 3 h. The resulting 
clear solution was concentrated, acidified to pH 1 by 
adding 6 M HCl, and extracted with EtOAc (25 mL). The 
extract was dried over MgSO4, filtered, and concentrated. 
The resulting residue was dissolved in DMSO (10 mL), and 
the solution was stirred at 130 °C for 3 h. The reaction 
mixture was taken up in EtOAc (80 mL), washed with water 
(40 mL x 2), dried over MgSO4, filtered, and concentrated. 
The residual material was purified by chromatography on 
silica gel eluting with 20 % EtOAc in hexanes to give the 
2-substituted-4-pentenoic acids 3.7a-3, 3.7a-4, 3.7a-5, 
3.7a-6. 
 
 
(±)-2-Benzyl-4-pentenoic acid 3.7a-5. 
 
Yield: 76 %; Acolourless waxy oil;1H NMR (400 MHz, CDCl3) δH 
2.2 (m, 1H, H-3a), 2.6 (m, 1H, H-3b),2.8(m, 1H, H-4),  2.9 
(dd, J = 12, 7 Hz, 1H, H-5a), 3.1 (dd, J = 12, 7 Hz, 1H, H-
5b), 5.0 (dd, J = 12, 5 Hz, H-1) 5.9 (m, 1H, H-2), 7.3 (m, 
5H, Ph-H);Anal. Calcd for C12H14O2: C, 75.76; H, 7.42; found: 
C, 75.50; H, 7.50. MS calculated for C12H14O2 m/z 190.3 
[M+H], found 189.1. 
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(±)-2-(Cyclohexylmethyl)-4-pentenoic acid3.7a-4. 
Yield: 67 %; 1H NMR (400 MHz, CDCl3) δH 0.9 (m, 2H, Cyclo-
CH), 1.1(m, 1H, Cyclo-CH), 1.3(m, 4H, Cyclo-CH),1.6(t, J = 
7 Hz, 1H, H-5), 1.7(m, 3H, H-Cyclo-CH), 1.8 (m, 3H, H-
5/Cyclo-CH), 2.1(m, 1H, H-4), 2.3(m, 1H, H-3a), 2.4(m, 1H, 
H-3b),5.1(dd, J = 12, 8 Hz, 2H, H-1), 5.8(m, 1H, H-2). 
 
 
(±)-2-Isobutyl-4-pentenoic acid 3.7a-3. 
Yield: 70 %; Clear colourless oil. 1H NMR (400 MHz, CDCl3) 
δH 0.9(d, J = 12Hz, 6H, H - 7/8), 1.5(m, 1H, H-6), 1.6(t, J 
= 7Hz, 1H, H-5a), 1.7(t, J = 7Hz, 1H, H-5b), 2.3(m, 2H, H-
3a/4), 2.4 (m, 1H, H-3b) 5.1(m, 2H, H-1), 5.9(m, 1H, H-2).  
 
 
 
(±)-2-(Naphthalen-1-ylmethyl)-4-pentenoic acid 3.7a-6. 
Yield: 88 %; 1H NMR (400 MHz, CDCl3) δH 2.3(m, 1H, H-3a), 
2.7(m, 1H, H-3b), 3.1(m, 2H, H-4/5a), 3.4 (dd, J = 12, 6 
Hz, 1H, H-5b) 5.1 (m, 2H, H-1), 6.0(m, 1H, H-2), 7.3 (m, 
7H, Ph-H). MS calculated for C16H16O2m/z 240.6 [M+1], found 
239.2. 
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General Procedure for the preparation of compounds 3.7b-3, 
3.7b-4. 3.7b-5, 3.7b-6 
 
The carboxylic acid (1.58 mmol) was dissolved in MeOH (8 
mL) and the mixture cooled to 0 oC in an ice bath. SOCl2 
(0.28 g, 0.173 ml, 2.37 mmol) was added dropwise over 10 
min. The reaction was stirred at 0 oC for one hour and 
allowed to warm to room temperature. It was allowed to stir 
further overnight. Thereafter, the solvent was removed in 
vacuo leaving the products 3.7b-3, 3.7b-4. 3.7b-5, 3.7b-6 
which were used in the next step without further 
purification. 
 
CO2CH31
2
3 4
5
 
 
(±) Methyl-2-benzyl-4-pentenoate 3.7b-5.  
Yield: 76 %; A colourless waxy oil;1H NMR (400 MHz, CDCl3) 
δH 2.2 (m, 1H, H-3a), 2.6 (m, 1H, H-3b),2.8(m, 1H, H-4),  
2.9 (dd, J = 12, 7 Hz, 1H, H-5a), 3.1 (dd, J = 12, 7 Hz, 
1H, H-5b),3.7(s, 3H, OCH3), 5.0 (dd, J = 12, 5 Hz, H-1) 5.9 
(m, 1H, H-2), 7.3 (m, 5H, Ph-H). 
 
CO2CH31
2
3 4
5
 
(±) Methyl-2-(cyclohexylmethyl)-4-pentenoate 3.7b-4. 
Yield: quant.; Colourless oil; 1H NMR (400 MHz, CDCl3) δH1.0 
(m, 2H, Cyclo-CH), 1.3(m, 4H, Cyclo-CH), 1.5(t, J = 8 Hz, 
1H, H-5a) 1.7 (m, 4H, H-5b/Cyclo-CH), 1.8(m, 2H, Cyclo-CH), 
2.1(m, 1H, H-4), 2.2(m, 1H, H-3a), 2.4(m, 1H, H-3b),  
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3.6(s, 3H, OCH3), 5.1(d, J = 9 Hz, 2H, H-1), 5.8(m, 1H, H-
2). 
 
 
(±) Methyl-2-isobutyl-4-pentenoate 3.7b-3.  
Yield: 70 %; Clear colourless oil. 1H NMR (400 MHz, CDCl3) 
δH 0.9(d, J = 12Hz, 6H, H - 7/8), 1.5(m, 1H, H-6), 1.6(t, J 
= 7Hz, 1H, H-5a), 1.7(t, J = 7Hz, 1H, H-5b), 2.3(m, 2H, H-
3a/4), 2.4 (m, 1H, H-3b), 3.6(s, 3H, OCH3), 5.1(m, 2H, H-
1), 5.9(m, 1H, H-2).  
 
CO2CH31
2
3 4
5
 
 
(±) Methyl-2-(naphthalen-1-ylmethyl)-4-pentenoate 3.7b-6.  
Yield: Quant; 1H NMR (400 MHz, CDCl3) δH 2.3(m, 1H, H-3a), 
2.7(m, 1H, H-3b), 3.1(m, 2H, H-4/5a), 3.4 (dd, J = 12, 6 
Hz, 1H, H-5b), 3.7(s, 3H, OCH3), 5.0 (m, 2H, H-1), 6.0(m, 
1H, H-2), 7.3 (m, 7H, Ph-H). MS calculated for C17H18O2 m/z 
254.3 [M+1], found 253.2. 
 
 
General Procedure for the preparation of compounds 3.7c-3, 
3.7c-4, 3.7c-5, 3.7c-6 
 
To a solution of alkene (1.42 mmol) in acetonitrile (10 
mL), CCl4 (5 mL) and H2O (5 mL) were added NaIO4 (1.82 g, 
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8.52 mmol) and a catalytic amount of ruthenium oxide (0.3 
eq., 0.06 g, 0.43 mmol). The mixture was stirred at room 
temperature for 20 h. The reaction mixture was filtered, 
and the filtrate was concentrated. The resulting mixture 
was extracted with EtOAc (40 mL x 2), and the combined 
extracts were washed with brine (40 mL), dried over MgSO4, 
filtered, and concentrated. The residual material was 
purified by silica gel chromatography eluting with 30 % 
EtOAc in Hexane to give the carboxylic acid products 3.7c-
3, 3.7c-4, 3.7c-5, 3.7c-6. 
 
 
 
 
(±)3-Benzyl-4-methoxy-4-oxobutanoic acid 3.7c-5 
Yield: 65 %; Clear colourless oil; 1H NMR (400 MHz, CDCl3) 
δH 2.7 (dd, J = 13, 5 Hz, 1H, H-1a), 2.9 (dd,  J = 12, 5 Hz, 
1H, H-1a), 3.1 (dd, J = 12, 8 Hz, 1H, H-3a), 3.2(m, 1H, H-
2), 3.5 (m, 1H, H-3b), 3.7 (s, 3H, OCH3),  7.1 (m, 5H, Ph); 
m/z = 222.1 [M+1]. Anal.Calcd.for C12H11O4: C, 64.85; H, 
6.35. Found: C, 64.61; H, 6.20%. 
 
 
(±)3-(Cyclohexylmethyl)-4-methoxy-4-oxobutanoic acid 3.7c-4 
Yield: 55 %; Clear colourless; 1H NMR (400 MHz, CDCl3): 
δH1.0 (m, 2H, Cyclo-CH), 1.1(m, 1H, Cyclo-CH), 1.3 (m, 4H, 
H-Cyclo-CH), 1.6(m, 1H, H-3a), 1.7(m, 3H, Cyclo-CH), 1.8(m, 
2H, Cyclohexyl-CH), 2.0 (t, J = 8 Hz, 1H, H-3b), 2.5(m, 1H, 
H-2), 2.7 (dd, J = 12, 5 Hz, 1H, H-1a), 3.0 (m, 1H, H-
1a)3.7 (s, 3H, OCH3). 
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(±)3-(Methoxycarbonyl)-5-methylhexanoic acid 3.7c-3 
Yield: 61 %; Clear colourless oil; 1H NMR (400 MHz, CDCl3) 
δH 0.9(d, J = 12Hz, 6H, H - 5/6), 1.6 (m, 1H, H-3a/4), 2.1 
(t, J = 7 Hz, 1H, H-3b) 2.5 (m, 1H, H-2), 2.7(dd, J = 12, 
5Hz, 1H, H-1a), 3.0 (dd, J = 12, 5 Hz, 1H, H-1b),3.7(s, 3H, 
OCH3). 
 
 
(±)4-Methoxy-3-(naphthalen-1-ylmethyl)-4-oxobutanoicacid 
3.7c-6. 
Yield: 60 %; Brown waxy oil; 1H NMR (400 MHz, CDCl3) δH 2.7 
(m, 1H, H-1a), 3.0(m, 1H, H-1b),3.3(m, 1H, H-3a), 3.5(m, 
2H, H-3b/2), 3.7(s, 3H, OCH3), 7.1-7.8(m,7H, Naphthyl-H).  
 
 
(±)4-Methoxy-3-methyl-4-oxobutanoic acid 3.13b-1 
A stirred suspension of 3-methyldihydrofuran-2,5-dione (1.0 
g, 8.76 mmol) and anhydrous methanol (0.43 mL, 0.34 g, 10.5 
mmol) was refluxed for 1 h. After the mixture had become 
homogeneous, heating was continued for an additional half 
an hour. After cooling, the excess methanol was removed 
under vacuum, and the desired compound isolated on silica 
gel (EtOAc/Hexane 1:9) yielding a white solid of 4-methoxy-
3-methyl-4-oxobutanoic acid 3.13b-1 (0.448, 3.07 mmol, 35 
%). 1H NMR (400 MHz, CDCl3): δH 1.3 (d, J = 12 Hz, 3H, H-3) 
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2.6 (m, 1H, H-1a), 2.7 (dd, J = 13, 7Hz, 1H, H-1b), 3.1 (m, 
1H, H-2), 3.7 (s, 3H).  
 
 
 
(±)4-Methoxy-3-methyl-4-oxobutanoic acid 3.13b-2 
A stirred suspension of dihydrofuran-2,5-dione (1.0 g, 9.99 
mmol) and anhydrous methanol (0.49 mL, 0.38 g, 11.9 mmol) 
was refluxed for 1 h. After the mixture had become 
homogeneous, heating was continued for an additional half 
an hour. After cooling, the excess methanol was removed 
under vacuum, yielding a white solid of 4-methoxy-4-
oxobutanoic acid 3.13b-2 (1.19 g, 8.99 mmol, 90 %).1H NMR 
(400 MHz, CDCl3): δH2.7 (t, J = 7 Hz, 2H, H-1), 2.8 (t, J = 
7 Hz, 2H, H-2),3.6(s, 3H, OCH3). 
 
General Procedure for the preparation of compounds 3.2a-1, 
3.2a-2, 3.2a-3, 3.2a-4, 3.2a-5 and 3.2a-6. 
 
The carboxylic acid(0.45 mmol) was dissolved in DMF (10 mL) 
and the mixture cooled to 0 oC. To the solution were added 
EDC (0.086 g, 0.45 mmol), O-benzylhydroxylamine 
hydrochloride (0.072 g, 0.45 mmol), diisopropylethylamine 
(0.060 g, 0.45 mmol), and 1-HOBt (0.07 g, 0.45 mmol). The 
reaction mixture was stirred overnight.Water (100 mL) was 
added to the mixture and then it was separated with EtOAc 
(50 mL x 3). Brine (20mL) was added to break up the 
emulsion that formed. The organic layer solution was washed 
with HCl (0.1 M, 40 mL x 1), NaHCO3(aq) (5 %, 50 mL x1) and 
brine (40 mL x 1), dried over MgSO4, filtered, and 
concentrated. The residue was dissolved in MeOH (10 mL) and 
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to this was added NaOH (aq) (4 M, 10 mL) and stirred for 3 
h. Most of the MeOH was removed in vacuo and the remaining 
acqueous solution was separated with diethyl ether (20 mL x 
1) The organic layer was discarded and the mixture 
acidified to pH 2 with 2 N HCl. The mixture was then 
separated with EtOAc (50 mL x 3) and the combined organics 
washed with H2O (50 mL x 1), brine (50 mL x 1), dried over 
MgSO4 and the solvent removed in vacuo. The title compounds 
were recrystallized from MeOH giving products 3.2a-1, 3.2a-
2, 3.2a-3, 3.2a-4, 3.2a-5 and 3.2a-6. 
 
 
(±)2-Benzyl-4-((benzyloxy)amino)-4-oxobutanoic acid 3.2a-5.  
Yield: 75%;Colourless crystals from MeOH; m.p. 122 - 124 oC; 
1H NMR (400 MHz, CDCl3): δH 2.5 (dd, J = 12, 3 Hz, 1H, H-2a) 
3.2 (m, 2H, H-2b/3), 3.3 (dd, J = 12, 5 Hz, 1H, H-4a) 3.6 
(dd, J = 12, 6 Hz, 1H, H-4b), 4.8 (s, 2H, H-1), 7.4 (m, 
10H);13C NMR (100 MHz, CDCl3): δ 35.7, 36.6, 44.9, 76.4, 
126.1, 127.1 (3C),128.1 (2C), 128.9 (2C), 129, 138, 141.2, 
169.9, 178.4; Calcd for C18H19NO4: C, 63.15; H, 5.35, N, 4.40  
Found: C, 62.03; H, 5.27, N, 4.36%. MS calculated for 
C18H19NO4 m/z = 313.13 [M+H], found 313.1. 
 
 
(±)4-((Benzyloxy)amino)-2-(cyclohexylmethyl)-4-oxobutanoic 
acid 3.2a-4.  
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Yield: 72%; Colourless crystals from MeOH; m.p. 91 – 93 oC; 
1H NMR (400 MHz, CDCl3): δH 0.9 (m, 2H, Cyclo-CH), 1.3(m, 
5H, Cyclo-CH), 1.7(m, 6H, Cyclo-CH, H-4), 2.3(d, J = 11 Hz, 
1H,  H-2a), 2.7(d, J = 13, 1H, H-2b), 2.8(m, 1H, H-3), 
4.9(s, 2H, H-1), 7.4(m, 5H, PhH). Calcd for C18H25NO4: C, 
67.69; H, 7.89; N, 4.39. Found: C, 67.11; H, 7.75; N, 
4.28%. MS calculated for C18H25NO4 m/z = 319.13 [M+H], found 
318.1. 
 
 
(±)2-(2-((Benzyloxy)amino)-2-oxoethyl)-4-methylpentanoic 
acid 3.2a-3. 
Yield: 70 % yield; White crystalline material from MeOH; 
m.p. 101 – 104 oC; 1H NMR (400 MHz, CDCl3): δH 0.9 (d, J = 9 
Hz, 6H, H-6/7) 1.5 (m, 1H, H-5), 1.6 (dd, J = 12, 9 Hz, 1H, 
H-4a), 1.9 (dd, J = 12, 8 Hz, 1H, H-4b), 2.1(m, 1H, H-2a), 
2.7 (m, 2H, H-2b/3) 4.8 (s, 2H, H-1), 7.4 (m, 5H, PhH). 
Calcd for C15H21NO4: C, 60.11; H, 6.99; N, 4.55. Found: C, 
59.04; H, 7.15; N, 4.28%. MS calculated for C15H21NO4 m/z = 
280.15 [M+H], found 279.5. 
 
 
 
(±)4-((Benzyloxy)amino)-2-methyl-4-oxobutanoic acid 3.2a-2 
Yield: 60%; Colourless crystals from MeOH; m.p. 123 – 125 
oC; 1H NMR (400 MHz, CDCl3): δH 1.2 (d, J = 9 Hz, 3H, H-4) 
2.6 (m, 1H, H-3), 2.8 (d, J = 8 Hz, 2H, H-2), 4.8 (s, 2H, 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Chapter 7: Experimental Section 
 
 181
H-1), 7.4 (m, 5H). Calcd for C12H15NO4: C, 60.75; H, 6.37; N, 
5.90. Found: C, 60.61; H, 6.42; N, 5.75%. MS calculated for 
C12H15NO4 m/z = 237.01 [M+H], found 237.1. 
 
 
(±)4-((Benzyloxy)amino)-4-oxobutanoic acid 3.2a-1 
Yield: 90 %; White crystals from MeOH; m.p. 113 – 117 oC;  
1H NMR (400 MHz, CDCl3) δH 2.6 (t, J = 7 Hz, 2H, H-3), 2.7 
(t, J = 7 Hz, 2H, H-2), 4.8 (s, 2H, H-1), 7.4 (m, 5H). MS 
calculated for C11H13NO4 m/z = 223.1 [M+H], found 223.2. 
 
 
 
(±)4-((Benzyloxy)amino)-2-(naphthalen-1-ylmethyl)-4-
oxobutanoic acid 3.2a-6.  
Yield: 84 %; Brown waxy oil; 1H NMR (400 MHz, CDCl3): δH 2.8 
(dd, J = 12, 4 Hz, 1H, H-2a) 3.1 (m, 1H, H-2b), 3.2 (m, 2H, 
H-4a/3), 3.5 (m, 1H, H-4b), 4.8 (m, 2H, H-1), 7.4 (m, 12H); 
13C NMR (100 MHz, CDCl3): δ 34.7, 37.6, 45.9, 77.4, 
125.1(5C), 127.1 (3C),127.3 (2C), 128.9 (2C), 130.1, 137.0, 
142.2, 169.9, 178.4; MS calculated for C22H21NO4 m/z = 362.4 
[M+], found 362.2. 
 
General Procedure for the preparation of compounds 
3.16b.3.16c. 3.16d, 3.16e, 3.16f and 3.16g. 
 
Hydroxylamine O-benzylated compound (0.179 mmol)was 
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dissolved in MeOH (10 mL). Pd-C (0.06 g, 0.564 mmol) was 
added to the mixture and the reaction carried out under 
hydrogen atmosphere (3 atm) for 2 h. The reaction mixture 
was filtered through celite and solvent removed in vacuo to 
leave the product free hydroxamate 3.16b. 3.16c. 3.16d, 
3.16e, 3.16f and 3.16g whichwere stored in a sealed plastic 
vial. 
 
(±)2-Benzyl-4-(hydroxyamino)-4-oxobutanoic acid 3.16f 
Yield: 41 %;1H NMR (400 MHz, CDCl3): δH 2.4 (dd, J = 13,6 
Hz, 1H, H-1a) 2.6 (dd, J = 13, 6 Hz, 1H, H-1b), 2.8 (dd, J 
= 12, 7 Hz, 1H, H-3a), 3.1 (m, 1H, H-2), 3.2 (dd, J = 12, 7 
Hz, 1H, H-3b), 7.3 (m, 5H);13C NMR (100 MHz, CDCl3): δ 34.7, 
37.6, 44.7, 127.1, 128.1 (2C),128.9, 129, 137.1, 170.9, 
178.7; Calcd for C11H13NO4 m/z = 223.4 [M+], found 222.1. 
CO2H
1
2
O
N
H
HO
3
 
 
(±)2-(Cyclohexylmethyl)-3-(hydroxyamino)-3-oxopropanoic 
acid 3.16e 
Yield: 60 %; White crystalline powder; m.p. 89 – 92 oC; 1H 
NMR (400 MHz, CDCl3): δH 0.9 (m, 2H, Cyclo-CH), 1.2 (m, 3H, 
Cyclo-CH), 1.3 (m, 2H, Cyclo-CH), 1.7 (m, 6H, Cyclo-CH, H-
3), 2.3 (dd, J = 12, 7 Hz 1H,  H-1a), 2.5 (dd, J = 12, 7 
Hz, 1H, H-1b), 2.7 (m, 1H, H-2).13C NMR (100 MHz, CDCl3): δ 
25.8 (2C), 26.4, 33.1, 33.7 (2C) 35.1 , 36.4, 47.2, 170.1, 
178.1. 
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(±)2-(2-(Hydroxyamino)-2-oxoethyl)-4-methylpentanoic acid 
3.16d 
Yield:58 %; White crystalline solid; m.p. 91 – 94 oC; 1H NMR 
(400 MHz, CDCl3): δH0.9 (d, J = 8 Hz, 3H, H-5) 0.95 (d, J = 
8 Hz, 3H, H-6), 1.2 (m, 1H, H-4), 1.7 (t, J = 7 Hz, H-3) 
2.2 (d, J = 9 Hz, 2H, H-1) 2.7 (m, 1H, H-2).  
 
 
(±)3-(Hydroxyamino)-2-methyl-3-oxobutanoic acid 3.16c 
Yield: 60 %; White crystalline powder; m.p. 76 – 78 %; 1H 
NMR (400 MHz, CDCl3): δH 1.3 (d, J = 11 Hz, 3H, H-3) 2.2 (d, 
J= 9 Hz, 1H, H-1a), 2.8 (m, 2H, H-2 and H-1b). 
 
 
3-(Hydroxyamino)-3-oxobutanoic acid 3.16b 
Yield: 55 %; White crystalline powder; m.p. 93 – 95%;1H NMR 
(400 MHz, CDCl3):δH 2.3 (t, J = 7 Hz, 2H, H-2), 2.7 (t, J = 
7 Hz, 2H, H-1). 
 
S
NH
HN
O
N
O
NH
H 1
2 4
5
6
7
8
9
10
11
3
12
 
 
(4S)-4-(5-(1H-Imidazol-1-yl)-5-oxopentyl)tetrahydro-1H-
thieno[3,4-d]imidazol-2(3H)-one 3.18c 
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5-((4S)-2-oxohexahydro-1H-thieno[3,4-b]pyrrol-4-
yl)pentanoic acid (0.2 g, 0.82 mmol) 3.18a  was dissolved 
in anhydrous DMF (15 mL) at 70 °C in a round bottom flask 
with magnetic stirrer. The solution was cooled to room 
temperature, and 1,1’-carbonyldiimidazole 3.18b (0.2 g, 
1.23 mmol) was added with stirring at room temperature 
until a white precipitate formed (30 min). The crude 
precipitate was filtered and washed with dry chloroform (20 
mL). The filter cake was re-suspended in chloroform (10 mL) 
and refluxed for 30 min. The suspension was cooled to room 
temperature and filtered to obtain pure (4S)-4-(5-(1H-
imidazol-1-yl)-5-oxopentyl)tetrahydro-1H-thieno[3,4-
d]imidazol-2(3H)-one 3.18c(0.206 g, 0.699 mmol, 85 % yield) 
as a white solid. 1H NMR (400 MHz, DMSO-d6): δH 1.5 (m, 4H, 
H-6/7),1.8 (m, 4H, H-5/8), 2.1 (t, 2H, J=7 Hz, H-9), 2.6 
(dd, 1H, J= 12, 5 Hz, H-2a), 2.8 (dd, 1H, J= 12, 5 Hz, H-
2b), 3.4 (m, 1H, H-4), 4.19 (m, 1H ,H-1), 4.28 (m, 1H, H-
2), 6.4 (s, 2H, NH), 7.1 (m, 1H, H-10), 7.5 (m, 1H, H-11), 
7.9 (m, 1H, H-12). 13C NMR (DMSO-d6) δC 23.5, 27.7, 27.9, 
34.0, 39.7, 55.2, 59.1, 60.9, 116.3, 130.1, 136.8, 162.5, 
171.4.In agreement with the literature.2 
 
 
(4S)-4-(6-(1H-Imidazol-1-yl)-6-oxohexyl)tetrahydro-1H-
thieno[3,4-b]pyrrol-2(3H)-one 3.18e. 
3.18c (4S)-4-(5-(1H-imidazol-1-yl)-5-oxopentyl)tetrahydro-
1H-thieno[3,4-d]imidazol-2(3H)-one (0.19 g, 0.65 mmol) and 
3.18d(R)-2-amino-3-(4-benzoylphenyl)propanoic acid (0.174 
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g, 0.645 mmol)) were dissolved in anhydrous THF (10 ml)  
and stirred overnight. The solvent was removed in vacuo 
leaving crude 3.18e(2S)-3-(4-benzoylphenyl)-2-(5-((4S)-2-
oxohexahydro-1H-thieno[3,4-d]imidazol-4-
yl)pentanamido)propanoic acid (0.192 g, 0.387 mmol, 60 % 
yield) which was used in the next step without further 
purification.1H NMR(400 MHz, DMSO-d6): δH1.30 (m, 2H, H-6), 
1.6 (m, 3H, H-5a/7), 1.7 (m, 1H, H-5b), 2.3 (t, J = 7 Hz, 
2H, H-8),  2.8 (dd, J = 12, 5 Hz, 1H, H-10a), 2.9 (m, 1H, 
H-4), 3.2 (m, 1H, H-10b), 3.3 (dd, J = 13, 7 Hz, H-3),  
4.30 (d, J = 8,1H, H-2), 4.7 (t, J = 6 Hz, 1H, H-1), 4.8 
(t, J = 6 Hz, 1H, H-9), 5.7 (br s, 2H, NH), 7.3-7.9 (m, 
9H); MS Calcd for C26H29N3O5Sm/z = 495.1 [M+H], found 495.1. 
 
 
2,2'-(3,6,9,12,15,18,21-Heptaoxatricosane-1,23-
diyl)bis(isoindoline-1,3-dione) 3.21a-1 
3,6,9,12,15,18,21-heptaoxatricosane-1,23-diol (1 g, 2.70 
mmol) was dissolved in DCM (20 ml). Tosyl-Cl (1.08 g, 5.67 
mmol)and pyridine (0.437 ml, 5.40 mmol) were added to the 
mixture and the reaction was stirred for 24 h. The 
volatiles were removed in vacuo and the residue taken up in 
CHCl3 (15 mL). Potassium phthalamide (1.05 g, 5.67 mmol)was 
added slowly over 15 minutes and the reaction stirred for 
12 h. CHCl3 (50 ml)was added and the mixture was washed with 
NaHCO3 (30 mL), brine (30 mL) and water (50 mL). The organic 
phase was dried over MgSO4, solvent removed under reduced 
pressure leaving the product 2,2'-(3,6,9,12,15,18,21-
heptaoxatricosane-1,23-diyl)bis(isoindoline-1,3-dione) 
3.21a-1(1.018 g, 1.620 mmol, 60 % yield)as a white solid.1H 
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NMR (400 MHz, CDCl3): δH3.25 (t, J = 6 Hz, 4H, H-1/16), 3.4 
(t, J = 6 Hz, 4H, H-2/15),  3.6 (m, 24H, OCH2CH2O),7.9 (m, 
8H, Phthalyl-H).MS Calcd for C32H40N2O11 m/z = 628.1 [M+H], 
found 628.1. 
 
 
2,2'-((Ethane-1,2-diylbis(oxy))bis(ethane-2,1-
diyl))bis(isoindoline-1,3-dione) 3.21a-2 
2,2'-(ethane-1,2-diylbis(oxy))diethanol (8.0 g, 53.3 mmol) 
was dissolved in DCM (20 ml). Tosyl-Cl (21.33 g, 112 
mmol)and pyridine (8.62 ml, 107.00 mmol) were added to the 
mixture and the reaction was stirred for 24 h. The 
volatiles were removed in vacuo and the residue taken up in 
CHCl3 (15 mL). Potassium phthalamide (20.72 g, 112.00 
mmol)was added slowly over 15 minutes and the reaction 
stirred for 12 h. CHCl3 (50 mL) was added and the mixture 
was washed with NaHCO3 (50 mL), brine (50 mL) and water (50 
mL). The organic phase was dried over MgSO4, solvent removed 
under reduced pressure leaving the product 2,2'-((ethane-
1,2-diylbis(oxy))bis(ethane-2,1-diyl))bis(isoindoline-1,3-
dione)3.21a-2(10.88 g, 26.6 mmol, 50 % yield).1H NMR (400 
MHz, CDCl3): δH3.5 (m, 4H, H-3/4),3.9 (s, 8H, H-1/2/5/6), 
7.8 (m, 8H, Phthalyl-H).MS Calcd for C22H20N2O6 m/z = 408.1 
[M+H], found 408.1. 
 
 
3,6,9,12,15,18,21-Heptaoxatricosane-1,23-diamine 3.25c-1 
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2,2'-(3,6,9,12,15,18,21-heptaoxatricosane-1,23-
diyl)bis(isoindoline-1,3-dione)3.21a-1 (1.35 g, 2.15 mmol) 
was dissolved in excess hydrazine hydrate (0.107 g, 2.15 
mmol) (6 ml) and stirred overnight. A white precipitate 
that formed was filtered off and the solvent removed. CHCl3 
(50 mL) and NaHCO3 (10mL, 10mM) was slowly added to the 
mixture. The aqueous layer was separated from the organic 
layer and retained. The aqueous layer was extracted with 
chloroform (2 x 20 mL) and once with Et2O (20ml). The 
aqueous layer was brought to ~ pH 7 by the drop-wise 
addition of HCl (1 M) and dried on the lyophilizer. The 
remaining residue was taken up in MeOH (20 mL) and 
filtered. The MeOH was removed under reduced pressure 
leaving the final product 3,6,9,12,15,18,21-
heptaoxatricosane-1,23-diamine 3.21c-1(0.51 g, 1.37 mmol, 
64 % yield) as a clear oily residue. 1H NMR (400 MHz, 
CDCl3): δH3.2 (t, J = 6 Hz, 4H, H-1/16), 3.5 (m, 24H, 
OCH2CH2O), 3.8 (t, J = 7 Hz, 4H, H-2/15);13C NMR (75.5 MHz, 
CDCl3) δC 41.8 (2C), 73.1 (2C), 71.5 (12C), 74.4 (2C). 
 
 
 
2,2'-(Ethane-1,2-diylbis(oxy))diethanamine 3.21c-2 
2,2'-((ethane-1,2-diylbis(oxy))bis(ethane-2,1-
diyl))bis(isoindoline-1,3-dione) 3.21a-2 was dissolved in 
hydrazine hydrate (20 mL) and the reaction was stirred for 
24 h. The precipitate that formed was filtered off and the 
solvent reduced in vacuo and the residue taken up in CHCl3 
(50 mL) and NaHCO3 (10mM) was slowly added to the mixture. 
The aqueous layer was separated from the organic layer and 
retained. The aqueous layer was extracted with chloroform 
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(2 x 20 mL) and once with Et2O (20ml). The aqueous layer was 
brought to ~ pH 7 by the drop-wise addition of HCl (1 M) 
and dried on the lyophilizer. The remaining residue was 
taken up in MeOH (20 mL) and filtered. The MeOH was removed 
under reduced pressure leaving the final product 2,2'-
(ethane-1,2-diylbis(oxy))diethanamine (4.5 g, 119.00 mmol, 
70 % yield) as a clear oily residue.1H NMR (400 MHz, CDCl3): 
δH3.0 (t, J = 7 Hz, 4H, H-1/6), 3.6 (s, 4H, H-3/4),3.7 (m, 
4H, H-2/5), 5.2 (br s, 4H);13C NMR (100 MHz, CDCl3): δc 43.1 
(2C), 70.1 (2C), 75.1 (2C).3 
 
 
Tert-butyl(23-amino-3,6,9,12,15,18,21-
heptaoxatricosyl)carbamate 3.28a 
HCl(g) (52 mg, 1.4 mmol, H2SO4/NaCl) was bubbled through 
cooled MeOH (10 ml, 0 oC) under closed vessel conditions. 
The mixture was stirred for 15 min at 0 oC and was carefully 
added to 3,6,9,12,15,18,21-heptaoxatricosane-1,23-diamine 
3.21c-1(0.50 g, 1.37 mmol). The mixture was stirred for 15 
min at room temperature before adding 10 mL of H2O and 
stirring for another 0.5 h. To the solution BOC2O (0.32 ml, 
1.36 mmol) in 10 mL of MeOH was added at room temperature 
over 10 min, and the resultant solution was stirred for 1 
h. The mixture was concentrated in vacuo. Unreacted diamine 
was removed by diethyl ether (20 mL x 2). The residue was 
treated with 2 N NaOH (20 mL) solution. The product in the 
organic layer was extracted with CH2Cl2 (50 mL x 3). The 
combined extracts were washed with brine, dried over 
anhydrous MgSO4, and concentrated in vacuo to yield tert-
butyl (23-amino-3,6,9,12,15,18,21-
heptaoxatricosyl)carbamate 3.28a (0.382 g, 0.814 mmol, 60 % 
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yield) the mono-BOC product as a colorless oil. 1H NMR, (400 
MHz, D2O): δH 1.4 (s, 9H, Boc-H), 2.8 (m, 2H, H-1)3.1 (m, 
2H, H-6), 3.5 (t, J = 7 Hz, 4H, H-2/5), 3.7 (s, 24H), 5.3 
(bs, 2H, NH2).  
 
 
 
Tert-butyl (2-(2-(2-aminoethoxy)ethoxy)ethyl)carbamate 
3.26d  
HCl (1.03 g, 28.01 mmol) was bubbled through cooled MeOH 
(150 ml, 0 oC). The mixture was stirred for 15 min at 0 oC 
and was carefully added to 2,2'-(ethane-1,2-
diylbis(oxy))diethanamine 3.21c-2(4.20 g, 28.30 mmol). The 
mixture was stirred for 15 min at room temperature before 
adding 25 mL of H2O and stirring for another 0.5 h. To the 
solution  BOC2O (6.58 ml, 28.30 mmol) in 100 mL of MeOH was 
added at room temperature over 10 min, and the resultant 
solution was stirred for 1 h. The mixture was concentrated 
in vacuo. Unreacted diamine was removed by diethyl ether 
(100 mL x 2). The residue was treated with 2 N NaOH (200 
mL) solution. The product in the organic layer was 
extracted with CH2Cl2 (150 mL x 3). The combined extracts 
were washed with brine, dried over anhydrous MgSO4, and 
concentrated in vacuo to yield tert-butyl (2-(2-(2-
aminoethoxy)ethoxy)ethyl)carbamate 3.26d (5.21 g, 20.97 
mmol, 74 % yield) the mono-BOC product as a colorless oil. 
1H NMR (400 MHz, CDCl3): δH 1.40 (s, 9H, t-butyl),2.9(m, 2H, 
H-1),3.2(m, 2H, H-6), 3.5 (t, J = 7 Hz, 4H, H-2/5), 3.6 (s, 
4H, H-3/4), 5.2 (br s, 2H, NH2), 8.0 (br s, 1H, NH). In 
agreement with the literature.3 
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N-((R)-1-((2-(2-(2-Aminoethoxy)ethoxy)ethyl)amino)-3-(4-
benzoylphenyl)-1-oxopropan-2-yl)-5-((4R)-2-oxohexahydro-1H-
thieno[3,4-d]imidazol-4-yl)pentanamide 3.21b-2 
(2S)-3-(4-benzoylphenyl)-2-(5-((4S)-2-oxohexahydro-1H-
thieno[3,4-d]imidazol-4-yl)pentanamido)propanoic acid 3.18e 
(0.100 g, 0.201 mmol) was dissolved in DMF (5 mL) and the 
mixture cooled to 0 oC. To the solution were added EDC 
(0.039 g, 0.201 mmol), tert-butyl (2-(2-(2-
aminoethoxy)ethoxy)ethyl)carbamate 3.25c-2 (0.05 g, 0.20 
mmol), DIEA (0.035 ml, 0.201 mmol), and HOBt (0.031 g, 0.20 
mmol). The reaction mixture was stirred overnight.Water (50 
mL) was added to the mixture and then it was separated with 
EtOAc (50 mL x 3). Brine (20mL) was added to break up the 
emulsion that formed. The organic layer solution was washed 
with HCl (0.1 M, 40 mL x 1), NaHCO3 (aq) (5 %, 50 mL x1) and 
brine (40 mL x 1), dried over MgSO4, filtered 
andconcentrated. The material, a light yellow 
oilwasdissolved in DCM (5 mL) and the mixture cooled to 0 
oC. TFA (3 ml, 38.9 mmol) was added to the solution and the 
mixture stirred overnight. The volatiles were removed in 
vacuo and the material re-dissolved in DCM (10 ml). 
Amberlyst A21 resin (1 g) were put in the mixture and it 
was stirred for 3 min. The resins were filtered off and the 
DCM removed in vacuo and the product was isolated on silica 
gel eluting with 40% EtOAc in hexanes leaving the productN-
((S)-1-((2-(2-(2-aminoethoxy)ethoxy)ethyl)amino)-3-(4-
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benzoylphenyl)-1-oxopropan-2-yl)-5-((4S)-2-oxohexahydro-1H-
thieno[3,4-d]imidazol-4-yl)pentanamide 3.21b-2(0.061 g, 
0.097 mmol, 80 % yield)as a clear brown oil. 1H NMR (400 
MHz, CDCl3): δH1.0 (m, 2H, H-10), 1.3 (m, 2H, H-11), 1.8 (m, 
2H, H-12), 1.6 (m, 2H, H-10), 2.2 (t, J = 7 Hz, 2H, H-9), 
2.9 (m, 1H,H-13), 3.1 (m, 3H, H-1/8a), 3.3 (m, 4H, H-
6a/8b/16), 3.6 (m, 6H, H-2/3/4), 3.5 (m, 3H, H-5/6b), 4.4 
(dd, J = 12, 5 Hz, 1H, H-14), 4.7 (m, 1H, H-15), 5.4 (t, J 
= 6 Hz, 1H, H-7), 7.0 – 7.8 (m, 9H, Ph-H). MS Calcd for 
C32H43N5O6Sm/z = 625.4 [M+H], found 625.1. 
 
Compound 3.28b below was synthesized using the same 
procedure as above. 
 
 
 
N-((R)-1-((2-(2-(2-Aminoethoxy)ethoxy)ethyl)amino)-3-(4-
benzoylphenyl)-1-oxopropan-2-yl)-5-((4R)-2-oxohexahydro-1H-
thieno[3,4-d]imidazol-4-yl)pentanamide 3.28b 
Yield: 47 %; Yellow oil; 1H NMR (400 MHz, CDCl3):δH 1.1 (m, 
2H, H-21), 1.6 (m, 2H, H-22), 1.7 (m, 2H, H-20), 2.1 (t, J 
= 7Hz, H-19), 2.6 (d, J = 9 Hz, 1H, H-26a), 2.8 (d, J = 9 
Hz, 1H, H-26b), 3.0 (m, 2H, H-1/16), 3.2 (t, J = 8 Hz,1H, 
H-23), 3.3 (d, J = 6 Hz, 2H, H-18), 3.5 (m, 4H, H-2 and H-
15), 3.6 (s, 24H, OCH2CH2O), 4.2 (s, 1H, H-24), 4.4 (s, 1H, 
H-25), 4.7 (d, J = 6 Hz, 1H, H-17), 6.9 (m, 2H, PhH), 7.2 
(m, 5H, PhH), 7.7 (m, 2H, PhH).  MS m/z 845.1 [M+1] 
Observed 844.1. 
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General Procedure for the preparation of compounds 4.2d-1, 
4.2d-2, 4.2d-3 and 4.2d-4. 
50 % aqueous Hypophosphorous acid (1.801 g, 28.00 mmol, 2.5 
ml) is added to a suspension of diphenylmethanamine (5 g, 
27.30 mmol) in EtOH (100 ml) and heated to 90 oC. At that 
temperature, the aldehyde (27.30 mmol) in EtOH (20 ml) is 
added slowly over 10 min and heating is continued for 3 h 
followed by stirring at ambient temperature overnight. The 
product is isolated as a precipitate which is filtered off, 
washed with cold EtOH and diethyl ether and used in the 
next step without further purification.  
 
 
(±) (1-(Benzhydrylamino)-2-phenylethyl)phosphinic acid 
4.23d-3 
Yield: 8.44 g, 24.01 mmol, 88 %;1H NMR (400 MHz, DMSO6): δH 
2.5 (d, J = 11 Hz, 2H, H-3), 3.1 (t, J = 8 Hz, 1H, H-2), 
5.2 (s, 1H, H-1), 7.3 (m, 15H, PhH).MS Calcd for 
C21H22NO2Pm/z = 351.4 [M+H], found 351.2. 
 
 
(±) (1-(Benzhydrylamino)ethyl)phosphinic acid 4.2d-1 
Yield: 2.70 g, 9.82 mmol, 60 % yield; 1H NMR (400 MHz, 
DMSO6): δH 1.2(d, J = 9 Hz, 3H, H-3), 2.1(bs, 1H, NH), 2.8(m, 
1H, H-2), 5.1(s, 1H, H-1), 7.2(m, 10H, PhH); C15H18NO2P MS 
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m/z [M+1] calculated 275.28. Observed [M+1] 275.1.   
 
 
(±) (1-(Benzhydrylamino)butyl)phosphinic acid 4.2d-4 
Yield:2.68 g, 8.84 mmol, 54 % yield; 1H NMR (400 MHz, 
DMSO6): δH 0.9(t, J = 7 Hz, 3H, H-5) 1.3(m, 2H, H-4), 1.6 (q, 
J = 6 Hz, 2H, H-3), 2.1(bs, 1H, NH), 2.5(m, 1H, H-2), 
5.1(s, 1H, H-1), 7.3(m, 10H, PhH); C17H22NO2P MS m/z [M+1] 
calculated 303.33. Observed [M+1] 303.1.   
 
 
(±) (1-(Benzhydrylamino)-2,2-dimethylpropyl)phosphinic acid 
4.2d-2 
Yield: 2.8 g, 8.95 mmol, 60%; 1H NMR (400 MHz, DMSO6): δH 
0.9(s, 9H, H-3/4/5), 2.0(bs, 1H, NH), 2.7(s, 1H, H-2), 
5.1(s, 1H, H-1), 7.3(m, 10H, PhH); C18H24NO2P MS m/z [M+1] 
calculated 317.36. Observed [M+1] 317.1. 
 
General Procedure for the preparation of compounds 4.2f-1, 
4.2f-2, 4.2f-3 and 4.2f-4. 
 
The phosphinic acid (14.23 mmol) was dissolved in 48% HBr 
(10 ml, 184 mmol) and heated to 120 oC for 2 h. The mixture 
was then concentrated under reduced pressure and the 
residue diluted with water and extracted with diethyl ether 
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(3 x 50 ml). The pH of the mixture was then adjusted to pH 
10 with NaOH (4 M) and brought to 0 oC on an ice-bath.  
Benzyl chloroformate (2.438 ml, 17.08 mmol) was added 
slowly over 5 minutes and the mixture stirred at 0 oC for 
one hour and at ambient temperature overnight and extracted 
with diethyl ether (2 x 50 ml). The aqueous phase is then 
acidified to pH 2 by the addition of 6 M HCl. The mixture 
was then extracted with EtOAc (3 x 50 ml), washed with H2O, 
dried over MgSO4 and the solvent removed in vacuo  leaving 
the benzyloxyphosphinic acid’s 4.2f-1, 4.2f-2, 4.2f-3 and 
4.2f-4.  
 
 
 
(±)(1-(((Benzyloxy)carbonyl)amino)-2-phenylethyl)phosphinic 
acid 4.2f-3 
Yield: 2.91 g, 64 %; White chrystalline solid; m.p. 131-133 
oC;1H NMR (400 MHz, DMSO6): δH 2.9 (d, J = 8 Hz, 2H, H-3), 
4.1 (t, J = 8 Hz, 1H, H-2), 5.2 (s, 2H, H-1), 7.3 (m, 10H, 
PhH).C16H18NO4P MS m/z [M+1] calculated 319.36. Observed 
[M+1] 319.1.   
 
 
(±) (1-(((Benzyloxy)carbonyl)amino)ethyl)phosphinic acid 
4.2f-1 
Yield: 2.83 g, 64 %; White chrystalline powder; m.p. 101 – 
104 oC; 1H NMR (400 MHz, DMSO6): δH 1.4 (d, J = 9 Hz, 3H, H-
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3), 3.6 (m, 1H, H-2), 5.2 (s, 2H, H-1), 7.3 (m, 5H, 
PhH).C10H14NO4P MS m/z [M+1] calculated 243.19. Observed 
[M+1] 243.1. 
 
 
(±) (1-(((Benzyloxy)carbonyl)amino)butyl)phosphinic acid 
4.2f-4 
Yield: 0.626 g, 70 %; 1H NMR (400 MHz, DMSO6): δH 0.9(t, J = 
7 Hz, 3H, H-5), 1.3 (m,2H, H-4), 1.7(m, 2H, H-3), 3.6 (t, 
J=7 Hz, 1H, H-2), 5.2 (s, 2H, H-1), 7.3 (m, 5H, PhH), 
8.1(m, 1H, NH).C12H18NO4P MS m/z [M+1] calculated 271.19. 
Observed [M+1] 271.1. 
 
 
(±)(1-(((Benzyloxy)carbonyl)amino)-2,2-
dimethylpropyl)phosphinic acid 4.2f-2 
Yield: 0.626 g, 70 %; White crystalline powder; m.p. 99 – 
103 oC; 1H NMR (400 MHz, DMSO6): δH 0.9(s, 9H, H-3/4/5), 3.4 
(d, J = 12 Hz, 1H, H-2), 5.2 (s, 2H, H-1), 7.3 (m, 5H, 
PhH), 8.1(s, 1H, NH).C13H20NO4P MS m/z [M+1] calculated 
285.34. Observed [M+1] 285.5.  
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(S)-methyl 2-amino-3-(1H-indol-3-yl)propanoate (Tryptophan 
methyl ester)  
Tryptophan (5.0 g, 24.50 mmol) was suspended in MeOH (20 
mL) and the mixture was cooled to 0 oC on an ice-bath. SOCl2 
(2.7 ml, 36.7 mmol) was added drop-wise over 20 min. Upon 
completion of addition and when all the tryptophan had 
dissolved into the mixture, the reaction was allowed to 
warm to room temperature and was stirred overnight. The 
volatiles were removed under reduced pressure leaving the 
product. Tryptophan methyl ester (5.3 g, 24.0 mmol, 99%) 
which was used in the next step without further 
purification.1H NMR (400 MHz, CDCl3): δH3.2 (d, J = 11 Hz, 
2H, H-2), 3.6 (s, 3H, OCH3), 4.2 (t, J = 7 Hz, 1H, H-1), 
7.1(s, 1H, H-3), 7.3 (m, 5H, PhH).C12H14N2O2 MS m/z [M+1] 
calculated 217.16. Observed [M+1] 217.1. 
 
General Procedure for the preparation of compounds 4.2i-1 
up to 4.2i-16. 
 
Tryptophan methyl ester (0.14 g, 0.63 mmol), an aldehyde 
(0.626 mmol) and the phosphinic acid (0.63 mmol)were 
dissolved in MeOH (5 ml) and 2 drops of HCl were added.  
The reaction mixture was refluxed for 16 h. The solvent was 
removed under reduced pressure and then dissolved in MeOH 
(5 ml). NaOH (3 ml, 4 M) was added and the mixture stirred 
overnight. The MeOH was removed under reduced pressure and 
the mixture separated with diethyl ether (2 x 20 ml). The 
aqueous phase was acidified to pH 2 (6 N HCl) and then 
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extracted with EtOAc (2 x 30 ml), dried over MgSO4and 
reduced under pressure. The crude product was 
recrystallized from MeOH giving the products 4.2i-1 up to 
4.2i-16. 
 
 
(±)2-((1-((1-(((Benzyloxy)carbonyl)amino)-2-
phenylethyl)(hydroxy)phosphoryl)ethyl)amino)-3-(1H-indol-3-
yl)propanoic acid 4.2i-3 
Yield: 0.147 g, 43 %; Brown crystalline powder from MeOH; 
m.p. 113 – 115 oC; 1H NMR (400 MHz, CDCl3): δH 1.3 (d, J = 9 
Hz, 3H, H-5), 3.0 (m,2H, H-4/7a), 3.2 (dd, J = 11, 6 Hz, 
1H,H-7b ), 3.3 (dd, J = 12, 5 Hz, 1H, H-3a), 3.6 (m, 1H, H-
3b), 4.4 (t, J = 7 Hz, 1H, H-6), 4.5 (m, 1H, H-2), 5.2 (s, 
2H, H-1)7.1 (s, 1H, H-8), 7.3 (m, 13H, PhH); 13C NMR, 
(CDCl3)19.9, 28.2, 40.3, 55.8, 59.3, 65.9, 66.8, 110.7, 
112.1, 118.8, 119.8, 121.7, 123.0, 125.9, 127.1 (2C), 
127.4, 127.6, 127.7 (2C), 128.6(2C), 128.9(2C), 136.1, 
136.5, 137.7, 155.9, 171.5; C29H32N3O6P MS m/z [M+1] 
calculated 549.1. Observed [M+] 548.1; HPLC Purity: 85%; tR’ 
= 25.1 min. 
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(±)2-((1-((1-
(((Benzyloxy)carbonyl)amino)ethyl)(hydroxy)phosphoryl)ethyl
)amino)-3-(1H-indol-3-yl)propanoic acid 4.2i-1 
Yield:0.141 g,81 %; Tan coloured crystalline material from 
MeOH; m.p. 91 – 95 oC; 1H NMR (400 MHz, CDCl3): δH 1.4(m, 6H, 
H-3/5), 2.8 (m, 1H, H-4), 2.9(bs, 1H, NH), 3.12 (dd, J = 
12, 5 Hz, 1H, H-7a), 3.3 (dd, J = 12. 5 Hz, 1H, H-7b), 4.2 
(m, 1H, H-2),4.5 (t, J = 7 Hz, 1H, H-4), 5.2(s, 2H, H-1), 
7.1 (s, 1H, H-8), 7.3 (m, 10H, PhH), 8.1(s, 1H, NH); 13C 
NMR, (100 MHz, CDCl3);18.7, 19.3, 28.2, 54.7, 55.5, 68.9, 
69.8, 109.7, 114.1, 120.8, 121.8, 122.1, 123.0, 127.1(4C), 
128.9(2C), 136.1(2C), 155.9, 171.5; C23H28N3O6P MS m/z [M+1] 
calculated 471.4. Observed [M+] 470.2. HPLC Purity: 75%; tR’ 
= 23.1 min. 
 
 
(±)2-((1-((1-
(((Benzyloxy)carbonyl)amino)butyl)(hydroxy)phosphoryl)ethyl
)amino)-3-(1H-indol-3-yl)propanoic acid 4.2i-4 
Yield:0.101 g, 66 %; Brown crystalline powder from MeOH; 
m.p. 112 – 115 oC; 1H NMR (400 MHz, CDCl3): δH 0.9(t, J = 7 
Hz, 3H, H-5), 1.2(d, J = 12 Hz, 2H, H-4), 1.5 (d, J = 12 
Hz, 3H, H-7), 2.0(m, 1H, H-3a), 2.1(m, 1H, 3b), 2.6 (m, 1H, 
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H-6),3.0 (dd, J = 12, 5 Hz, 1H, H-9a), 3.1(m, 2H, H-8/9b), 
4.0(m, 1H, H-2), 5.1 (s, 2H, H-1), 7.1 (s, 1H, H-10), 7.3 
(m, 9H, PhH), 8.0(s, 1H, NH); 13C NMR, (CDCl3);14.9, 18.9, 
21.3, 26.6, 27.2(2C), 54.9, 65.9, 66.8, 107.7, 109.4, 
118.8, 119.8, 121.7, 125.0, 128.1(2C), 128.4(2C), 128.9 
(2C), 136.1(2C), 155.9,175.5;  C25H32N3O6P MS m/z [M+1] 
calculated 500.5. Observed [M+] 499.2.HPLC Purity: >95%; tR’ 
= 24.3 min. 
 
 
 
(±)2-((1-((1-(((Benzyloxy)carbonyl)amino)-2-
phenylethyl)(hydroxy)phosphoryl)butyl)amino)-3-(1H-indol-3-
yl)propanoic acid 4.2i-7 
Yield: 0.130 g,72 %; White crystalline material from MeOH; 
m.p. 134 – 137 oC; 1H NMR (400 MHz, CDCl3): δH 0.9(t, J = 8 
Hz, 3H, H-7), 1.5 (m, 2H, H-6), 1.9 (m, 2H, H-5), 2.5(m, 
1H, H-4), 2.7(dd, J = 12, 5 Hz, 1H, H-9a), 3.1 (dd, J = 12, 
5 Hz, 1H, H-9b), 3.3 (dd, J = 12, 5 Hz, 1H, H-3a), 3.6 (m, 
2H, H-3a/8),  4.3 (m, 1H, H-2), 5.2(s, 2H, H-1), 7.3 (m, 
15H, PhH), 8.0(s, 1H, NH); 13C NMR, (100 MHz, CDCl3);13.8, 
16.1, 18.2, 27.2(2C), 39.3, 57.6(2C), 66.8(2C), 109.7(2C), 
119.8(2C), 121.7, 123.0, 125.9, 
127.1(6C),128.6(4C),136.1(2C), 137.7, 171.5.; C31H36N3O6P MS 
m/z [M+1] calculated 576.5. Observed [M+1] 575.1. HPLC 
Purity: >95%; tR’ = 29.1 min.  
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(±)2-((1-((1-
(((Benzyloxy)carbonyl)amino)butyl)(hydroxy)phosphoryl)butyl
)amino)-3-(1H-indol-3-yl)propanoic acid 4.2i-8 
Yield: 0.066 g, 68%; White crystalline material from MeOH; 
m.p. 91 – 94 oC; 1H NMR (400 MHz, CDCl3): δH 0.9 (m, 6H, H-
5/9), 1.2 (m, 2H, H-4), 1.6(m, 2H, H-8), 1.8 (m, 2H, H-
3a/7b), 2.2 (m, 1H, H-3b), 2.4 (bs, 1H, NH), 2.8(d, J = 6 
Hz, 1H, H-6), 2.9 (dd, J = 12, 6 Hz, 1H, H-11a), 3.4 (dd, J 
= 12, 6 Hz, 1H, H-11b), 3.9 (d, J = 9 Hz, 1H, H-2), 4.4 (t, 
J = 7 Hz, 1H, H-10), 5.2(s, 2H, H-1), 7.3 (m, 10H, PhH), 
7.9(s, 1H, NH);C27H36N3O6P MS m/z [M+1] calculated 527.6. 
Observed [M+] 527.1.HPLC Purity: >90%; tR’ = 25.9 min. 
 
(±)2-((1-((1-
(((Benzyloxy)carbonyl)amino)ethyl)(hydroxy)phosphoryl)butyl
)amino)-3-(1H-indol-3-yl)propanoic acid 4.2i-5 
Yield: 0.070 g, 68 %; White crystalline powder from MeOH; 
m.p. 101 – 103 oC; 1H NMR (400 MHz, CDCl3): δH 0.9(t, J = 8 
Hz, 3H, H-7), 1.4 (d, J = 9 Hz, 2H, H-3), 1.6 (m, 2H, H-6), 
1.9 (m, 2H, H-5), 2.0(bs, 1H, NH), 2.7 (t, J = 8 Hz, 1H, H-
4), 2.9 (d, J = 12 Hz, 2H, H-9),3.9(m, 1H, H-2), 4.3 (t, 
1H, J = 7 Hz, H-8), 5.2(s, 2H, H-1), 7.3 (m, 10H, PhH), 
8.2(s, 1H, NH);C25H32N3O6P MS m/z [M+1] calculated 501.5. 
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Observed [M+] 500.2.HPLC Purity: >95%; tR’ = 24.9 min.  
 
 
(±)2-((1-((1-(((Benzyloxy)carbonyl)amino)-2,2-
dimethylpropyl)(hydroxy)phosphoryl)butyl)amino)-3-(1H-
indol-3-yl)propanoic acid 4.2i-6 
Yield: 0.066 g, 70 %; Tan crystalline powder from MeOH; 
m.p. 113 – 115 oC; 1H NMR (400 MHz, CDCl3): δH 0.9 (t, J = 7 
Hz, 3H, H-7), 1.1(s, 9H, H-10/11/12), 1.4 (m, 4H, H-6), 1.8 
(m, 2H, H-5),  2.0(bs, 1H, NH), 2.5(t, J = 8 Hz, 1H, H-4), 
3.1 (d, J = 9 Hz, 2H, H-9), 4.2 (s, 1H, H-2), 4.5 (t, 1H, J 
= 7 Hz, H-8), 5.2(s, 2H, H-1), 7.3 (m, 10H, PhH), 8.2(s, 
1H, NH);C28H38N3O6P MS m/z [M+1] calculated 541.6. Observed 
[M+1] 541.1.HPLC Purity: >94%; tR’ = 28.2 min.  
 
 
(±)2-((1-((1-(((Benzyloxy)carbonyl)amino)-2-
phenylethyl)(hydroxy)phosphoryl)-2,2-dimethylpropyl)amino)-
3-(1H-indol-3-yl)propanoic acid 4.2i-11 
Yield: 0.076 g, 82 %; 1H NMR (400 MHz, CDCl3): δH 0.9(s, 9H, 
H-5/6/7), 2.1(bs, 1H, NH), 2.6(m, 1H, H-4), 2.9 (dd, J = 
11.5 6 Hz, 1H, H-9a), 3.1 (dd, J = 11.5, 6 Hz, 1H, H-9b), 
3.2 (m, 1H, H-3a), 3.4 (dd, J = 11.5, 6 Hz, 1H, H-3b), 4.4 
(m, 1H, H-8), 4.8 (m, 1H, H-2), 5.2(s, 2H, H-1), 7.3 (m, 
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15H, PhH), 8.1(s, 1H, NH);C32H38N3O6P MS m/z [M+1] calculated 
590.6. Observed [M+] 589.1.HPLC Purity: >90%; tR’ = 29.8 
min.  
 
 
(±)2-((1-((1-
(((Benzyloxy)carbonyl)amino)ethyl)(hydroxy)phosphoryl)-2,2-
dimethylpropyl)amino)-3-(1H-indol-3-yl)propanoic acid 4.2i-
9 
Yield: 0.083 g, 79 %; Brown crystalline powder from MeOH; 
m.p. 116 – 119 oC; 1H NMR (400 MHz, CDCl3): δH 1.1(s, 9H, H-
5/6/7), 1.6(d, J = 9 Hz, 2H, H-3), 2.0(bs, 1H, NH), 2.6(s, 
1H, H-4), 3.0 (dd, J = 12, 5 Hz, 1H, H-9a),3.3 (m, 1H, H-
9b), 3.9(m, 1H, H-2/8), 5.2(s, 2H, H-1), 7.3 (m, 10H, PhH), 
8.0(s, 1H, NH);C26H34N3O6P MS m/z [M+1] calculated 514.5. 
Observed [M+] 513.3.HPLC Purity: >95%; tR’ = 28.4 min. 
 
 
(±)2-((1-((1-(((Benzyloxy)carbonyl)amino)-2,2-
dimethylpropyl)(hydroxy)phosphoryl)-2,2-
dimethylpropyl)amino)-3-(1H-indol-3-yl)propanoic acid 4.2i-
10 
Yield: 0.077 g, 79 %; 1H NMR (400 MHz, CDCl3): δH 1.1 (m, 
18H, H-5/6/7/10/11/12), 2.0(bs, 1H, NH), 2.6(s, 1H, H-4), 
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3.0 (d, J = 12 Hz, 2H, H-9), 4.1 (s, 1H, H-2), 4.4 (t, J = 
7 Hz, 1H, H-8), 5.2(s, 2H, H-1), 7.3 (m, 10H, PhH), 8.0(s, 
1H, NH);C29H40N3O6P MS m/z [M+1] calculated 556.6. Observed 
[M+1] 555.1.HPLC Purity: >95%; tR’ = 29.1 min.  
 
 
 
(±)2-((1-((1-
(((Benzyloxy)carbonyl)amino)butyl)(hydroxy)phosphoryl)-2,2-
dimethylpropyl)amino)-3-(1H-indol-3-yl)propanoic acid 4.2i-
12 
Yield: 0.088 g, 88 %; Brown crystalline solid from MeOH; 
m.p. 77 – 80 oC; 1H NMR (400 MHz, CDCl3): δH 0.9 (t, J = 6 
Hz, 3H, H-10), 1.1 (s, 9H, H-5/6/7), 1.2 (m, 2H, H-12), 1.9 
(m, 1H, H-11a), 2.2 (m, 1H, H-11b), 2.6 (s, 1H, H-4), 3.0 
(dd, J = 13, 6 Hz, 1H, H-9a), 3.4 (m, 1H, H-9b), 4.0 (m, 
2H, H-2/8), 5.2 (s, 2H, H-1), 7.3 (m, 10H, PhH), 8.0(s, 1H, 
NH);C28H38N3O6P MS m/z [M+1] calculated 541.6. Observed [M+] 
540.1.HPLC Purity: >95%; tR’ = 27.9 min.  
 
(±)2-((1-((1-
(((Benzyloxy)carbonyl)amino)ethyl)(hydroxy)phosphoryl)-2-
phenylethyl)amino)-3-(1H-indol-3-yl)propanoic acid 4.2i-13 
Yield: 0.09 g, 80 %; Light brown crystalline solid from 
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MeOH; 1H NMR (400 MHz, CDCl3): δH 1.1 (d, J = 7 Hz, 3H, H-
3), 3.0(m, 1H, H-7a), 3.4 (m, 4H, H-4/5/7b), 4.0 (m, 1H, H-
2), 4.4 (m, 1H, H-6), 5.2(s, 2H, H-1), 7.3 (m, 15H, PhH), 
8.0(s, 1H, NH);C29H32N3O6P MS m/z [M+1] calculated 548.6. 
Observed [M+] 547.1.HPLC Purity: 70%; tR’ = 26.1 min. 
 
 
 
(S)-1-((S)-3-(Acetylthio)-2-methylpropanoyl)pyrrolidine-2-
carboxylic acid 3.29d 
(S)-3-(acetylthio)-2-methylpropanoic acid 3.29a (0.100 g, 
0.616 mmol) was dissolved in DCM (10 ml) and cooled to 0 oC 
on ice. SOCl2 (0.054 ml, 0.740 mmol) was added dropwise over 
3 min. Upon completion of SOCl2 addition, the reaction 
mixture was heated at 70 oC for 4 h. The reaction mixture 
was then allowed to cool to ambient temperature and then 
the solvent was removed in vacuo. The residue was then 
dissolved in dioxane (10 ml) and then water (10 ml) was 
added. The mixture was cooled to 5 oC then NaHCO3 (0.078 g, 
0.925 mmol) was added. The mixture was stirred until all 
the solids dissolved completely and then proline (S)-
pyrrolidine-2-carboxylic acid (0.071 g, 0.616 mmol) was 
added. The mixture was allowed to warm to ambient 
temperature and then stirred overnight. Most of the dioxane 
was removed under reduced pressure and water (20 ml) was 
added and the mixture was separated with EtOAc (50 ml x 2) 
and the organic layer discarded. The aqueous layer was then 
acidified to pH 2 with HCl (6 N). The mixture was separated 
with EtOAc and the organic layer washed with water ( 2 x 50 
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ml) and brine (1 x 50 ml). It was then dried over MgSO4 and 
then solvent removed under reduced pressure leaving (S)-1-
((S)-3-(acetylthio)-2-methylpropanoyl)pyrrolidine-2-
carboxylic acid 3.29d(0.128 g, 0.493 mmol, 80 % yield)  as 
a clear colourless residue which was used in the next step 
without further purification.1H NMR (400 MHz, CDCl3): δH 
1.1(d, J = 8 Hz, 3H, H-4), 1.9(m, 3H, H-6a/7), 2.1(m, 1H, 
H-6b), 2.4(s, 3H, Acetyl-H), 3.5(m, 3H, H-2a/3/8a), 3.6(m, 
1H, H-8b), 3.8(m, 1H, H-2a), 4.7(t, J = 7 Hz, 1H, H-5). 
 
 
(S)-1-((S)-2-(((S)-1-Ethoxy-1-oxo-4-phenylbutan-2-
yl)amino)propanoyl)pyrrolidine-2-carboxylic acid 
(Enalapril) 3.30c 
 
(S)-2-(((S)-1-ethoxy-1-oxo-4-phenylbutan-2-
yl)amino)propanoic acid 3.30a(0.10 g, 0.36 mmol) was 
dissolved in DCM (10 ml) and cooled to 0 oC on ice and 
PCl5(0.08 g, 0.36 mmol)  was added slowly over 3 min. Upon 
completion of PCl5 addition, the reaction mixture was 
stirred at ambient temperature for 5 h. The solvent was 
removed in vacuo. The residue was then dissolved in 1,4-
dioxane (10 ml) and then water (10 ml) was added. The 
mixture was cooled to 5 oC then NaHCO3(0.045 g, 0.537 mmol) 
was added. The mixture was stirred until all the solids 
dissolved completely and then proline (S)-pyrrolidine-2-
carboxylic acid (0.041 g, 0.358 mmol) was added. The 
mixture was allowed to warm to ambient temperature and then 
stirred overnight. Most of the 1,4-dioxane was removed 
under reduced pressure and water (20 ml) was added and the 
mixture was separated with EtOAc (50 ml x 2) and the 
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organic layer discarded. The aqueous layer was then 
acidified to pH 2 with HCl (6 N). The mixture was seperated 
with EtOAc and the organic layer washed with water ( 2 x 50 
ml) and brine (1 x 50 ml). It was then dried over MgSO4 and 
then solvent removed under reduced pressure leaving (S)-1-
((S)-2-(((S)-1-ethoxy-1-oxo-4-phenylbutan-2-
yl)amino)propanoyl)pyrrolidine-2-carboxylic acid 
3.30c(0.081 g, 0.215 mmol, 60 % yield)  as a clear 
colourless residue which was used in the next step without 
further purification.1H NMR (400 MHz, CDCl3): δH 1.2(t, J = 
7 Hz, 3H, H-5), 1.4(d, J = 11 Hz, 3H, H-7), 1.9(m, 3H, H-
2a/10), 2.1(m, 1H, H-9a), 2.3(m, 2H, H-2b/9b), 2.7(t, J = 7 
Hz, 2H, H-1), 3.1(m, 1H, H-11a), 3.5(t, J = 7 Hz, 1H, H-3), 
7.2(m, 5H, Phe-H). C20H28N2O5 MS m/z [M+1] calculated 376.4. 
Observed [M+] 375.2. 
 
 
 
(2S)-2-(((2S)-1-((1-Carboxy-2-(1H-indol-3-yl)ethyl)amino)-
1-oxopropan-2-yl)amino)-4-phenylbutanoic acid 4.4e 
(S)-2-(((S)-1-ethoxy-1-oxo-4-phenylbutan-2-
yl)amino)propanoic acid 4.4a(0.10 g, 0.36 mmol) was 
dissolved in DCM (10 ml) and cooled to 0 oC on ice and PCl5 
(0.08 g, 0.36 mmol)  was added slowly over 3 min. Upon 
completion of PCl5 addition, the reaction mixture was 
stirred at ambient temperature for 5 h. The solvent was 
removed in vacuo. The residue was then dissolved in dioxane 
(10 ml) and then water (10 ml) was added. The mixture was 
cooled to 5 oC then NaHCO3 (0.045 g, 0.537 mmol) was added. 
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The mixture was stirred until all the solids dissolved 
completely and then phenylalanine methyl ester was added. 
The mixture was allowed to warm to ambient temperature and 
then stirred overnight. Most of the 1,4-dioxane was removed 
under reduced pressure and water (20 ml) was added and the 
mixture was separated with EtOAc ( 50 ml x 2) and the 
organic layer was washed with HCl (50 ml, 0.05 M), NaHCO3 
(aq) (50 ml, 5 %) water (2 x 50 ml) and brine (1 x 50 ml). 
It was then dried over MgSO4 and then solvent removed under 
reduced pressure. The residue was then dissolved in MeOH 
(10 ml) and NaOH (15 ml, 4M) was added and the mixture 
stirred overnight. The reaction mixture was separated with 
EtOAc and the organic layer discarded. The aqueous layer 
was then acidified to pH 2 with HCl (6 N) and separated 
with EtOAc, washed with water (2 x 50 ml) and brine (1 x 50 
ml). It was then dried over MgSO4 and the solvent removed 
under reduced pressure. The residue was purified on silica 
gel (EtOAc: Hexane: 1:5) and the product was collected as a 
white solid 4.4e(0.108 g, 0.247 mmol, 69 % yield); 1H NMR 
(400 MHz, CDCl3): δH 1.2 (d, J = 7 Hz, 3H, H-5), 1.9 (m, 2H, 
H-2), 2.7 (t, J = 7 Hz, 2H, H-1), 2.9 (t, J = 7 Hz, 1H, H-
3), 3.0 (m, 2H, H-4/7a),  3.3( dd, J = 12, 5 Hz, 1H, H-7b), 
5.1 (t, J =  Hz, 1H, H-6), 7.1(m, 8H, Phe-H/Indolyl-H), 
7.3(s, 1H, Indolyl-H), 7.6(s, 1H, Indolyl-H). C24H27N3O5 MS 
m/z [M+1] calculated 437.5. Observed [M+1] 437.1. 
 
 
(2S)-2-(((2S)-1-((1-Carboxy-2-phenylethyl)amino)-1-
oxopropan-2-yl)amino)-4-phenylbutanoic acid 4.4d 
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(S)-2-(((S)-1-ethoxy-1-oxo-4-phenylbutan-2-
yl)amino)propanoic acid 4.4a(0.100 g, 0.358 mmol) was 
dissolved in DCM (10 ml) and cooled to 0 oC on ice and PCl5 
(0.075 g, 0.358 mmol)  was added slowly over 3 min. Upon 
completion of PCl5 addition, the reaction mixture was 
stirred at ambient temperature for 5 h. The solvent was 
removed in vacuo. The residue was then dissolved in 1,4-
dioxane (10 ml) and then water (10 ml) was added. The 
mixture was cooled to 5 oC then NaHCO3 (0.045 g, 0.537 mmol) 
was added. The mixture was stirred until all the solids 
dissolved completely and then phenylalanine methyl ester 
methyl 2-amino-3-phenylpropanoate (0.064 g, 0.358 mmol) was 
added. The mixture was allowed to warm to ambient 
temperature and then stirred overnight. Most of the 1,4-
dioxane was removed under reduced pressure and water (20 
ml) was added and the mixture was separated with EtOAc (50 
ml x 2) and the organic layer was washed with HCl (50 ml, 
0.05 M), NaHCO3 (aq) (50 ml, 5 %) water ( 2 x 50 ml) and 
brine (1 x 50 ml). It was then dried over MgSO4 and then 
solvent removed under reduced pressure. The residue was 
then dissolved in MeOH (10 ml) and NaOH (15 ml, 4M) was 
added and the mixture stirred overnight. The reaction 
mixture was separated with EtOAc and the organic layer 
discarded. The aqueous layer was then acidified to pH 2 
with HCl (6 N) and separated with EtOAc, washed with water 
(2 x 50 ml) and brine (1 x 50 ml). It was then dried over 
MgSO4 and the solvent removed under reduced pressure.The 
residue was purified on silica gel (EtOAc: Hexane: 1:5) and 
the product was collected as a white crystalline solid 4.4d 
(0.086 g, 0.215 mmol, 60 % yield); 1H NMR (400 MHz, CDCl3): 
δH 1.4 (d, J = 9 Hz, 3H, H-5), 2.0 (m, 1H, H-2a), 2.2 (m, 
1H, H-2b), 2.7(t, J = 7 Hz, 1H, H-3), 2.8 (t, J = 7 Hz, 2H, 
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H-1), 2.9 (dd, J = 12, 5 Hz, 1H, H-7a), 3.1 (dd, J = 12, 5 
Hz, 1H, H-7b), 3.6 (q, J = 6 Hz, 1H, H-4), 5.0 (t, J = 7 
Hz, 1H, H-6), 7.3(m, 5H, Phe-H); C22H26N2O5 MS m/z [M+1] 
calculated 398.45. Observed [M+] 397.1. 
 
 
 
 
2-((S)-3-Mercapto-2-methylpropanamido)-3-phenylpropanoic 
acid 4.5d. 
(S)-3-(acetylthio)-2-methylpropanoic acid 4.5a(0.100 g, 
0.616 mmol) was dissolved in DCM (10 ml) and cooled to 0 oC 
on ice. SOCl2 (0.054 ml, 0.740 mmol) was added dropwise over 
3 min. Upon completion of SOCl2 addition, the reaction 
mixture was heated to 70 oC for 4 h. The reaction mixture 
was then allowed to cool to ambient temperature and then 
the solvent was removed in vacuo. The residue was then 
dissolved in dioxane (10 ml) and then water (10 ml) was 
added. The mixture was cooled to 5 oC then NaHCO3 (0.078 g, 
0.925 mmol) was added. The mixture was stirred until all 
the solids dissolved completely and then phenylalanine 2-
amino-3-phenylpropanoic acid (0.102 g, 0.616 mmol) was 
added. The mixture was allowed to warm to ambient 
temperature and then stirred overnight. Most of the dioxane 
was removed under reduced pressure and water (20 ml) was 
added and the mixture was separated with EtOAc (50 ml x 2) 
and the organic layer discarded. MeOH (10 ml) and NaOH (aq) 
(15 ml, 4 M) was added and the mixture stirred overnight.  
The mixture was separated with EtOAc (50 ml x 2) and the 
organic layer discarded. The aqueous layer was then 
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acidified to pH 2 with HCl (6 N). The mixture was separated 
with EtOAc and the organic layer washed with water ( 2 x 50 
ml) and brine (1 x 50 ml). It was then dried over MgSO4 and 
then solvent removed under reduced pressure leaving a clear 
yellow residue. Purification on silica gel with EtOAc and 
Hexane (1:4) gave the pure product 2-((S)-3-mercapto-2-
methylpropanamido)-3-phenylpropanoic acid 4.5d(0.105 g, 
0.395 mmol, 64 % yield) as a clear yellow solid.1H NMR (400 
MHz, CDCl3): δH 1.3 (d, J = 8 Hz, 3H, H-3), 1.4(s, 1H, SH), 
2.5 (dd, J = 12, 5 Hz, 1H, H-1a), 2.9(m, 1H, H-5a), 3.0 
(dd, J = 12, 5 Hz, 1H, H-1b), 3.0 (dd, J = 12, 5 Hz, 1H, H-
1b), 3.1(m, 1H, H-4), 3.2 (dd, J = 12, 5 Hz, 1H, H-5b), 4.8 
(t, J = 6 Hz, 1H, H-4), 7.2(m, 5H, Phe-H). C13H17NO3S MS m/z 
[M+1] calculated 267.34. Observed[M+] 266.3. 
 
3-(1H-Indol-3-yl)-2-((S)-3-mercapto-2-
methylpropanamido)propanoic acid 4.5e 
(S)-3-(Acetylthio)-2-methylpropanoic acid 4.5b (0.100 g, 
0.616 mmol) was dissolved in DCM (10 ml) and cooled to 0 oC 
on ice. SOCl2 (0.054 ml, 0.740 mmol) was added dropwise over 
3 min. Upon completion of SOCl2 addition, the reaction 
mixture was heated to 70 oC for 4 h. The reaction mixture 
was then allowed to cool to ambient temperature and then 
the solvent was removed in vacuo. The residue was then 
dissolved in dioxane (10 ml) and then water (10 ml) was 
added. The mixture was cooled to 5 oC then NaHCO3 (0.078 g, 
0.925 mmol) was added. The mixture was stirred until all 
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the solids dissolved completely and then tryptophan 2-
amino-3-(1H-indol-3-yl)propanoic acid (0.126 g, 0.616 mmol) 
was added. The mixture was allowed to warm to ambient 
temperature and then stirred overnight. Most of the 1,4-
dioxane was removed under reduced pressure and water (20 
ml) was added and the mixture was separated with EtOAc (50 
ml x 2) and the organic layer discarded. MeOH (10 ml) and 
NaOH (aq) (15 ml, 4 M) was added and the mixture stirred 
overnight.  The mixture was separated with EtOAc (50 ml x 
2) and the organic layer discarded. The aqueous layer was 
then acidified to pH 2 with HCl (6 N). The mixture was 
separated with EtOAc and the organic layer washed with 
water (2 x 50 ml) and brine (1 x 50 ml). It was then dried 
over MgSO4 and then solvent removed under reduced pressure 
leaving a clear yellow residue. Purification on silica gel 
with EtOAc and Hexane (1:4) gave the pure product 3-(1H-
indol-3-yl)-2-((S)-3-mercapto-2-methylpropanamido)propanoic 
acid 4.5e (0.121 g, 0.395 mmol, 64 % yield) as a clear 
yellow solid. 1H NMR (400 MHz, CDCl3): δH 1.3(d, J = 9 Hz, 
3H, H-3), 2.9 (m, 1H, H-1a), 3.1(m, 2H, H-1b/2), 3.1(dd, J 
= 13, 7 Hz, 1H, H-5a), 3.3(dd, J = 13, 7 Hz, 1H, H-5b) 4.9 
(t, J = 6 Hz, 1H, H-4), 7.1(m, 3H, Indolyl-H), 7.3(s, 1H, 
Indolyl-H), 7.6(s, 1H, Indolyl-H). C15H18N2O3S MS m/z [M+1] 
calculated 306.34. Observed [M+] 307.2. 
 
 
2-((R)-4-(Hydroxyamino)-2-methyl-4-oxobutanamido)-3-(1H-
indol-3-yl)propanoic acid 4.7e 
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(R)-4-((benzyloxy)amino)-2-methyl-4-oxobutanoic acid 3.2a-1 
(0.05 g, 0.211 mmol) was dissolved in DMF (10 ml) and 
cooled to 0 oC in an ice bath. EDC (0.040 g, 0.211 mmol), 
HOBT (0.032 g, 0.211 mmol), DIEA (0.037 ml, 0.211 mmol) 
were added. The reaction mixture was stirred overnight. 
Water (100 ml) was added and the mixture was separated with 
EtOAc (50 ml x 3) and the organic layer was washed with HCl 
(50 ml, 0.05 M), NaHCO3 (aq) (50 ml, 5 %) water ( 2 x 50 
ml) and brine (1 x 50 ml). It was then dried over MgSO4 and 
then solvent removed under reduced pressure. The residue 
was dissolved in MeOH (10 ml) and NaOH (15 ml, 4M) was 
added and the mixture stirred overnight. The reaction 
mixture was separated with EtOAc and the organic layer 
discarded. The aqueous layer was then acidified to pH 2 
with HCl (6 N) and separated with EtOAc, washed with water 
(2 x 50 ml) and brine (1 x 50 ml). It was then dried over 
MgSO4 and the solvent removed under reduced pressure. The 
residue was purified on silica gel (EtOAc: Hexane: 1:5) and 
the product was collected as a white solid. The white solid 
was dissolved in MeOH (20 ml) and Pd-C (0.09 g, 0.846 mmol) 
was added. The mixture was shaken on a Parr hydrogenator 
for three hours. The mixture was filtered through celite 
and MeOH was removed under reduced pressure leaving the 
product 2-((R)-4-(hydroxyamino)-2-methyl-4-oxobutanamido)-
3-(1H-indol-3-yl)propanoic acid (0.046 g, 0.139 mmol, 66 % 
yield) as white solid.1H NMR (400 MHz, CDCl3): δH 1.2(d, J = 
7 Hz, 3H, H-3), 2.5(dd, J = 12, 5 Hz, 2H, H-1a), 2.9(m, 1H, 
H-2), 3.1 (m, 2H, H-1b/5b), 3.3 (dd, J = 12, 6 Hz, 1H, H-
5b), 3.3 (t, J = 6 Hz, 1H, H-4), 7.1 (m, 3H, Indolyl-H), 
7.3 (s, 1H, Indolyl-H), 7.6 (s, 1H, Indolyl-H). C16H19N2O2 MS 
m/z [M+1] calculated 333.33. Observed [M+] 332.1. 
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This is the general method that was employed in the 
preparation 4.7a, 4.7b, 4.7c and 4.7d. 
 
 
 
(±)2-((R)-2-(Cyclohexylmethyl)-4-(hydroxyamino)-4-
oxobutanamido)-3-(1H-indol-3-yl)propanoic acid 4.7a 
Yield: 0.046 g, 71 %; White crystalline material; 1H NMR 
(400 MHz, CDCl3): δH 1.4(m, 13H, H-3/Cyclohexyl-H), 2.6(d, 
J= 9 Hz, 2H, H-1), 2.9(m, 1H, H-2), 3.4(d, J = 6 Hz, 1H, H-
5) 4.5(t, J = 6 Hz, 1H, H-4), 7.1(m, 3H, Indolyl-H), 7.3(s, 
1H, Indolyl-H), 7.6(s, 1H, Indolyl-H). C22H29N3O5 MS m/z 
[M+1] calculated 415.48. Observed [M+] 414.1. 
 
 
(±)2-((R)-2-(2-(Hydroxyamino)-2-oxoethyl)-4-
methylpentanamido)-3-(1H-indol-3-yl)propanoic acid 4.7b 
Yield: 0.022 g, 70 %;1H NMR (400 MHz, CDCl3): δH 0.9(d, J = 
9 Hz, 6H, H-5/6), 1.4 (m, 1H, H-3a), 1.8 (m, 1H, H-4), 1.9 
(t, J = 7 Hz, 1H, H-3b), 2.2(m, 1H, H-1a), 2.5 (m, 1H, H-
1b), 3.1 (m, 2H, H-2/8a), 3.3 (m, 1H, H-8b), 4.8 (t, J = 7 
Hz, 1H, H-7), 7.1 (m, 3H, Indolyl-H), 7.3 (s, 1H, Indolyl-
H), 7.6 (s, 1H, Indolyl-H). C19H25N3O5 MS m/z [M+1] 
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calculated 375.4. Observed [M+] 374.1. 
 
 
(±)2-(2-Benzyl-4-(hydroxyamino)-4-oxobutanamido)-3-(1H-
indol-3-yl)propanoic acid 4.7c 
1H NMR (400 MHz, CDCl3):δH 1.2 (d, J = 7 Hz, 3H, H-3), 2.5 
(d, J= 8 Hz, 2H, H-1), 2.9 (m, 1H, H-2), 3.3 (d, J = 7 Hz, 
1H, H-5) 4.5(t, J = 6 Hz, 1H, H-4), 7.1 (m, 3H, Indolyl-H), 
7.3 (s, 1H, Indolyl-H), 7.6(s, 1H, Indolyl-H). C22H23N3O5 MS 
m/z [M+1] calculated 409.44. Observed [M+] 408.1. 
 
HO
N
H
H
N CO2H
O
O
NH
1
2
4
5
3
 
(±)2-(4-(Hydroxyamino)-2-(naphthalen-1-ylmethyl)-4-
oxobutanamido)-3-(1H-indol-3-yl)propanoic acid 4.7d 
1H NMR (400 MHz, CDCl3): δH 1.3(d, J = 9 Hz, 3H, H-3), 2.3 
(d, J = 8 Hz, 2H, H-1), 3.0 (m, 1H, H-2), 3.3 (d, J = 7 Hz, 
1H, H-5) 4.6(t, J = 6 Hz, 1H, H-4), 7.1 (m, 3H, Indolyl-H), 
7.3(m, 5H, Naphth-H/Indolyl-H), 7.6 (s, 1H, Indolyl-H). 
C26H25N3O5 MS m/z [M+1] calculated 459.49. Observed [M+] 
458.1. 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Chapter 7: Experimental Section 
 
 215
 
N1-((11S)-11-(4-Benzoylbenzyl)-10,13-dioxo-17-((4S)-2-
oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)-3,6-dioxa-9,12-
diazaheptadecyl)-2-benzyl-N4-hydroxysuccinamide 3.27c-5 
2-benzyl-4-((benzyloxy)amino)-4-oxobutanoic acid (7.51 mg, 
0.024 mmol) was dissolved in DMF (2 mL) and the mixture 
cooled to 0 oC. To the solution were addedEDC (4.60 mg, 
0.024 mmol),N-((S)-1-((2-(2-(2-
aminoethoxy)ethoxy)ethyl)amino)-3-(4-benzoylphenyl)-1-
oxopropan-2-yl)-5-((4S)-2-oxohexahydro-1H-thieno[3,4-
d]imidazol-4-yl)pentanamide (0.015 g, 0.024 mmol), DIEA 
(4.19 µl, 0.024 mmol), and HOBT (3.67 mg, 0.024 mmol). The 
reaction mixture was stirred overnight. Water (20 mL) was 
added to the mixture and then it was separated with EtOAc 
(10 mL x 3). Brine (5mL) was added to break up the emulsion 
that formed. The organic layer solution was washed with HCl 
(0.1 M, 5 mL x 1), NaHCO3 (aq) (5 %, 5 mL x1) and brine (10 
mL x 1), dried over MgSO4, filtered, and concentrated.  The 
residue was dissolved in MeOH (5 mL) and Pd-C (0.026 g, 
0.248 mmol) added. The reaction mixture was stirred under 
H2 overnight. The mixture was filtered through celite and 
the solvent removed under reduced pressure leaving the 
product N1-((11S)-11-(4-benzoylbenzyl)-10,13-dioxo-17-
((4S)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)-3,6-
dioxa-9,12-diazaheptadecyl)-2-benzyl-N4-hydroxysuccinamide 
(0.014 g, 0.017 mmol, 80 % yield) as a yellow solid. 
1H NMR (400 MHz, CDCl3): δH1.4 (m, 2H, H-5), 1.7 (m, 1H, H-
4a), 1.8 (m, 2H, H-6), 2.3 (m, 1H, H-4b), 2.4 (m, 3H, H-
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9/18a), 2.7 (m, 3H, H-15a/17a/18b), 2.99 – 3.5 (m, 8H, H-
2a/9/10a/15a/16a/17b/19), 3.56 (m, 2H, H-13), 3.7 (m, 2H, 
H-11), 3.74 (m, 2H, H-12), 3.85 – 4.00 (m, 4H, H-
2b/10b/14), 4.6 (dd, J = 7.7, 1.1 Hz, 1H, H-3), 4.9 (m, 1H, 
H-1), 5.2 (t, J = 6.0 Hz, 1H, H-8), 6.9 – 7.9 (m, Phe-H). 
13C NMR (75.5 MHz, CDCl3): δc 24.4, 25.3, 28.3, 34.5, 36.1, 
37.1(2C), 41.1(3), 46.3, 55.6, 58.7, 62.4, 63.7, 70.1(4C) 
126.0, 127.4(2C), 128.1(6C), 130.2(4C), 132.4, 135.6, 
138.0, 138.4, 140.3, 164.7, 171.7, 173.9, 174.6, 175.1, 
194.3; C43H54N6O9 MS m/z [M+1] calculated 830.99. Observed 
[M+] 829.8. 
 
This was the general method employed for the synthesis of 
3.27c-2, 3.27c -3, 3.27c -4 and 3.27c below. 
 
 
N1-(11-(4-Benzoylbenzyl)-10,13-dioxo-17-((4S)-2-
oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)-3,6-dioxa-9,12-
diazaheptadecyl)-N4-hydroxy-2-isobutylsuccinamide 3.27c-3 
Yield: 0.014 g, 80 %; Yellow glassy material; 1H NMR (400 
MHz, CDCl3): δH 0.9(d, J = 9 Hz, 6H, H-19/20), 1.0 (m, 1H, 
H-17a) 1.4 (m, 3H, 5/18), 1.6 (m, 1H, H-17b),1.8 (m, 1H, H-
4a), 1.9 (m, 2H, H-4b/6), 2.3 (m, 2H, H-7), 2.7 (m, 2H, H-
21), 2.8 (m, 1H, H-16), 3.0 (m, 2H, H-9a/23), 3.2 (m, 1H, 
H-2a), 3.5(m, 10H, H-2b/9b/10/12/13/15), 3.9 (m, 4H, H-
11/14), 4.3(m, 1H, H-3), 4.7(m, 1H, H-1), 5.2 (m, 1H, H-8), 
7.0-8.0 (m, 9H, Phe-H);13C NMR (75.5 MHz, CDCl3): 22.8(2C), 
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24.2(2C), 25.2, 28.3, 36.1, 37.0, 37.4, 40.2, 41.1(4C), 
55.6, 58.7, 62.4, 63.7, 70.1(4C), 127.4(2C), 128.4(2C), 
130.2(4C), 132.4, 135.6, 138.4, 140.3, 164.7, 169.9, 
171.7(2C), 175.0, 194.3; C40H56N6O9S MS m/z [M+1] calculated 
796.9. Observed [M+] 795.5. 
 
 
N1-((11S)-11-(4-Benzoylbenzyl)-10,13-dioxo-17-((4S)-2-
oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)-3,6-dioxa-9,12-
diazaheptadecyl)-2-(cyclohexylmethyl)-N4-hydroxysuccinamide 
3.27c-4 
Yield:0.014 g, 80 %; Yellow glassy solid from MeOH, 1H NMR 
(400 MHz, CDCl3): 1.4-1.8 (m, 6H, H-4/5/Cyclohexyl-H), 2.0 
(m, 2H, H-6), 2.4 (m, 4H, H-7/17), 2.8 (m, 2H, H-16/18a), 
2.9 (m, 3H, H-9a/18b/19), 3.2  (m, 4H, H-10a/2a/11), 3.5 
(m, 9H, H-2b/9b/10b/12/13/15), 3.9 (m, 2H, H-14), 4.3 (m, 
1H, H-3), 4.7 (m, 1H, H-1), 5.0 (m, 1H, H-8), 7.0 – 7.7 (m, 
9H, PheH); 13C NMR (75.5 MHz, CDCl3): 24.4, 25.2, 25.8(3C), 
28.3, 32.3, 33.2(2C), 35.5, 36.1, 37.0, 37.4, 41.1, 
41.3(3C), 55.6, 58.7, 62.4, 63.7, 70.1(4C), 127.4(2C), 
128.4(2C), 130.2 (4C), 132.4, 135.6, 138.4, 140.3, 164.7, 
169.9, 171.7, 173.9, 174.5, 194.3; C43H60N6O9S MS m/z [M+1] 
calculated 837.1. Observed [M+] 836.5. 
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N1-((11S)-11-(4-Benzoylbenzyl)-10,13-dioxo-17-((4S)-2-
oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)-3,6-dioxa-9,12-
diazaheptadecyl)-N4-hydroxy-2-methylsuccinamide3.27c-2 
Yield: 0.024 g, 90%; Yellow oil; 1H NMR (400 MHz, 
CDCl3):1.4(m, 5H, H-5/17), 1.8 (m, 1H, H-4a), 2.0 (m, 2H, H-
6), 2.1 (m, 1H, H-4), 2.7 (m, 3H, H-16/18), 3.1-3.7 (m, 
17H, H-2/9/10/11/12/13/14/15/19), 4.4 (dd, J = 9, 5 Hz, 1H, 
H-3), 4.8 (m, 1H, H-1), 5.4 (m, 1H, H-8), 7.0 – 7.8 (m, 9H, 
Phe-H); 13C NMR (75.5 MHz, CDCl3): 16.5, 23.4, 25.2, 27.3, 
35.1, 36.4, 37.9, 39.1, 41.1(2C), 42.6, 56.6, 59.7, 62.4, 
63.7, 71.1(4C), 127.4(4C), 130.2(4C), 133.4, 136.6, 139.4, 
141.3, 165.7, 169.9, 170.7, 172.9, 173.0, 191.3; C37H50N6O9S 
MS m/z [M+1] calculated 754.34. Observed [M+1] 754.1. 
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N1-((11S)-11-(4-Benzoylbenzyl)-10,13-dioxo-17-((4S)-2-
oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)-3,6-dioxa-9,12-
diazaheptadecyl)-N4-hydroxy-2-(naphthalen-1-
ylmethyl)succinamide 3.27c-6 
Yield:39 mg, 66; Yellow oil; 1H NMR (400 MHz, CDCl3): δH1.4 
(m, 2H, H-5), 1.8 (m, 1H, H-4a), 1.9 (m, 3H, H-4b/6), 2.3 
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(t, J = 8 Hz, 2H, H-7), 2.8 (m, 2H, H-21a/17a), 2.9 (m, 3H, 
9a/21b/23), 3.3 (m, 2H, 2a/15a), 3.3 – 3.7 (m, 13H, H-
2a/9a/10/12/13/14/15a/16/17b), 3.8 (t, J = 7 Hz, 2H, H-11), 
4.3 (dd, J = 9, 6 Hz, 1H, H-3), 4.7 (m, 1H, H-1), 5.21 (t, 
J = 7 Hz, 1H, H-8), 6.9-7.9 (m, Phe-H); 13C NMR (75.5 MHz, 
CD3OD): 24.4 , 25.2, 28.3, 34.5, 35.4, 36.1, 37.6, 41.1, 
41.3, 41.6, 46.7, 55.6, 58.7, 62.4, 63.7, 70.1(2C), 
70.2(2C), 120.6, 125.6, 125.8, 126.1, 126.5, 126.9, 
127.4(2C), 128.4, 128.5, 128.6, 130.2(3C),, 131.3, 131.7, 
132.4, 132.6, 135.3, 135.6, 138.4, 140.3, 164.7, 171.7, 
173.9, 174.6, 175.2, 192.3; C47H56N6O9S MS m/z [M+1] 
calculated 881.05 Observed [M+] 880.1. 
 
 
 
(2S,4S)-5-(2-(((26S)-26-(4-Benzoylbenzyl)-25,28-dioxo-32-
((4S)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)-
3,6,9,12,15,18,21-h ptaoxa-24,27-
diazadotriacontyl)carbamoyl)pyrrolidin-1-yl)-4-methyl-5-
oxo-2-phenethylpentanoic acid 3.32a 
 
1-((2S,4S)-4-(ethoxycarbonyl)-2-methyl-6-
phenylhexanoyl)pyrrolidine-2-carboxylic acid (0.036 g, 
0.095 mmol) was dissolved in DMF (2 mL) and the mixture 
cooled to 0 oC. To the solution were added EDC (0.018 g, 
0.095 mmol), N-((S)-1-amino-27-(4-benzoylphenyl)-25-oxo-
3,6,9,12,15,18,21-heptaoxa-24-azaheptacosan-26-yl)-5-((4S)-
2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamide 
(0.08 g, 0.095 mmol), DIEA (0.017 ml, 0.095 mmol), and HOBT 
(0.014 g, 0.095 mmol). The reaction mixture was stirred 
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overnight.Water (20 mL) was added to the mixture and then 
it was separated with EtOAc (20 mL x 3). Brine (20mL) was 
added to break up the emulsion that formed. The organic 
layer solution was washed with HCl (0.1 M, 40 mL x 1), 
NaHCO3 (aq) (5 %, 50 mL x1) and brine (40 mL x 1), dried 
over MgSO4, filtered, and concentrated. The residue was 
dissolved in MeOH (5 mL) and to this was added NaOH(aq) (4 
M, 5 mL) and stirred for 3 h. Most of the MeOH was removed 
in vacuo and the remaining acqueous solution was separated 
with diethyl ether (20 mL x 1) The organic layer was 
discarded and the mixture acidified to pH 2 with 2 N HCl. 
The mixture was then separated with EtOAc (20 mL x 3) and 
the combined organics washed with H2O (20 mL x 1), brine 
(20 mL x 1), dried over MgSO4 and the solvent removed in 
vacuo. The title compound (2S,4S)-5-(2-(((26S)-26-(4-
benzoylbenzyl)-25,28-dioxo-32-((4S)-2-oxohexahydro-1H-
thieno[3,4-d]imidazol-4-yl)-3,6,9,12,15,18,21-heptaoxa-
24,27-diazadotriacontyl)carbamoyl)pyrrolidin-1-yl)-4-
methyl-5-oxo-2-phenethylpentanoic acid (0.067 g, 0.057 
mmol, 60 % yield) was a yellow oil;. 1H NMR (400 MHz, CDCl3) 
δH 1.3 (d, J = 7 Hz, 3H), 1.5 (m, 2H, ), 1.6 (m, 2H), 1.7 
(m, 2H), 1.9 (m, 2H), 2.1 (m, 2H), 2.3 (m, 1H), 2.4 (m, 
1H), 2.6 (t, J = 7, 2H), 2.7 (t, J = 7 Hz, 2H), 2.9 (t, J = 
7.1 Hz, 1H), 3.16 (m, 2H), 3.2 (m, 2H), 3.7 (m, 2H), 3.4 
(t, J = 3.7 Hz, 1H), 3.5 (m, 1H), 3.7 (m, 21H), 3.8 (m, 
10H), 3.9 (m, 1H), 4.8 (m, 1H), 5.1 (t, J = 4.1 Hz, 1H), 
5.2 (m, 1H), 5.4 (m,1H), 5.7 (d, J = 6 Hz, 2H), 6.3 (s, 
1H), 6.9  (m, 2H), 7.3 (m, 5H), 7.5 (m, 2H), 7.6 (m, 1H), 
7.7 (m, 2H), 7.9 (m, 4H), 8.8 (s, 1H). 13C NMR (75.5 MHz, 
CDCl3): 23.7,  24.1,  24.4, 25.2,  28.3, 29.5, 30.3, 32.1, 
36.1, 37.4, 41.1, 41.3(2C), 49.5, 55.6, 57.2, 58.7, 62.4, 
63.6(2C), 68.2, 70.1(14C) 126.0, 127.4(2C), 128.1(4), 
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128.8(2C), 130.2(4C), 132.4, 135.6, 138.4, 140.3, 142.0, 
164.7, 171.0, 171.7, 173.3, 173.9, 174.7, 192.3; C60H85N7O15S 
MS m/z [M+1] calculated 1174.3. Observed [M+] 1174.1. 
 
 
 
N-((26S)-26-(4-Benzoylbenzyl)-25,28-dioxo-32-((4S)-2-
oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)-
3,6,9,12,15,18,21-heptaoxa-24,27-diazadotriacontyl)-1-((R)-
3-mercapto-2-methylpropanoyl)pyrrolidine-2-carboxamide 
3.32b 
1-((R)-3-(acetylthio)-2-methylpropanoyl)pyrrolidine-2-
carboxylic acid (0.025 g, 0.095 mmol) was dissolved in DMF 
(2 mL) and the mixture cooled to 0 oC. To the solution were 
added EDC (0.018 g, 0.095 mmol), N-((S)-1-amino-27-(4-
benzoylphenyl)-25-oxo-3,6,9,12,15,18,21-heptaoxa-24-
azaheptacosan-26-yl)-5-((4S)-2-oxohexahydro-1H-thieno[3,4-
d]imidazol-4-yl)pentanamide (0.08 g, 0.095 mmol), DIEA 
(0.017 ml, 0.095 mmol), and HOBt (0.014 g, 0.095 mmol). The 
reaction mixture was stirred overnight. Water (20 mL) was 
added to the mixture and then it was separated with EtOAc 
(20 mL x 3). Brine (20mL) was added to break up the 
emulsion that formed. The organic layer solution was washed 
with HCl (0.1 M, 40 mL x 1), NaHCO3 (aq) (5 %, 50 mL x1) 
and brine (40 mL x 1), dried over MgSO4, filtered, and 
concentrated.  The residue was dissolved in MeOH (5 mL) and 
to this was added NaOH (aq) (4 M, 5 mL) and stirred for 3 
h. Most of the MeOH was removed in vacuo and the remaining 
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acqueous solution was separated with diethyl ether (20 mL x 
1) The organic layer was discarded and the mixture 
acidified to pH 2 with 2 N HCl. The mixture was then 
separated with EtOAc (20 mL x 3) and the combined organics 
washed with H2O (20 mL x 1), brine (20 mL x 1), dried over 
MgSO4 and the solvent removed in vacuo. The title compound 
N-((26S)-26-(4-benzoylbenzyl)-25,28-dioxo-32-((4S)-2-
oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)-
3,6,9,12,15,18,21-heptaoxa-24,27-diazadotriacontyl)-1-((R)-
3-mercapto-2-methylpropanoyl)pyrrolidine-2-carboxamide 
(0.049 g, 0.047 mmol, 50 % yield) was a yellow oil. 1H NMR 
(400 MHz, CDCl3) δH 1.1 (m, 2H), 1.3 (m, 5H), 1.4 (s, 1H), 
1.7 (m, 1H), 2.0 (m, 4H), 2.1 (m, 1H), 2.2 (t, J = 8 Hz, 
2H), 2.9 (m, 2H), 3.1 (m, 2H), 3.2 (dd, J = 13, 5 Hz, 1H), 
3.4 (m, 4H), 3.6 (m, 26H), 3.8 (m, 6H), 4.1 (m, 1H), 4.4 
(m, 1H), 4.8 (m, 2H), 5.4 (t, J = 8 Hz, 1H), 5.6 (s, 1H), 
5.7 (s, 1H), 5.71 (s, 1H), 6.5 (s, 1H), 6.9 (m, 2H), 7.5 
(m, 2H), 7.6 (m, 1H), 7.7 (m, 2H), 7.8 (m, 2H), 8.9 (s, 
1H). 13C NMR (75.5 MHz, CDCl3):16.4, 24.1, 24.4, 24.8, 25.2, 
28.3, 29.5, 36.1, 37.4, 41.1(4C),49.8, 55.6, 58.7, 62.4, 
63.1, 68.5, 70.1(5C), 127.4, 128.4(2C), 130.2(2),  
130.3(2C), 132.4, 135.6, 138.4, 140.3, 164.7, 171.0, 171.7, 
173.9, 178.8, 194.3;C51H76N6O13S2 MS m/z [M+1] calculated 
1044.31. Observed [M+] 1044.1. 
 
 
 
 
 
 
 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Chapter 7: Experimental Section 
 
 223
References 
                                                 
1
 Desai, U. V.; Pore, D. M.; Mane, R. B.; Solabannavar, S.  
  B.; Wadgaonkar, P.P.,Synthetic Communications 2004,   
  34(1), 25-32.  
2Nandkishor S. Chindarkar and Andreas H. Franz ARKIVOC  
2008 (xv) 21-33 
 
3
 Lee, DW.; Ha, H-J.; Lee, WK. Synthetic Communications  
2007;37: 737-742 
 
